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Atherosclerosis is a pathology associated with the induction of inflammatory reactions in the 
vascular wall. Given the multifactorious of inflammation in atherosclerotic processes, in the last 
years, generic drugs, like Methotrexate (MTX) and Colchicine (COL) that have broad anti-
inflammatory properties for atheroprotection, were taken in consideration. Nowadays, 
Nanomedicine offers many advantages in boosting the therapeutic efficacy and mitigating adverse 
effects compared to administering free drugs. New studies are showing the potential application of 
nanomedicine in controlling the progression and inducing the regression of atherosclerosis through 
the use of “old” chemotherapeutic drugs. In this thesis, different approaches were developed for 
the delivery of Methotrexate (MTX). Liposomes (LIP) and spherical polymeric nanoparticles (SPNs) 
were synthesized and characterized to reduce atherosclerosis inflammation. In the last part of the 
work, the anti-inflammatory activity was enhanced by introducing in the liposomes, together with 
MTX, another chemotherapeutic, Colchicine (COL).  
In Chapter 1 (Introduction), the pathophysiology of atherogenesis, therapies, and the rationale of 
using the two drugs (MTX and COL) are introduced and explained. It is shown that, even if the 
clinical trial related to the MTX (CIRT) failed, several studies demonstrated the efficacy of the drug 
on the atherosclerosis model. Also, the clinical trials of COL are presented. Finally, it is raised an 
ongoing clinical trial of the use of COL and MTX to reduce the inflammation and some study that 
proves the excellent results on delivering the drugs through nanoparticles.  
In Chapter 2 (Synthesis of Two Methotrexate Prodrugs for Optimizing Drug Loading into 
Liposomes), two different synthetic modifications of the methotrexate were presented (PEG-MTX 
and DSPE-MTX). Both prodrugs, together or alone, were loaded into liposomes. The work presents 
the in vitro chemical, physical, and biological characterizations of the three formulations.  
In Chapter 3 (Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation 
in ApoE–/– Mice via Nanoformulated Lipid–Methotrexate Conjugates), the DSPE-MTX was loaded 
in two different nanoparticles: LIP and SPNs. Both nanoparticles were analyzed and tested in vitro 





The mechanism of action of MTX was studied, confirming the anti-inflammatory effect. The MTX-
LIP was selected for the in vivo study. 
In Chapter 4 (Lipid nanoparticles encapsulating Methotrexate and Colchicine to enhance the anti-
inflammatory therapy), liposomes with MTX were enriched with Col to increase the anti-
inflammatory effect of the nanoparticles. Particles were synthesized by Nanossemblr, and all the 
chemical and physical characterization were done. Anti-inflammatory effects were evaluated on 
two different in vitro models.  
In Chapter 5 (Conclusion), a summary of all the work was done, pointing out the future experiments 
that can be carried away to prove, in vivo, the capability of these particles to reduce inflammation 
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Over the last decade, many studies suggest that inflammation has an important role in 
atherosclerosis progression and development. In the last years, old cheaper drugs, Methotrexate 
(MTX) and Colchicine (COL) were considered to treat this pathology due to their anti-inflammatory 
effects. MTX, a conventional chemotherapeutic medicine currently representing the first-line option 
in inflammatory diseases like rheumatoid arthritis (RA) and psoriatic arthritis, was proposed in the 
clinical trial Cardiovascular Inflammation Reduction Trial (CIRT). Even though many studies have 
demonstrated this drug's beneficial activity on animals/patients with atherosclerosis, the clinical 
trial failed. Col is known for its therapeutic use in gout and Familial Mediterranean Fever (FMF). In 
these patients, it was noticed a reduction of myocardial infarctions after the use of Colchicine. Its 
effect is associated with a stronger effect in the inhibition of inflammasome activation and IL-1β 
secretion. These observations are at the base of different clinical trials like Low-Dose Colchicine 
(LoDoCo), A second Low Dose Colchicine (LoDoCo2), Low Dose Colchicine after Myocardial 
Infarction (LoDoCo-MI).  
In general, their clinical use is limited by their several side effects and, furthermore, in MTX’s case 
is even more difficult due to its poor bioavailability and solubility in biological fluids. Taking this into 
account, nanomedicine might become a valid ally in furnishing potent tools to ease combined 
treatment and increase drug accumulation at the target site. Thus, this work aims to propone 
nanoparticles, polymeric, and lipid to improve the stability and solubility of encapsulated cargos, 
promote transport across membranes, and prolong circulation times to increase safety and efficacy. 
Here, it was proposed two different strategies for modifying the methotrexate by conjugating the 
DSPE and PEG. The prodrugs obtained (DSPE-MTX and PEG-MTX) were used to synthesize 
liposomes, including one or both of them. Physiochemical features were tested. The DSPE-MTX 
was selected (due to the instability at pH 6.8 of the system) and delivered by liposomes (MTX-LIP) 
and spherical polymeric nanoparticles (MTX-SPNs). Both nanoparticle formulations presented 
similar features. For the lipidic nanoparticles, the size is 174±2 nm (PdI: 0.15 ± 0.0007), and Zeta 
Pot -48 ± 0.02 mV; for the polymeric nanocarriers, the size is 208±2 nm (PdI: 0.15 ± 0.02), and 





for SPNs-MTX. Foam cells were obtained by treating rat bone marrow-derived monocytes (BMDM) 
with oxLDL. The treatment with the two nanoformulations was able to reverse foam cells maturation 
into macrophages. Both MTX-LIP and MTX-SPNs decreased cholesterol amounts after 24 hours 
in BMDM. The efficacy of the treatment was also proved by gene expression analysis. RT-PCR 
showed that the CD36 and SRA-1 gene expression (regulating oxLDL influx) was minimal. The 
reverse cholesterol transporter (ABCA1) in foam cells treated with the nanoformulations was 
inducing a 2-fold compare the CTRL. MTX-LIP and MTX-SPNs also reduced inflammatory gene 
expression (IL-6, IL-1β, and TNFα). MTX-LIP was used in vivo in a murine model of atherosclerosis. 
ApoE-/- mice, fed with a high-fat diet for 28 days, were treated for 4 weeks (once every three days) 
with MTX-LIP. Plaque burden was measured, revealing a reduction in plaque area for the treated 
mice. These results influenced a new line of thinking; it could be possible to boost the liposomes' 
anti-inflammatory effect combining in the same particles the MTX and the Colchicine (Col). 
Particles have a size around 100 nm with stability upon 4 days. The liposomes' encapsulation 
efficiency was ~ 28 % for MTX and ~ 33 % for COL with a ratio of 1:16. The anti-inflammatory effect 
was tested on the primary cell line (BMDM). Specifically, liposomes with MTX and Col were able 
to reduce the inflammation caused by the LPS. At the same time, they were able to modulate the 
foam cell marker (ABCA1), reflecting a reduction of the expression of IL-1β by 3-fold, IL-6 by 2-
fold, and moderately of TNF-α. These results would suggest that combining the chemotherapeutic 
drugs in the liposomes could strongly reduce the inflammation modulating the disease progression. 
These data suggest that MTX and COL loaded nanoparticles could be the new strategy for the 






Chapter 1  
 
Introduction 
1.1. The pathophysiology of atherogenesis 
Atherosclerosis is a complex inflammatory condition developed in the intima of an arterial 
vessel, and it is the primary cause of cardiovascular disease (CVD) [1]. Vascular inflammation 
and the accumulation of lipid-laden macrophages and their products induce the maturation of 
the atheroma or plaque, which can rupture and lead to ischemic stroke and myocardial 
infarction. Atherosclerotic cardiovascular disease (ACD) is divided into two major events: 
cerebrovascular disease (mainly ischemic stroke) and ischemic heart disease (IHD). The stroke 
and ischemia are the first and the third causes of death in the world [1]. In 2015 the Global 
Burden of Diseases, Injuries, and Risk Factor Study reported that 422.7 million people were 
affected by cardiovascular diseases and were responsible for 31% of all the word deaths (17.9 
million of individuals) [2, 3]. Presently, the World Health Organization estimated that by 2030, 
almost 23.6 million people will die from cardiovascular disease [4].  
 
Atherosclerosis is an inflammatory disorder characterized by a gradual accumulation of 
lipoproteins and fibrous elements beneath the vascular wall [5]. The early stage of 
atherosclerosis is characterized by the sub-endothelium accumulation of cholesterol-engorged 
macrophages, also known as “foam cell”. The accumulated foam cells and T lymphocytes are 
the initial constituents of the vascular wall lesions and are denominated as “fatty streaks”. In 
the second step, smooth-muscle cells (SMCs) become an integral part of the lesion area. The 
formation of this fatty streak occurs mainly during the first decade of life of an individual. During 
the second decade, these formations spread to the coronary arteries, while in the third and 





Fatty streaks formed during the initial lesion are clinically irrelevant and, in some situations, can 
even regress [5]. With the passage of time, they become the precursor of more advanced 
lesions characterized by the accumulation of lipid-rich necrotic debris and smooth muscle cells 
(Figure 1.1.) [6]. It is well known the atherosclerosis is multifocal disease that attacks 
reproducible regions of the arterial tree. The vascular lesions tend to develop at sites 
characterized by blood flow disturbance and at regions of the wall experiencing lower shear 
stress [7, 8]. Specifically, regions located near the branch points and along inner curvatures, 
are most susceptible. Generally, the most area affected are the abdominal aorta, coronary 
arteries, iliofemoral arteries, and carotid bifurcations. 
 
Figure 1.1. Pathogenesis of atherosclerosis. In the first step, low density lipoprotein-cholesterol 
(LDL) are oxidized in endothelium. OxLDL stimulate endothelium to express adhesion 
molecules, such as vascular cell adhesion molecule-1 (VCAM-1), P-Selectin and various 
chemokines. Macrophage engulf oxLDL through scavenger receptors and simultaneously, 
leucocytes are activated and recruited. This leads to increase the plaque volume, to promote 
the neovascularization and to stabilize the fibrous plaque by the proliferation of smooth muscle 





necrotic core formation. The proteases secreted from foam cells can destabilize the plaque and 
possibly cause thrombotic events. Adapted from Gargiulo et al [9]. 
 
Complications might arise when the vessel lumen is obstructed, and the blood flow does not 
guarantee sufficient oxygen and nutrient supply to the surrounding tissue. Mainly these 
complications include myocardial infarction, stroke, and peripheral vascular disease; 
pathologies are well known for being listed among the leading causes of mortality in modern 
society [10].  
 
The pathology's initial step and the inflammation involve dysfunction of the endothelium, 
allowing the infiltration and entrapment of Low-Density Lipoprotein (LDL) [5]. The accumulation 
of LDL is due to the increase in the permeability or to the disruption of the endothelium, leading 
to an increase in the accumulation into the intima, resulting in an increased thickness. Another 
factor that causes the intima's thickening is the friction of blood flow in certain points of the 
inner vessel surface (hemodynamic stress) [9]. In fact, spots with low or oscillatory endothelial 
shear stress, located near branch points and along inner curvatures, are the most susceptible 
to these kinds of thickening. LDL, linked by ionic bonds between their Apo-Lipoprotein B and 
proteoglycans in the extracellular matrix, is modified by enzymes and reactive oxygen species, 
turning into oxidized LDL (oxLDL) [11]. Simultaneously, conditions that stimulate the 
endothelium, like dyslipidemia, localized oxidation, inflammatory factors, and hypertension, 
promote monocyte recruitment into the vessel walls. Upon that, adhesion molecules, such as 
E-Selectin, P-Selectin, VCAM-1, and ICAM-1 are secreted which enable the monocytes 
adhesion to the endothelium [12]. Monocytes activated by growth factors, cytokines, and 
modified lipid species, such as oxLDL differentiate into macrophages. The accumulation of 
oxLDL through scavenger receptors (CD36, SRA, SRB) into the macrophages leads to the 
formation of foam cells. [13] This event, consequently, promotes the cytokines (TNF, 
interleukins, and interferon), enzymes (cysteine proteinase, serine proteinase, 
metalloproteinases) and growth factors (PDGF, VEGF, IGF) expression. The complex signaling 





increase the inflammatory process, the proliferation, and the migration of smooth muscle and 
endothelial cells within the intima.  
Atherosclerosis progression ultimately leads to foam cell death and increase plaque volume. 
The secretion of chemokines and cytokines attracts more monocytes, turning into foam cells, 
further fueling the inflammation and plaque volume. Eventually, plaque destabilization and 
rupture induced by the foam cells' proteolytic activity might lead to athero-thrombosis and 
ischemic events such as myocardial infarction or stroke [10]. 
 
1.2. Therapy  
Atherosclerosis is a metabolic disorder characterized by chronic inflammation and 
hyperlipidemia. Starting from this concept, the therapeutical approaches used for the treatment 
of the pathology are based on reducing of cholesterolemia, to mitigate the incidence of plaque 
formation, or on decreasing inflammation. The classical drugs used are: 
 Statins: also known as hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase 
inhibitors, blocking the synthesis of endogenous cholesterol; 
 Fibrates: activating peroxisome proliferator-activated receptors (PPAR), especially 
PPARα. These receptors are involved in the lipid metabolism; 
 Niacin: a nicotinic acid, vitamin B used, alone or combined with statins, reducing the 
plasma VLDL, LDL, and apoB levels in vivo. Recent studies also demonstrated that it also 
increases the ABCA1 levels (a receptor involved in cholesterol efflux)[14]. 
 Endoglin modulator: also known as CD105 or TGF-β type III receptor, has a regulating 
the role of transforming growth factor-β (TGF-β) signaling. The action of this modulator 
reduces the inflammatory response [15].  
 Bile Acid Sequestrates (BAS): polymers preventing the reabsorption of bile salts into the 
enterohepatic circulation pathway after binding them in the small intestine. The depletion 
of bile acids leads to increased cholesterol metabolism for bile salt synthesis (thereby 






During the past years, the cardiology community has focused on treating the responsible 
plaque or the “culprit plaque” for coronary occlusion and death upon detecting the disease. The 
concept of “vulnerable plaque” recently led cardiologists into more in-depth research into the 
disease morphology and biochemical characteristics. This analysis increased the probability to 
identify plaques that could become dangerous in a short time and earlier intervention [17]. For 
a better understanding, imaging techniques including  X-ray angiography, virtual histology 
intravascular ultrasound (VH-IVUS), computed tomographic (CT), single-photon emission 
computed tomography (SPECT), optical coherence tomography (OCT), positron emission 
tomography (PET), and magnetic resonance (MR) are currently being used to understand the 
morphological and functional aspects of the plaques [18]. However, the prevention of possible 
factors that cause vulnerable plaque remains a challenge. The main reason is that multiple 
vulnerable plaques were already developed in patients affected by ischemic heart disease, [19] 
and the inflammatory process is extended in the arterial tree and the myocardium [20]. The 
atheromatous process appears to be supported by the inflammatory one that is not localized 
in the culprit plaque, but it is widespread in the patients' vascular vessels.  
In fact, in the last 30 years, it has been proved that inflammation is a cause and not a 
consequence of the disease [21, 22]. Researchers have started to dedicate their studies 
towards developing new-antiinflammatory therapeutical approaches. Mainly, studies were 
conducted with drugs commonly known for their use in other pathologies, and some of them 
have shown promising results in patients suffering from cardiovascular events [23]. Over the 
last few years, drugs such as Methotrexate (MTX) and Colchicine have received significant 
attention for their potential use in Cardiovascular Diseases. In this context, the anti-
inflammatory action of both the drugs has been exploited in the Cardiovascular Inflammation 
Reduction Trial (CIRT) –Methotrexate– and the low dose Colchicine (LoDoCo) clinical trials 
[23].   
  





The inflammatory activity associated with Atherosclerosis is not confined to a small lesion but 
occurs throughout all vascular tree lesions. At the same time, vulnerable plaques are relatively 
rare, and the inflammation may play a causal role in the plaque rupture only if it is located within 
a thin fibrous cap [24]. Thus, Macrophages are considered key players in the whole process. 
They are an integral part of innate and adaptive immunity. Macrophages could assume either 
proinflammatory (M1) or anti-inflammatory (M2) phenotype [25]. An overproduction of the M1 
phenotype causes cytokine secretion, like tumor necrosis factor (TNF)-α and is linked to the 
development of atherosclerosis [26]. Under these conditions, inflammation and different stress 
forms cause hypoxia and an increase of extracellular adenosine accumulation [27]. There is a 
growing evidence that adenosine receptors are crucial in anti-inflammatory response for 
increasing the protection from ischemic damage in several organs [27]. The agonist effect on 
the adenosine receptors causes the suppression of cells involved in inflammation, like natural 
killer cells, T cells, macrophages, monocytes, and neutrophils. The inhibition of leukocytes and 
platelet activation also decreases cytokine production and may have protective action against 
ischemic injury [28]. Simultaneously, stimulation of the adenosine receptor prevents foam cells 
formation, promoting the synthesis of receptors involved in the expulsion of lipoprotein from the 
macrophages [29]. Under normal conditions, macrophages represent the primary regulator of 
plasma lipoprotein metabolism and content. Specifically, they balance the lipoprotein 
concentration through scavenger receptors, such as CD36 and SR-A1 (for the internalization 
of the lipids) and ATP-Cassette (ABC) transporters, such as ABCA1, ABCG1 and SR-B1 for 
the expulsion of cholesterol from the cells [30]. In contrast, under inflammatory conditions, the 
internalization of ox-LDL and the decreased expression of ATP Cassette, gradually increase 
the intracellular amount of lipids, promoting foam cells formation [31]. 
 
Methotrexate (MTX), a conventional chemotherapeutic drug that currently represents the first-
line option in inflammatory diseases like rheumatoid arthritis (RA) and psoriatic arthritis, was 
proposed for the treatment of atherosclerosis [32]. 
Bulgarelli et al, were the first to demonstrate the effect of MTX in the atherosclerotic lesions. 





and treated weekly by intravenous injections of MTX (4 mg/kg). The treatment produced a 
reduction of the lesion area by 75% and the intima-media ratio by 2%. Consequently, it led to 
the inhibition of macrophage migration in the intima by 50% and the reduction of apoptotic cells 
by 84% [33]. Also, Nishina et al, demonstrated the reduction of IL-6 in patients affected by RA 
after the use of MTX. Specifically, 49 women suffering from RA were treated for three months 
with the drug. At the end of their study, the levels of plasma IL-6 and TNF-α levels were 
measured. Data obtained showed a reduction of plasma IL-6, but not TNF-α, after MTX 
treatment [34]. Due to the widespread use of low dose of MTX on patients in several studies, 
the American College of Rheumatology collected guidelines regarding the patients' risk, doses, 
and regimes [35]. From the data, the use of this drug was associated with a 21% lower risk of 
total CVD and 18% lower risk of myocardial infarction compared to patients receiving other 
disease-modifying anti-rheumatic therapy [36]. These findings strongly strengthened the idea 
that the treatment of inflammation may reduce the risk of CVD. 
Further studies confirmed that MTX reduced the inflammation in patients with RA by decreasing 
interleukin (IL)-1β, IL-1 receptor antagonist, IL-6, and TNF-a [37, 38]. The use of MTX for 
Atherosclerosis treatment is also supported by the increase in the adenosine release and 
subsequent agonistic effect of the adenosine on the A2A receptor [39, 40]. As a result of this 
stimulation, an increase in the expression of proteins involved in reverse cholesterol transport, 
such as 27-hydroxylase and adenosine 5′-triphosphate-binding cassette transporter A1 







   
Figure 1.2. Mechanism of action of MTX. Adapted from Coomes et al [39]. 
 
The stimulation of A2A receptor not only inhibits the early inflammatory processes but also 
resulted in a marked and sustained attenuation in neointimal formation [41]. 
Simultaneously, it reduced the expression of vascular cell adhesion molecule-1 and 
intercellular adhesion molecule-1, responsible for the development of atheroma [41].  As a 
consequence, the adenosine receptor stimulation limited foam cells formation by promoting 
lipoprotein expulsion from the macrophages [27]. 
MTX showed anti-inflammatory activity on macrophages, by lowering the production of 
proinflammatory cytokines; increasing the levels of adenosine monophosphate adenosine; 
suppressing cytokine secretion by the immune cells and protecting actions against ischemic 
injury [28]. All these observations formed the foundation for the clinical trial CIRT, which 






1.4.  CIRT/CANTOS 
The Cardiovascular Inflammation Reduction Trial (CIRT) was a clinical trial conducted to 
investigate the impact on the reduction of strokes, heart attacks, or the death of people 
affected by metabolic syndrome by weekly administration of a low dose of MTX (target 
dose 15 to 20 mg per week) Table 1.1. People with a history of myocardial infarction or 
coronary artery disease with metabolic syndrome or type 2 diabetes were recruited as 
participants for the trial. From the 9321 potential participants, 6158 patients were chosen, 
and 4786 completed the trial. From this, 61% of the participants had a previous MI and the 
remaining 39% suffered from multivessel coronary disease. The results also demonstrated 
that a lower MTX dose did not decrease the levels of IL-1β, IL-6, or high-sensitivity C-
reactive protein. MTX was not associated with a higher reduction of cardiovascular events 
compared to patients who were administered the placebo. Additionally, the use of MTX 
showed a higher incidence of non-basal-cell skin cancers, and a reduction in leukocyte 
counts and hematocrit levels, and elevations in liver enzyme levels [42]. 
Despite expected result were not met, and MTX was found not efficacious for the specific 
purpose, further reasoning needs to be associated to this results in order to correctly interpret 
it. Several studies had previously demonstrated the anti-inflammatory effect of MTX in 
atherosclerosis. Thornton et al. showed that a low dose of MTX (1 mg/kg/week) in the 
(NZW×BXSB)F1 murine model of inflammatory vasculopathy could add protection 
against cardiovascular events [43]. De Vecchis et al, demonstrated in his study that chronic 
use of MTX in patients with psoriatic or rheumatoid arthritis (RA) decreased the risk of 
ischemic cardiovascular events [32]. For this study, only adults receiving methotrexate at 
least for one year was taken into consideration. The cardiovascular endings of patients who 





that MTX, at low doses, was associated with a 27% decrease of the risk of ischemic 
cardiovascular events [32]. 
The development of proper nanoparticles (NPs) for the systemic introduction in the 
organism but aimed to a specific site constitute one of the main motives of Nanomedicine. 
In fact, nanoparticles have been demonstrated to be useful for systemic delivery and 
controlled release of therapeutic agents in a number of biomedical applications [44]. Thanks 
to their physic-chemical and geometrical properties, these nanovectors have the 
opportunity, by moving within biological systems, to transport and deliver different 
biomedical payloads for the treatment, prevention, and diagnosis of many diseases. They 
are able to efficiently to target disease sites, increasing the therapeutic efficacy and 
decreases the side effects in neighbor (healthy) cells [45]. Moreover, it is well known that 
spherical NPs with a diameter of a hundred nanometers are easily and rapidly engulfed by 
macrophages [46]. In another study, the delivery of MTX using nanoparticles increased the 
therapeutic effect on atherosclerosis. Polymeric nanoconstructs loaded with MTX, at 0.06 
mg/mL, significantly reduced the production of IL-6 and TNF α in vitro experiments. In the 
ApoE−/− mice, fed with a high-fat diet up to 17 weeks, 4 weeks of treatment with biweekly 
administration of MTX-nanoparticles reduced the plaque burden  by 50% [47]. Several 
papers showed the capability of MTX loaded nanoparticles in decreasing the side effects of 
the drugs [48, 49]. This mass of data not correlating with CIRT trial lead some experts to 
possible re-interpretations of this study. 
In parallel with the CIRT, another clinical trial (Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study (CANTOS)) was conducted. The objective was to investigate 
if canakinumab, a monoclonal antibody targeting interleukin-1β, reduced the rate of 
recurrent cardiovascular events in patients with a history of myocardial infarction (MI) and 





under stable conditions but with high cardiovascular risk and were treated with lipid-
lowering therapies. Also, included patients with residual inflammatory risk (elevated high-
sensitivity C-reactive protein levels – in median 4.2 mg per liter) [50]. In contrast, CIRT 
had recruited people suffering from metabolic syndrome with median high-sensitivity C-
reactive protein level (hsCRP) that was 1.6 mg per liter. This is an important aspect because 
people with elevated hsCRP generally have the highest risk of cardiovascular disease. In 
particular, in CANTOS, significantly reduced IL-6 and hsCRP levels were observed after 
the canakinumab treatment, while in CIRT, MTX did not present the same result. 
Before starting the CIRT, several papers had highlighted that low MTX dose reduced 
cardiovascular events in individuals with rheumatoid arthritis or psoriatic arthritis [36, 51, 
52]. These patients had existing systemic inflammatory conditions. Also, there was 
evidence in patients affected by RA that the use of methotrexate reduced the C-reactive 
protein level. [53]. Is it possible that CIRT results were a consequence of selecting patients 
with low hsCRP? Is it possible that MTX could reduce hsCRP only when its levels are high? 
Maybe, the criteria for the patient selection were not adequate. New studies to understand 
these factors will be needed and specifically the influence of the hsCRP in CVD. Studies 
with other anti-inflammatory drugs could complement these observations. 
 
1.5.  The mechanism of action of Colchicine in 
Atherosclerosis 
The release of cytokines in the lesions and the ability of oxLDL to activate innate and 
adaptive immunity leads to the classification of atherosclerosis as an immune-mediated 
disorder [54]. Blocking cholesterol regulating genes leads to the pathology, while the 
interference with the inflammatory mediators hinders the pathogenesis [55, 56]. Another 





atherosclerosis, is the inflammasome. Inflammasome is a cytoplasmic multiprotein 
intracellular complex that is found in different forms, in which the most important segment 
is the leucine‐rich repeat–containing receptor (NLR) family pyrin domain‐containing 3 
(NLRP3) [57]. Nowadays, the idea that the inflammasome is involved in lipid‐driven 
vascular inflammation is increasing. Studies involving the  NLRP3 were done in 
macrophages that are over recruited in the human carotid atherosclerotic plaques [58]. The 
activation of the NLRP3 caused the maturation and the release of the IL-1β and IL-18 
(major contributors of atherogenesis) [59, 60]. There is an overexpression of these cytokines 
in human atherosclerotic plaques compared to the normal condition [61, 62]. Several studies 
demonstrated that the genetic ablation of the IL-18 modulated atherosclerosis development, 
while, the administration of recombinant IL-18 promotes plaque growth [62, 63]. IL-1β is 
a proinflammatory cytokine involved in different inflammatory disorders [64]. Its 
contribution in the atherogenesis was both local and systemic, and it was discussed in the 
review by Libby et al. published in the Journal of the American College of Cardiology  [65]. 
IL-1β is released by different cells types involved in the atherosclerosis process, such as 
endothelial cells, vascular smooth muscle cells, macrophages, and the liver [66]. The 
NLRP3 is able to promote the release of the IL-1β and IL-18 and increases the migratory 
capability of the macrophages, and stimulates the lipid deposition in lysosomes. These 
events induce the formation of foam cells, and consequently, the formation of the plaque 
[67].  
Colchicine is an alkaloid extracted from the plant Colchicum autumnale. It is known for its 
therapeutic use in gout and Familial Mediterranean Fever (FMF). A study following these 
patients noticed a reduction of myocardial infarctions after the use of Colchicine [68]. 
Moreover, Crittender et al. conducted a retrospective, cross-sectional study on gout patients 





(MI) after using the drug. The result showed that patients treated with Colchicine had a 
significantly lower prevalence of MI [69]. Also, Langevitz et al., led another study on 
patients affected by FMF, studying the presence of ischemic heart disease and its risk 
factors. The study followed 290 patients with FMF and 2 control groups (the spouses of the 
FMF and other patients with inflammatory diseases). This study suggested that colchicine 
was able to reduce the incidence of CVD. In fact, patients treated with the alkaloid had the 
same probability of the normal population of having ischemic heart disease [70]. Both 
studies demonstrated the drug's safety and effectiveness when used continuously over 
decades as secondary prevention of acute inflammatory flares [71, 72]. Nidorf et al. showed 
that a low dose of colchicine was able to reduce high-sensitivity C-reactive protein levels 
in patients with stable coronary disease [73]. In general, Colchicine has a large spectrum of 
effects in the cells that targets multiple aspects of the innate immune response. The 
administration of colchicine showed a stronger effect in the inhibition of inflammasome 
activation and IL-1β secretion proving a rational for its use in atherosclerosis treatment 
Figure 1.3 [54, 74, 75]. All these results are the primary motivation for the studies based 
on the Low-Dose Colchicine (LoDoCo). They suggest that the drug may act on the 
prevention of cardiovascular events by inhibiting the inflammation in patients with unstable 






Figure 1.3. Mechanism of action of Colchicine 
 
1.6. LoDoCo 
The Low-Dose Colchicine (LoDoCo) was a clinical trial conducted by the Heart Research 
Institute of Western Australia that was approved in 2008 [76]. The objective of the study 
was to investigate whether colchicine (0.5 mg/day) reduced the risk of cardiovascular 
events in patients with clinically stable coronary disease. Table 1.1. 532 patients with 
angiographically proven coronary disease were recruited and they were under treatment 
with aspirin and/or clopidogrel (93%) and statins (95%). Colchicine or placebo was 
randomly assigned to them for a median of 3 years [76]. This first trial demonstrated that 
colchicine added to a standard therapy in patients with a stable coronary disease, decreased 
the cardiovascular events. These effects were reached under a scenario of wide use of 
effective secondary prevention strategies, such as high-dose of statins. These results also 
suggested that this drug may have a role in the prevention of cardiovascular problems 
caused by the instability of the plaque. This can be associated with the inhibition of 
inflammation, recognized in unstable native coronary plaques [77]. In particular, the study 





chemotaxis, ingress, and activation within a proinflammatory environment. Activated 
neutrophils could destabilize a plaque in patients with coronary syndromes [77]. Despite 
some early intolerance problems, this study suggested that colchicine (0.5 mg/daily) could 
be a candidate for the secondary prevention in patients with stable coronary disease.  
Moreover, results from CANTOS supported the hypothesis that reducing the effects of 
activation of the NLRP3 inflammasome by targeting the IL-1β with the monoclonal 
antibody canakinumab. This led to the creation of a new clinical trial for more in depth 
study into the effect of the colchicine on patients with coronary disease. A second Low 
Dose Colchicine (LoDoCo2) started. 5522 patients, with stable coronary artery disease and 
already showed a tolerance for 30 days of colchicine treatment, were recruited and were 
randomly administered with colchicine 0.5 mg daily or matching placebo [78]. Attention 
was mainly focused on CV death, myocardial infarction, ischemic stroke, and ischemia-
driven coronary revascularization. Colchicine has been revealed to decrease post-operative 
atrial fibrillation and, perhaps, improve metabolic status in diabetes. These last conditions 
are common inflammatory diseases affecting patients with coronary artery disease [79, 80]. 
Another observation that emerged from the study, was that colchicine didn’t affect lipid 
levels and blood pressure [78]. The LoDoCo2 is ongoing and will provide data on the 
efficacy of low-dose colchicine administration and safety for secondary prevention in 
patients with stable coronary artery disease. 
With the evidence that i) canakinumab reduced adverse cardiovascular events by the 
targeting of the IL-1 β, and ii) Colchicine decreased the responsiveness of neutrophils to 
inflammatory signals and the activation of NLRP3, formed the basis of the clinical trial 
Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI). In this trial, researchers 
investigated the reduction of inflammation in patients following an acute MI through the 





of Colchicine in patients after a MI would decrease C-reactive protein (CRP) levels after 
30 days of treatment, hence reducing the risk of recurrent vascular events [81]. With this 
trial, clinicians wanted to understand the effect of IL-6 (that regulate the inflammation and 
the hepatic CRP production [82]), and the safety and tolerability of colchicine. Their report 
showed that a low dose of Colchicine was well tolerated and, was safe after acute MI, but 
they were unable to find a significant reduction in the median level of CPR after 30 days 
[81].  
From the LoDoCo pilot study, another clinical trial emerged, the Cardiovascular Outcomes 
Trial (COLCOT). This trial investigated the effect of low dose of Colchicine in individuals 
who had a myocardial infarction within 30 days before enrollment. A total of 4745 patients 
were recruited and were followed for a median of 22.6 months. The objective was to 
understand if a low dose of colchicine (0.5mg/daily), was able to reduce the risk of an 
ischemic cardiovascular event. The results of the trial highlighted a decrease of stroke, or 
urgent hospitalization for angina leading to coronary revascularization and death from 
cardiovascular causes, or cardiac arrest. Besides these, it emerged that people treated with 
this drug reported episodes of diarrhea and pneumonia [83]. 
Currently, two other ongoing randomized clinical trials “COVINCE” and “CLEAR-
SYNERGY” aim to evaluate the effect of colchicine in patients with cerebrovascular 
disease and acute coronary syndrome Table 1.1. Colchicine for Prevention of Vascular 
Inflammation in Non-cardio Embolic Stroke (CONVINCE) evaluates the use of 0.5 mg/day 
of Colchicine in adults over 40 years of age that have suffered an ischemic stroke or 
transient ischemic attack. This study has the objective to prevent non-fatal recurrent 
ischemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina, 
and vascular death after ischemic stroke or transient ischemic attack (TIA) not caused by 





STEMI/SYNERGY (CLEAR-Synergy), a multi-international trial  center 2x2 randomized 
placebo-controlled colchicine and spironolactone trial in patients affecting within 24 hours 
of ST Elevation Myocardial Infarction [85] is currently ongoing. 
Table 1.1. Clinical Trials of Methotrexate and Colchicine 
 
 
1.7. Conclusion and future prospective: combination and 
nanomedicine strategy. 
The evidence produced from the several experimental and human studies, over the last 
decade, suggests that inflammation has an important role in the onset and progression of 
atherosclerosis and thrombosis. In particular, the chronic inflammation, immune activation, 
and the oxidative stress at the arterial wall characterized the atherosclerosis [86]. Besides, 
all cardiovascular risk factors activate these events at some stage, promoting the beginning 





endothelium roles is the release of nitric oxide (NO) under stress conditions. The relevant 
role of NO on the endothelium is the maintenance of vascular homeostasis. Based on these 
considerations, Robert G. Weiss of Johns Hopkins University, started a clinical trial where 
he studies the function (Inflammation and Coronary Endothelial Function) of coronary 
arteries, specifically the endothelium, using magnetic resonance imaging (MRI). The study 
will evaluate the flow and the dimension of the artery in the two conditions: normal and 
under stress. The researchers believed that inflammation influenced the normal function of 
the artery. For this reason, they will test the combinatorial effect of Methotrexate/Colchicine 
on the artery in order to produce a reduction in inflammation [88]. This study is ongoing. 
Another ongoing clinical trial follows the Treatment of Patients With Atherosclerotic 
Disease With Methotrexate-associated to LDL - Like Nanoparticles. The goal is to 
investigate the safety and efficacy of an anti-inflammatory agent, methotrexate, in a 
cholesterol-rich non-protein nanoparticle (MTX-LDE) in patients with stable coronary 
disease [89]. 
A work was recently published on the use of lipid modified Methotrexate, and its delivery 
by two types of nanosystems: spherical polymeric nanoparticles and liposomes.[90] With 
both formulation, in vitro results showed that the MTX modulated the trafficking of lipid, 
thereby decreasing the inflammation over time. Especially, the treatment revealed that 
MTX, delivered with nanoparticles, decreased the growth of the plaque in ApoE-/- after a 
brief treatment [90].  Gomes et al. also showed the efficient effect of MTX delivered by the 
nanoparticles (solid lipid particles) in atherosclerosis. In fact, in this work paclitaxel loaded 
nanoparticles were tested with and without nanoparticles containing MTX on thirty-eight 
rabbits (fed 1% cholesterol chow for 8 weeks). The results showed that the co-delivery had 
the ability to increase the regression of plaque areas more than the delivery of nanoparticles 





with MTX reduced the presence of macrophages in aortic lesions and lowered the level of  
TNFα, thus accelerating plaque reduction after cholesterol feeding, without any observed 
toxicity compared to the injection of nanoparticles with paclitaxel [49]. 
Zoghebi et al., investigated the use of Colchicine, modified with a peptide 
(FDAIAEIGNQLYLFKDGKYW), on an in vitro model of crystal-induced inflammation. 
Using this peptide, they were able to target the macrophages and reduce the inflammation 
more than free Colchicine (also reducing the ROS generation and IL-8 secretion). They also 
demonstrated that the modified Colchicine reduced the cytotoxic effect of Colchicine while 
preserving its anti-inflammatory activity [91]. Furthermore, Chen et al., developed an 
intramyocardial delivery system of Colchicine, using a thermo-sensitive polymer hydrogel, 
to treat MI. The in vivo study showed that this system alleviated cardiac inflammation and 
inhibited myocardial apoptosis and fibrosis. Moreover, the mouse survival increased 
compare to the free administration of Colchicine, at the same time reducing the severe 
systemic toxicity [92].  
Atherosclerosis is a silent, progressive disease, and many times, it is very difficult to detect 
by current imaging methods at its early stage. Current approaches to treat the disease are 
systemically and this could be associated with side effects. The use of anti-inflammatory 
drugs combined with the nanomedicine could represent an innovative strategy to overcome 
this problem. Methotrexate and Colchicine are promising therapeutic agents for the clinical 
treatment of inflammatory disease, particularly pathologies involved in cardiovascular 
diseases. The use of the nanoparticles may enhance the stability and bioavailability of the 
drugs and improve their pharmacokinetics, improving the effect of anti-inflammatory 
drugs. Future studies are expected to investigate significantly deeper into the effects of 











Chapter 2  
 
Synthesis of Two Methotrexate Prodrugs for Optimizing 




Methotrexate (MTX), a compound originally used as an anticancer drug, found applications 
also in a broad variety of autoimmune disorders thanks to its anti-inflammation and 
immunomodulatory functions. The broad application of MTX is anyway limited by its poor 
solubility in biological fluids, its poor bioavailability, and its toxicity. In addition, encapsulating 
its original form in nanoformulation is very arduous due to its considerable hydrophobicity. In 
this work, two strategies to efficiently encapsulate MTX into liposomal particles are proposed 
to overcome the limitations mentioned above and to improve MTX bioavailability. MTX solubility 
was increased by conjugating the molecule to two different compounds: DSPE and PEG. These 
two compounds commonly enrich liposome formulations, and their encapsulation efficiency is 
very high. By using these two prodrugs (DSPE-MTX and PEG-MTX) we were able to generate 
liposomes comprising one or both of them and characterized their physiochemical features and 
their toxicity in primary macrophages. These formulations represent an initial step to the 
development of targeted liposomes or particles, which can be tailored for the specific 








Methotrexate, 2,4-diamino-N10-methyl propylglutamic acid (MTX) is a folic acid antagonist, 
widely used as therapeutic agent [93, 94]. The molecule is a weak dicarboxylic acid with a 
molecular weight of 454.5 g/mol. It possesses pKa values of 4.7–5.5 and low permeability (Clog 
P = 0.53) with poor aqueous solubility (0.01 mg/mL). The first form of MTX, known as 
amethopterin, was originally synthesized in 1947. In the following years, after a slight 
modification of its chemical structure, it was first applied for the treatment of life-threatening 
neoplastic diseases (acute lymphoblastic leukemia, breast cancer, choriocarcinoma) [95, 96]. 
Being an analog and antagonist of folic acid, MTX competes for the binding site of folate on 
dihydrofolate reductase (DHFR), an enzyme required in the process of DNA and RNA 
production [97-99]. At lower dosages (1:50 – 1:100), it also found application in a series of other 
diseases: Rheumatoid Arthritis (RA), Multiple Sclerosis, Vasculitis, Systemic Lupus 
Erythematosus, Psoriasis, Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis [28, 97]. It 
is widely accepted the positive effects in the treatment of RA depends by MTX anti-
inflammatory and immunomodulatory activity. These many applications of MTX are limited by 
the intrinsic features of the molecule, which impede harnessing the full potential of this drug. 
As mentioned before, MTX possesses poor water solubility and low permeability, which 
determines its low bioavailability [95, 100]. Its uptake by cells is in fact extremely limited as 
demonstrated by in vitro assays [101]. Upon administration, MTX is rapidly excreted by the 
kidneys, showing a short half-life, and its plasma concentration drops rapidly upon intravenous 
administration, being nearly undetectable after only 4 h [94, 102, 103]. For the mentioned 
reasons, out of a discrete administered dose of drug, the amount effectively reaching its 
biological target tissues is supposed to be very low. Moreover, even when used at low dosages, 
MTX is not free from drug toxicity; rather than inefficacy, toxicity is the main cause of MTX 
treatment withdrawal [96]. MTX toxic effects can be severe and include hepatotoxicity, liver 





considered, to optimize its use, it would be beneficial to develop novel formulation and targeted 
therapies to maximize its therapeutic effect, reduce its dosage and thus its toxic effects.  
In the recent past, various Novel Drug Delivery Systems (NDDS) such as microemulsions [108], 
nano-conjugates [109], nanoparticles [110], nanocapsules [111], polymeric micelles [112], pH-
responsive polymersomes [113] and liposomes [101, 114] were proposed. The development 
of these nanoformulations allowed to the introduction of novel targeting and release strategies 
and to the improvement of MTX loading through some modification of the molecule. Despite 
these valuable advancements, MTX loading still remained suboptimal and a series of 
characterizations and studies are needed to approve and safely apply the majority of these 
novel technologies. Among the listed formulations, liposomes represent one of the most 
common nanocarrier for targeted and untargeted delivery [115]. They are mainly constituted 
by endogenous compounds, represent a very well tolerated drug delivery system, and are 
generally considered as pharmaCologically inactive. These formulations currently represent a 
more efficient and less harmful alternative to conventional chemotherapy and possess the 
potential to positively influence therapeutic efficacy and reduce drug toxicity [116]. Their use 
improves the biodistribution of therapeutics to the diseased site, increases cell uptake and 
stabilizes the vectored compounds by protecting them from degradation and early inactivation 
[117]. Their biomedical application have improved the therapy of a broad variety of pathologies, 
and their continued translation success is progressing over time [117, 118]. 
In this work we modified MTX molecule with the aim to furtherly improve it’s loading into 
liposomes. In particular, we generated two prodrugs by covalently binding MTX to DSPE 
(DSPE-MTX) or polyethylene glycol (PEG-MTX). Three different liposomal formulations were 
obtained by loading into liposomes the two prodrugs, individually or in combination. The physio-
chemical features of these MTX-Liposomal formulations, generated by loading into liposome 
DSPE-MTX, PEG-MTX or both were acquired and compared. The stability of the formulations 
was analyzed in neutral or acidic environment and the prodrug release profile was analyzed. 
The uptake of Cy5 loaded liposomes in primary Bone Marrow Derived Macrophages (BMDM) 
from rat was studied: confocal imaging, revealing liposome internalization and flow cytometry 





toxicity analysis was performed in BMDM, in order to assess any possible difference among 
the formulations. 
 
2.3. Materials and Methods 
 
Materials: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-Hydroxysuccinimide 
(NHS), Triethylamine (TEA), was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Methotrexate (MTX) and NH2-PEG (1K) was bought by AlfaAesar (Haverhill, MA, USA). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinyl(polyethylene glycol)-2000] (DSPE-
PEG-COOH), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-NH2), 1,2-
Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti Polar Lipid 
(Alabaster, AL, USA). All reagents and solvents were used without further purification. Cy5 was 
purchased from Luminoprobe (Hunt Valley, MD, US). 
 
Synthesis of DSPE-MTX. 
DSPE-MTX was synthesized as reported by Ferreira and coworkers with some modifications 
[49]. Briefly, 30 mg of MTX was incubated with 1eq of 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 1eq. of N-Hydroxysuccinimide (NHS) in 2mL 
Dimethyl sulfoxide (DMSO) for 30 minutes, at room temperature. 0.98 eq DSPE-NH2 dissolved 
in 0.5mL DMSO were added. The reaction was left to stir for 72 hours after added a catalytic 
amount of triethylamine (TEA). The mixture was washed three times with cold diethyl ether. 
Finally, the pro-drug was lyophilized and stored at -20°C. 
 
Synthesis of PEG-MTX.  
For PEG-MTX synthesis, 20 mg of NH2-PEG (1,000 Da) were dissolved in a mixture of 
dichloromethane (DCM) and MeOH (2:1 Ratio). 0.98 eq of MTX was dissolved in 200 mL of 
dimethylformamide (DMF) and added to the previous solution. A catalytic amount of 





product was precipitated with cold diethyl ether, and then washed 3 times with cold diethyl ether 
getting the final product with a yield of 90%. More details of this procedure can be found in 
previous author's literature [119]. 
 
Synthesis of DSPE-Cy5.  
DSPE-Cy5 was synthetized as reported elsewhere [119]. Briefly, DSPE-NH2 (15 mg) was 
dissolved in dichloromethane (DCM)/Methanol (MeOH ), 2:1 v/v. Cyanine-5 NHS ester (0.98 
eq) was dissolved in 200 ml of dimethylformamide (DMF) and added to the previous solution. 
Triethylamine (TEA) was added in order to catalyze the reaction, stirring was maintained for 16 
h. cold diethyl ether was used for precipitating the product which was then washed three times 
with cold diethyl ether obtaining the final compound with a yield equals to 90%. 
 
Determination Log P.  
DSPE-MTX and PEG-MTX Log P was determined recurring to the help of three computational 
software's: Biovia Draw, DASSAULT SYSTEMES, https://www.3ds.com/. VCCLAB, Virtual 
Computational Chemistry Laboratory, http://www.vcclab.org, 2005. ChemSketch, ACD/LABS; 
https://www.acdlabs.com/. Log P. is given by the following equation:  





Synthesis of MTX liposomes (MTX-LIP) and Cy5 liposomes (Cy5-LIP). 
Liposomes (LIP) were prepared by thin-layer evaporation (TLE) [31]. Briefly, DPPC, 
cholesterol, DSPE-PEG (6:3:1) (total amount 40 mg), and DSPE-MTX/PEG-MTX or both 
prodrugs (1 mg of prodrug) were dissolved in chloroform in a round-bottomed flask. After the 
evaporation of the organic solvent at 60° under reduced pressure, the lipid film was left under 
the hood overnight to remove any trace of residual solvent. The lipid film was hydrated with 2 
mL of HEPES buffer (pH=7.4, 10 mM) and then subjected to three alternate cycles (3 min each) 
of warming at 60 °C (thermostated water bath) and vortexing at 700 rpm. The sample was 





For the preparation of Cy5-LIP, DSPE-Cy5 was used instead of the prodrugs. More in details, 
0.3 mg of DSPE-CY5 were dissolved in chloroform together with lipids and cholesterol in a 
round-bottomed flask; the same procedure was followed. The purification step to remove the 
excess of Cy-5 was conducted by ultracentrifugation (1h, 45,000 rpm). All the formulation 
obtained were freshly used or stored at 4°C overnight as concentrated dispersions. 
 
Liposome morphological characterization.  
SEM Characterization: Liposomes were fixed for 2 h in 2% glutaraldehyde in 0.1 M cacodylate 
buffer. After fixation, the samples were washed twice with the same buffer and post fixed for 
1h in 1% osmium tetroxide, in 0.1 M cacodylate buffer. After several washes with distilled water, 
samples were subsequently dehydrated in a graded ethanol series, 1:1 ethanol: 
hexamethyldisilazane (HMDS), and 100% HMDS and dried overnight. Samples were sputtered 
using gold. SEM images were Collected using JEOL JSM-7500FA (Jeol, Tokyo, JAPAN), 
operating at 5 kV of accelerating voltage.  
TEM Characterization: Transmission electron microscopy (TEM) micrographs were acquired 
using JEOL JEM 1011 (Jeol, Japan) electron microscope operating with an acceleration 
voltage of 100 kV and recorded with a 11 MegaPixel fiber optical charge-coupled device (CCD) 
camera (Gatan Orius SC-1000). LIP was diluted 1:100, dropped on 150-mesh glow discharged 
'Ultrathin’ carbon-coated Copper TEM grids and dried. Dried TEM samples were negatively 
stained using 2% Uranyl Acetate aqueous solution. 
 
Particles size, surface charge and stability characterizations.  
Particle size, size distribution and ζ-Potential of all the formulations were measured using 
Dynamic Light scattering (DLS). For stability studies, 1 mL of each formulations was put in 9 
mL of PBS (pH=7.4, 1X) or slightly acidic buffer (pH = 6.5, 1X) (final volume = 10 mL) in 
physiologic temperature (37 ± 2°C), under agitation. At specific time intervals of 1, 2, 3, and 4 






Drug loading and release analysis.  
To measure the MTX encapsulation efficiency (EE), samples were destroyed with cold 
methanol, left to dry, dissolved in acetonitrile (AcN)/H2O (1:1, v/v), and analyzed by high-
performance liquid chromatography (HPLC) (Agilent 1260 Infinity, Germany) equipped with a 
100 μL sample loop injector. A C18 Column (2.1× 250 mm, 5 μm particle size, Agilent, USA) 
was used for the chromatographic separation. MTX was eluted under isocratic conditions using 
a binary solvent system [H2O + 0.1% (v/v) TFA and AcN + 0.1% (v/v) TFA 43:57 v/v] pumped 
at a flow rate of 1.0 mL/min. The ultraviolet (UV) detection was set at 430 nm. 
EE was determined using the following equation:  
𝐸𝐸 (%) =
𝑀𝑇𝑋 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑀𝑇𝑋 𝑖𝑛𝑖𝑧𝑖𝑎𝑙 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
× 100 
 
To study MTX and Cy5-release kinetics, 200 μL of MTX-LIP or Cy5- LIP solution were placed 
into Slide-A-Lyzer MINI dialysis microtubes with a molecular cutoff of 10 kDa (Thermo 
Scientific) and dialyzed against 4 L of PBS buffer (pH 7.4, 1X). For each time point, three 
samples were collected and dried. LIP samples were destroyed with cold methanol, left to dry, 
dissolved in AcN/H2O (1:1, v/v), and analyzed by HPLC for the MTX. The experimental data 
were fitted using different mathematical models: the zero-order, the first-order, the Higuchi, the 
square root, the two-phase Weibull, and Korsmeyer-Peppas models [37, 38]. 
 
Cy5 Loading and release analysis.  
For determining DSPE-CY5 encapsulation efficiency (EE), liposomes were destroyed by 
adding cold methanol. After solvent evaporation the destroyed formulation was dissolved in 
acetonitrile (AcN) and analyzed at the spectrophotometer (ʎ=640 nm). EE was determined 
using the following equation: 
 
𝐸𝐸 (%) =
𝐷𝑆𝑃𝐸 − 𝐶𝑌5 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠







For studying DSPE-Cy5-release kinetic, 200 μL DSPE-Cy5-LIP suspension were placed into 
Slide-A-Lyzer MINI dialysis microtubes with a molecular cutoff of 10 kDa (Thermo Scientific) 
and dialyzed against 4 L of PBS buffer (pH 7.4, 1X). For each time point, three samples were 
collected and dried. Samples were subsequently destroyed with cold methanol and solvent was 
left to dry. The sample were than dissolved in AcN and analyzed at the spectrophotometer 
following the indications used for EE de-termination. 
 
Bone Marrow Derived Macrophages harvesting.  
BMDMs from rats were cultured at 37°C in 5% CO2, in high-glucose DMEM, supplemented 
with 15% FBS and 1% L-glutamine, according to ATCC instructions. Cells were isolated by the 
following procedures, also indicated elsewhere [50, 51]. After sacrificing the animal, femurs 
were explanted, cleaned from surrounding tissues, and washed in PBS (Thermo Fisher 
Scientific, USA), and a cut was performed at both ends. PBS was used for flushing the cavities 
to harvest cells, and the sample was centrifuged for 10’ at 800 RPM at 4°C. Cells were plated 
in media supplemented with macrophage Colony-stimulating factor (mCSF) (10 ng mL–1) 
(Sigma-Aldrich, USA). Three days after media was completely replaced after one wash in PBS 
and the following day, cells were scraped, counted, and seeded for being furtherly processed. 
The procedures were conducted following the guidelines of the Institutional Animal Care and 
Use Commit-tee of IIT. 
 
Confocal Fluorescent Microscopy Imaging.  
Confocal images were obtained using a Nikon-A1 confocal microscope (Nikon Corporation, 
Japan). Cy5-DSPE was used in the fabrication step of liposomes, allowing their visualization 
at confocal microscope. Liposomes were suspended in HEPES Buff-er. 65000 BMDM were 
seeded into each well of a Nunc Lab-Tek II chamber slide system (Thermo Fisher Scientific, 
USA), maintaining culturing conditions, as described above. Cells were treated with 10 µL of 
Cy5-LIP for 30’. To favor the homogeneous distribution of the particles in the wells, all the 
treatments were performed by sus-pending liposomes in an adequate volume of culturing 





After 30’, the culturing medium was removed, and cells were washed in PBS (Thermo Fisher 
Scientific, USA). Fixation was performed using a 3.7% solution of paraformaldehyde (Sig-ma-
Aldrich, USA) for 5 min. Cell Mask was used to stain the plasma membrane and nuclei were 
stained using DAPI (Thermo Fisher Scientific, USA). A z-stack section was acquired using a 
60× objective (12 steps of 1000 nm each were acquired). The maximum intensity profile is 
presented in Figure 2.5a. Surface reconstruction of macrophages is shown in Figure 2.5c. 
 
Cell internalization studies.  
Flow cytometry was performed using a FACS ARIA (Becton Dickinson, USA). 200000 BMDM 
were seeded into each well of a 12-well plate, maintaining culturing conditions indicated in the 
cell culturing section. Cells were treated for 30’ with different volumes (5, 10, 15, 30 µL) of Cy5-
LIP. After treatment, cells were washed using cold PBS in order to ease the scraping 
procedures. Cold DMEM, high glucose, no glutamine, and no phenol red (Thermo Fisher 
Scientific, USA) was added, and cells were harvested by gentle scraping the plastic bottom (a 
volume of 200 μL of was used). Samples were immediately stored in ice and vortexed right 
before the analysis. 
 
Toxicity Analysis.  
BMDMs were cultured according to the conditions above indicated. Cell viability was 
determined using MTT assay; this assay detects the reduction of MTT [3-(4,5-
dimethylthiazolyl)-2,5-diphenyltetrazolium bromide] (Sigma-Aldrich, USA) by mitochondrial 
dehydrogenase to blue formazan product. Cells were seeded into 96-well plates at a density of 
20 × 103 cells per well and incubated for 24, 48, 72 hours. Cells were treated with different 
concentrations of free MTX, DSPE-MTX, PEG-MTX, DSPE-MTX/PEG-MTX, DSPE-MTX-LIP, 
PEG-MTX-LIP and PEG-MTX/DSPE-MTX-LIP (namely, 0.0064, 0.032, 0.16, 0.8, 4, 10 and 0 
μM of MTX), or empty LIP. For free MTX condition, MTX was pre-dissolved in DMSO due to 
the impossibility to dissolve the compound in culturing media. The MTT solution was added for 





at 570 nm, using 650 nm as the reference wavelength (Tecan, Männedorf, Swiss). The 
percentage of cell viability was assessed according to the following equation: 




Where, AbsT is the absorbance of treated cells and AbsC is the absorbance of untreated cells 
(control). 
 
Statistical Analysis.  
All the in vitro data were represented as the average ± standard deviation (SD) of 3 different 
measurements, unless differently specified. The statistical significant difference was assessed 
using ANOVA test, with Bonferroni’s Multiples Comparison Test as posthoc test. All statistical 
in vitro analyses were performed using GraphPad Prism v.5 (GraphPad Software, USA).  
 
2.4. Results and Discussion 
 
MTX prodrug synthesis and characterizations.  
To improve MTX solubility and loading efficiency into liposomes, two different prodrugs, DSPE-
MTX and PEG-MTX, were developed (Figure 2.1). The two molecules were chosen since they 
are easily incorporated into liposomes and other nanoparticles and are commonly part of the 
formulations themselves. The size of the two molecules was kept similar, being PEG: 1KDa 
and DSPE: 0.748 KDa. For the synthesis of both DSPE-MTX and PEG-MTX, MTX was pre-
activated with a mixture of EDC and NHS, before the conjugation with 0.98 eq. DSPE-NH2 or 
PEG-1k-NH2. A low amount of the substituent was used to avoid the conjugation on MTX 
second carboxylic position. TLC analysis did not show any signal of the bi-substitute product. 
The absence of such compound is most likely due to the steric hindrance created by the bigger 
size of the substituent in the vicinity of the second reaction point. Product purification was 
achieved through precipitation with diethyl ether. Both products were obtained with a yield 





2.1. Table 2.1 reports the formula weight, the exact mass, and the molecular formula and log 
P values of the three compounds.  
 
Figure 2.1. Synthesis of DSPE-MTX and PEG-MTX. 
 
Table 2.1. Summarizes formula weight, exact Mass, Molecular Formula, Log P value (Bovia, 




Log P is defined as the logarithm of a particular ratio of the concentrations of a solute between 
two solvents (for instance, for an octanol–water partition), specifically for un-ionized solutes. 
Three different software (Biovia, VCCLab and ACD ChemSchetch) were used to analyze this 
parameter for MTX and the two generated prodrugs. The software use different combination of 
algorithms to perform the calculatation. Biovia is based on an algorithm which considers the 
ionization states of the molecule [120]; log P is calculated using pKa information for each atom 
in the molecule. VCCLab (ALOGPs) was developed with 12908 molecules from the 





molecules selected by chance from the whole set. The logP prediction accuracy is root mean 
squared error rms=0.35 and standard mean error s=0.26 [121]. ACDLabs uses a consensus 
model for the determination of log P. Applying both Classic algorithms (Based on >12,000 
experimental log P values, by using the principle of isolating carbons) and GALAS algorithms 
(Based on a training set of >11,000 compounds, that provides a value for log P that is adjusted 
with data from the most similar compounds), the consensus algorithm weights the calculation 
to the model best suited for each structure [122]. Results are presented in Table 2.1 and 
reported here for convenience, respecting the software order indicated above. Following results 
were obtained for MTX: log P. = 0.11; -0.91; 0.023, for DSPE-MTX: log P. = 13.84; 7.53; 16.63 
and for PEG-MTX: log P. = -0.67; 0.42; -0.43. The similar results obtained for MTX and PEG-
MTX indicate that these molecules can be equally dissolved in water and organic solvents. 
While for MTX-DSPE, regardless the discrepancy between VCCLab software results and the 
two other software (to be ascribed to the different combination of algorithms used), all three 
programs show that MTX-DSPE is mainly soluble in organic solvents. The higher value of log 
P for MTX-DSPE, is due to the two aliphatic chains of the lipid. These aliphatic chains are very 
hydrophobic and led the software to predict MTX-DSPE to be mainly soluble in the organic 
phase. Instead, the amphiphilic behavior of PEG chain led the software to predict that the chain 
will not influence MTX solubility. 
Experimentally, MTX has shown low solubility in water and organic solvents, such as 
Dichloromethane and Chloroform, which are commonly used to prepare Liposomes. The 
theoretical MTX-PEG log P (log P. = -0.67; 0.42; -0.43) could indicate similar solubility features 
for this compound and naïve MTX (log P. = 0.11; -0.91; 0.023). Nonetheless, MTX-PEG 
showed a more hybrid behavior regarding these solvents, revealing to have higher solubility in 
water and organic solvents with respect to MTX. This is due to the amphiphilic properties of 
this prodrug, which can spontaneously organize in small structures, accordingly to the solvent 
used. This factor is probably not taken into consideration by the software algorithms. Similar 
amphiphilic behavior is observed for MTX-DSPE (log P. = 13.84; 7.53; 16.63) for the same 
capability of self-organizing into small structures, it was possible to dissolve DSPE-MTX at low 





both prodrugs into the liposomes with high yielding, conversely MTX direct loading was not 
successful. 
 
MTX Liposome Assembly and Characterization. 
Liposomes were synthesized via the thin layer evaporation method (TLE), using DPPC, 
cholesterol, carboxyl-terminated DSPE-PEG chains, and the two prodrugs: DSPE-MTX and 
PEG-MTX (Figure 2.2). The DSPE-MTX and PEG-MTX were added during the lipid film 
formation phase. It might be speculated that the DSPE-MTX could intercalate with the DPPC 
and DPSE-PEG chains, considering that the lipid part of DSPE-MTX is identical to DSPE-PEG 
and similar to DPPC [90]. Regarding the localization of PEG-MTX, there are two options: it 
could be intercalated into the lipid membranes, with a similar configuration reported for DSPE-
MTX, or in the inside of the phospholipid bilayer. The loading of the combination of both 
prodrugs increases the complexity of the allocation, making even harder to produce hypothesis 
on their possible disposition inside the liposome. A schematic of the putative structures of the 
three liposomes is proposed in Figure 2.2a. 
 
 
Figure 2.2. a) Schematic representation of liposomes. b) Hydrodynamic diameter of PEG-
MTX-LIP, DSPE-MTX-LIP and Combo-LIP via dynamic light scattering analysis. c) Scanning 
electron microscopy images of PEG-MTX-LIP, DSPE-MTX-LIP and Combo-LIP, respectively 







Table 2.2. Summarizes sizes, PdI, -Potential and encapsulation efficiency (%EE).  
 
DLS analysis showed an average hydrodynamic diameter of 159 ± 3.0 nm, 166 ± 0.6 nm, and 
148 ± 1.0 nm for the DSPE-MTX-LIP, PEG-MTX-LIP, and Combo-LIP, respectively (Figure 
2.2b and Table 2.2). A similar size was reported for empty liposomes (157.8 ± 2.2 nm), 
confirming that lipophilic drug encapsulation cannot affect particle size [123]. All the 
formulations are characterized by a very homogenous population: with a polydispersity index 
(PDI) of ~ 0.15 (Table 2.2). Images of the formulations were acquired by SEM (Figure 2.2c) 
and TEM analyses (Figure 2.S3), confirming formulations sphericity and size. Liposomes 
presented a negative surface electrostatic -potential of -38 ± 0.26 mV, -41 ± 0.4 mV, and -
41.3 ± 3 mV for the DSPE-MTX-LIP, PEG-MTX-LIP and Combo-LIP, respectively (Table 2.2). 
It is important to note that the unchanged surface electrostatic -potential found for PEG-MTX-
LIP supports the hypothesis of the localization of the compound between the two membranes. 
To evaluate the encapsulation efficiency (EE) of MTX inside liposomes, High-Performance 
Liquid Chromatography (HPLC) was used. The EE was calculated as the percentage ratio 
between the drug loaded mass and the drug input mass, used during nanoparticle synthesis. 
For DSPE-MTX-LIP, the encapsulation efficiency was equal to 79.9 ± 5.6 % (799 ±56 µg), while 
for PEG-MTX-LIP: 82 ± 7.5 % (820 ±75 µg) and the Combo-LIP: 80.2 ± 1.8 % (802±18µg) as 
reported in the Table 2.2. The direct loading of MTX unmodified molecule into liposomes was 
extremely difficult due to the extremely poor solubility of the compound both in water and 
organic solvents as also reported elsewhere [90, 124]. A series of MTX modification based 





produced a MTX sodium salt and loaded it into liposomes through the ethanol injection method 
achieving an EE% equal to 32 % [114]. In another study, Li et al. synthetized a MTX prodrug 
by conjugating the drug to a phospholipid (PC) achieving a EE% equal to 20.7 ± 2.4% [101]. 
Our results reveal that the approach proposed in this work, based on the use DSPE-MTX and 
PEG-MTX, led to achieve a significantly higher EE (around 80%). Such a result represents a 
considerable step forward in the encapsulation of MTX into liposomes. 
 
Figure 2.3. a-c) Stability of all the formulations at pH=7.4 and d-f) at pH=6.5. 
 
In order to investigate liposomes stability under the conditions found in vivo (37°C); two buffer 
solutions were used to reproduce in vitro physiological condition (pH 7.4) and mildly acidic 
microenvironment (pH 6.5) typical of solid malignant tumors [125], and of inflamed tissues [126, 
127]. Liposome size and size distribution were monitored over a period of 4 days. As reported 
in Figure 2.3a-c, both DSPE-MTX-LIP and the PEG-MTX-LIP showed to be stable at 37 ± 2 
°C and pH=7.4 with a percentage change in size and PDI lower than 15% for the entire 
observation period. The Combo-LIP showed an increase in size and PDI already after the first 
day, indicating a formulation instability, which was also evident for the entire observation period. 
A different behavior was documented at pH = 6.5 (Figure 2.3d-f). All the three liposomal 
formulations resulted unstable under a slightly acidic environment, with a rapid size increase. 
DSPE-MTX formulation resulted anyway to be more stable than the other two after one day of 
observation. In any case, it is possible to conclude that a slight decrease in pH is able to 





the liposomes. This last consideration might be particularly relevant in vision of using these 
vectors for the therapy of cancer and other inflammatory diseases MTX is used for. By 
exploiting the slightly acidic environment, characterizing malignant tumors and inflamed areas, 
drug release could be fostered in those areas rather than in healthy tissues.  
 
Figure 2.4. In vitro release profile of DSPE-MTX (red line), PEG-MTX (light green line) and 
their combinations (purple line) from liposomes (A). Data are presented as the average of 3 
different experiments ± Standard deviation (SD). In vitro release profile of DSPE-MTX (red 
line), PEG-MTX (light green line) and their combinations (purple line) from liposomes (A). Data 
are presented as the average of 3 different experiments ± Standard deviation (SD).  
Table 2.3. The R2 values of the zero-order, first-order kinetic, Higuchi models, Korsmeyer-
Peppas and Weibull models. Kinetic parameters for the Korsmeyer-Peppas model: K 
represents the release rate constant; n represents the release mechanism of drug; Kinetic 
parameters for the Weibull model: a represents a constant based on the system, and b a 



































 MTX-Liposome Release Profiles. 
The release profiles of DSPE-MTX, PEG-MTX, and Combo liposomes were determined under 
infinite sink conditions (4L release volume). Briefly, the three liposomal formulations were 
placed in 4L of PBS buffer (1X, pH 7.4) at 37 ± 2 °C under magnetically stirring. Three samples 
for each time point were collected, destroyed with cold methanol, and left to dry. The obtained 
powder was dissolved in AcN / H2O (1:1, v/v) to release the remaining DSPE-MTX, PEG-MTX 
for HPLC analysis. The three liposomal formulations showed similar biphasic kinetics with 
different percentages of drug released (Figure 2.4). Specifically, DSPE-MTX and PEG-MTX 
formulations showed a burst drug release within the first 9 hours, with approximately 60% rapid 
release. The Combo formulation exhibited a faster release with 75% of DSPE-MTX/PEG-MTX 
after 9 hours. The faster release was also supported by stability data relative to this formulation 
(Figure 2.3c). Combo liposomes size and polydispersity index increased after 1 day confirming 
the lower stability of this formulation. The remaining portion of drugs was slowly and 
continuously released over time, yielding a ~ 95% release after 1 day for Combo and 3 days 
for both DSPE-MTX or PEG-MTX. The initial phase release under sink conditions is likely 
associated with drug molecules closer to the particle surface. These molecules diffuse out more 
rapidly and over a short distance upon exposure to a release medium in vitro or extracellular 
fluid in vivo. To better understand which kinetic model better described the three different 
liposomal formulation release profiles, experimental data were fitted on various mathematical 
models: zero order, first order, Higuchi, Korsemeyer–Peppas and Weibull [128, 129]. The 
cumulative % drug released versus time, the log cumulative % drug remained versus time, the 
cumulative % drug released versus the square root of time plot, the log cumulative % drug 
released versus the log time plot [129] for all the three formulations are reported in Figure 2.S4-
6. Their correlation coefficient (R2) values are reported in Table 2.3. According to data, all the 
models provided an accurate fitting for the three release profiles, with some differences. All the 
three formulations followed a Korsemeyer–Peppas law (Highest correlation coefficient R2 
value): DSPE-MTX showed a MTX non – Fickian diffusion (super case-II transport mechanism) 





(anomalous transport) (0.43 ≤ n ≤ 0.85) [130]. On the contrary, the b value obtained (b ≥ 0.75) 
with the Weibull equation suggested a super case-II transport mechanism for all three 
formulations. Anyway, obtained data suggested that multiple mechanisms, such as diffusion 
and erosion [131], act simultaneously during the release study for all the three liposomal 
formulations. This could depend on the different interactions of prodrugs with lipids and PEG-
lipids in the liposome structure previously reported for guanosine [132]. Similar non – Fickian 
diffusion was reported for other drugs delivered using liposomes [133-137]. 
 
Liposomes Uptake.  
In order to investigate liposomes cell uptake, liposomes were loaded with the tracer molecule 
DSPE-Cy5. The resulting liposomes (Cy5-LIP) were found to be comparable in size and -
potential with the other formulation presented in this paper, as shown in figure 2.S7A. Their 
release profile revealed DSPE-Cy5 is slowly released over time (Fig. S7B), indicating this 
formulation possesses suitable characteristics for imaging purposes. BMDM were treated with 
Cy5-LIP. Confocal imaging showing Cy5-LIP (red signal) internalized into BMDM is reported in 
Figure 2.5a as the maximum intensity profile of a z-stack. From the figure, liposomes appeared 
to be within plasma membrane (green signal); the nucleus was stained by DAPI (blue signal). 
An image reporting each of the acquired channels is presented in Figure 2.S8. A high 
magnification image of one cell was also acquired (Figure 2.5b). From this image, it is possible 
to clearly appreciate that Cy5-LIP were quite uniformly disposed inside cell cytosol. A single 
cell 3D reconstruction is shown in Figure 2.5c. The image reports a reconstruction of the 
surface for each of the acquired channels. The surface reconstruction confirms Cy5-LIP 
internalization: in the merged image, a minor Cy5 signal was retrieved on the BMDM 
membrane, indicating that most of the liposomes were found inside the cell while only a minor 






Figure 2.5. a) Image reporting a maximum intensity profile of a z-stack of BMDM treated with 
liposome reporting in blue the nuclei, in green the plasma membrane and in red the liposomes. 
b) Higher magnification inset of a single cell. c) Single cell 3D reconstruct. d) Flow Cytometry 
analysis of BMDM uptaking Cy5-liposomes. 
 
Flow Cytometry analysis reveals the uptake of Cy5-LIP is dose-dependent (Figure 2.5d). By 
increasing the amount of liposomes used for BMDM treatment, also the percent of cells positive 
for internalization increases. Treating BMDM with 5 µL of Cy5-LIP suspension, 33% of cells 
were found positive for internalization; The percentage increased to 54.2% and 60.7% when 
BMDM were treated with 10 µL and 15 µL, reaching its maximum (86.4%) when 30 µL of 
liposome suspension were used. All the treatments were performed for 30 minutes. 
Taken together, these data indicate that liposomes were easily uptaken by BMDM and that at 
the considered time point, 33% of cells are already positive for internalization when using a 
small amount of liposomes. Only very few liposomes were found on cell membrane, probably 
taken in the process of being internalized. These observations confirm that this kind of 
formulation can easily penetrate cell membrane to deliver its payload (in this case, represented 





forms, using a liposomal formulation is thus expected to favor its cell penetration. MTX 
dispersion inside body fluids, its circulation half-life (as also reported elsewhere [101, 138]) and 
thus its availability to the biological target [103] is supposed to be improved. Moreover, it is 
important to underline that liposomes can be easily functionalized with targeting ligands, 
imaging agents, small molecules, peptides, proteins, antibodies [117] and also aptamers [139]. 
This versatility should also allow to tailor our MTX liposomes basing on the specific pathology 
to treat. 
 
Figure 2.6. Viability of BMDM incubated with MTX, DSPE-MTX, DSPE-MTX-LIP, empty LIP, 
PEG-MTX, PEG-MTX-LIP, Combo and Combo-LIP a 3 different time points. 
 
Cell cytotoxicity Analyses. 
To evaluate the cytotoxicity of the prodrugs and prodrug-loaded-LIP, cell viability was 
measured using the MTT assay. This assay calculates the reduction of MTT by mitochondrial 
dehydrogenase to blue formazan product, which reflects the normal function of mitochondria. 
Hence, the measurement of cytotoxicity and cell viability was obtained. Different concentrations 
of free MTX, DSPE-MTX and/or PEG-MTX, DSPE-MTX-LIP, PEG-MTX-LIP, and Combo-LIP 
with a drug concentration ranging from 60 nM to 10 µM were tested on BMDM for different time 
points, 24, 48, 72 hours. Empty liposomes were tested as a control. For the treatment with free 
MTX, it is important to note that the molecule was dissolved in DMSO, considering the difficulty 





calculated at 72 h are reported in Table 2.4. MTX IC50 was found to be equal to 2.41±0.14 µM. 
DSPE-MTX, free or loaded into liposomes was found to have a slightly higher toxicity (IC50 = 
0.9±0.1 µM and 0.7±0.12 µM, respectively). A minor difference in IC50 was found for free or 
loaded PEG-MTX (IC50 = 2.5±0.08 µM and 1.6±0.1 µM, respectively). The co-administration of 
the two prodrugs and the administration of combo liposomes showed an IC50 very similar to 
DSPE-MTX: IC50 values for the combo were found as equal to: 0.6±0.1 µM and 0.9±0.1 µM 
(free prodrugs and combo-LIP, respectively). These results were in agreement with results 
obtained in other works produced by our group and others [90, 119, 136]. In summary, a slight 
difference in IC50 between MTX, DSPE-MTX, PEG-MTX and the liposomal formulation derived 
was found. This finding support the hypothesis that the activity of the molecule is possibly 
maintained, despite the changes operated in the structure. 
 
Table 2.4. Table of IC50 showing the viability of BMDM incubated with MTX, DSPE-MTX, 









In the present manuscript, a strategy to efficiently load a high content of MTX into liposomes is 
presented. Two different prodrugs were generated by binding the compound to DSPE and 
PEG. The modifications operated to the molecule positively influenced MTX solubility. While 
the loading of the naïve molecule is particularly inefficient, the two prodrugs can be easily and 
directly loaded into the liposomes, singularly and in combination. The generated formulations 
turned out to be comparable in terms of physicochemical features, presenting a similar size of 
~155 nm, a narrow size distribution, and a mean surface charge of about –40 mV. At 
physiologic pH, DSPE-MTX and PEG-MTX liposomes were found more stable than the 
formulation comprising both the prodrug. At slightly acidic pH all the formulations showed to be 
unstable after one day of observation. As for the release, all three liposomal formulations 
showed a biphasic release; both mechanisms of diffusion and erosion are involved in the 
process, as demonstrated by the mathematical fitting. The data acquired at confocal and by 
flow cytometry confirmed the suitability of liposomes in granting cell uptake. Considering that 
DSPE-MTX and PEG-MTX are constituents of the liposomes structure, a higher MTX uptake 
is expected if compared to the naïve molecule. These considerations, taken together with the 
benefits offered by liposomal formulations (i.e., extended circulation half-life, favored 
accumulation at the diseased site), support the potential advantages of MTX liposomes as a 









2.6. Supporting Information 
 
  
Figure 2.S1. 1H NMR spectrum of DSPE-MTX in CDCl3 
 
 







Figure 2.S3. Transmission electron microscopy images of PEG-MTX-LIP, DSPE-MTX-LIP 
and Combo-LIP, respectively (scale bar: 100 nm). 
 
Figure 2.S4. Mathematical models showing the fitting of DSPE-MTX-LIP. Results are 






Figure 2.S5. Mathematical models showing the fitting of PEG-MTX-LIP. Results are 
representative of three independent experiments ± S.D. (n = 3). 
 
 
Figure 2.S6. Mathematical models showing the fitting of Combo-LIP. Results are 













Figure 2.S8. Image reporting a maximum intensity profile of a z-stack of BMDM treated with 






Chapter 3  
 
Modulating Lipoprotein Transcellular Transport and 
Atherosclerotic Plaque Formation in ApoE–/– Mice via 




Macrophage inflammation and maturation into foam cells, following the engulfment of oxidized 
low-density lipoproteins (oxLDL), are major hallmarks in the onset and progression of 
atherosclerosis. Yet, chronic treatments with anti-inflammatory agents, such as methotrexate 
(MTX), failed to modulate disease progression, possibly for the limited drug bioavailability and 
plaque deposition. Here, MTX-lipid conjugates, based on 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE), were integrated in the structure of spherical polymeric 
nanoparticles (MTX-SPN) or intercalated in the lipid bi-layer of liposomes (MTX-LIP). Although, 
both nanoparticles were colloidally stable with an average diameter of  200 nm, MTX-LIP 
exhibited a higher encapsulation efficiency (> 70%) and slower release rate (50% at 10h) 
compared to MTX-SPN. In primary bone marrow derived macrophages (BMDM), MTX-LIP 
modulated the transcellular transport of oxLDL more efficiently than free MTX mostly by 
inducing a 2-fold overexpression of ABCA1 (regulating oxLDL efflux); while the effect on CD36 
and SRA-1 (regulating oxLDL influx) was minimal. Furthermore, in BMDM, MTX-LIP showed a 
stronger anti-inflammatory activity than free MTX reducing the expression of IL-1β by 3-fold, 
IL-6 by 2-fold and also moderately of TNF-α. In 28 days of high-fat-diet fed apoE-/- mice, MTX-
LIP reduced the mean plaque area by 2-fold and the hematic amounts of RANTES by half as 
compared to free MTX. These results would suggest that the nano-enhanced delivery to 
vascular plaques of the anti-inflammatory DSPE-MTX conjugate could effectively modulate the 








Atherosclerosis is an inflammatory disorder affecting large and medium size arteries and is 
responsible for acute cardiovascular syndromes, such as myocardial infarction (MI) and stroke. 
[140] Immune cells play a key role in all the stages of the pathology, from endothelial 
dysfunction to plaque formation and rupture. [141] Atherosclerotic vascular lesions are 
established by the continuous infiltration of circulating monocytes into the arterial walls and 
their progressive maturation into macrophages and foam cells. [142] These are lipid-rich 
macrophages that have up-taken large amounts of oxidized low-density lipoproteins (oxLDL), 
mostly through specific surface receptors such as CD36 and SRA-1. [143] Therefore, one 
strategy to prevent atherosclerotic plaque formation and progression relies on reducing 
vascular inflammation. [144, 145] 
 
Recently, methotrexate (MTX), which is a potent chemotherapeutic and anti-inflammatory 
agent, was proposed for the treatment of atherosclerosis in patients affected by chronic 
inflammatory diseases, such as rheumatoid arthritis and psoriatic arthritis. MTX is known to 
possess anti-inflammatory properties and is capable to lower the production of pro-
inflammatory cytokines by macrophages. [146] MTX has been shown to increase cellular levels 
of adenosine monophosphate and adenosine, which consequently suppress the secretion of 
cytokines by immune cells and may protect against ischemic injury. [28] In particular, 
upregulation of the adenosine receptor limits the formation of foam cells by promoting 
lipoprotein efflux out of macrophages. [147] Despite all these properties, in the Cardiovascular 
Inflammation Reduction Trial (CIRT), a low-dose MTX treatment failed to lower secondary 
cardiovascular event rates. [42] It is important, however, to note that the free molecule MTX is 
hydrophobic, suffers of low solubility in physiological environments, has a modest half-life in 
blood, and can induce severe adverse effects, including myelosuppression, neutropenia, 





MTX reformulation into nanoparticles could help in overcoming the above-mentioned limitations 
thus harnessing the full potential of this drug. Indeed, many groups have investigated the 
benefits associated with the encapsulation of MTX into liposomes, specifically focusing their 
attention on the pharmacokinetic parameters. For instance, Chen and coworkers (2019) 
showed that the plasma concentration of MTX drops rapidly upon intravenous administration 
being nearly undetectable after only 4h.[27] Conversely, MTX – loaded liposomes provided an 
over 5-fold increase in circulation half-life and mean residence time and a 16-fold increase in 
the area under the concentration−time curve (AUC 0-24), as compared to the free 
molecule.[149] Similar results were also reported by Alekseeva et al. (2017) documenting a 4-
fold improvement in drug bioavailability for the MTX-liposomes over the free drug.[150]Also, a 
few studies have started to show that the atheroprotective properties of MTX can be more 
effectively exploited by administering nanoparticles loaded with the drug rather than the free 
molecule. [48, 151] For instance, MTX-loaded polymeric nanoparticles were shown by the 
authors to mitigate atherosclerotic progression in apolipoprotein-E (apoE)-/- mice, fed with a 
high-fat diet (HFD). [47] Indeed, accumulation of blood-borne nanoparticles into atherosclerotic 
plaques would increase the dose of MTX delivered specifically to the inflamed arterial wall, 
avoiding side effects associated with systemic exposure. Nanoparticles accumulation is 
supported by different and multiple mechanisms, including the direct nanoparticle uptake by 
phagocytic macrophages;[152-154] the deposition within the diseased tissue due to favorable, 
local hydrodynamic conditions (recirculation area and low wall shear stresses), hyper-
permeability of a dysfunctional endothelium and increased angiogenesis; [155-159] the direct 
plaque localization via molecular targeting; [160-163] and the nanoparticle uptake by circulating 
monocytes that would eventually infiltrate the plaque. [164, 165]  
 
In this work, two different types of nanoparticles – polymeric- and lipid-based nanoparticles – 
were designed, realized and tested in vitro and in vivo for the delivery of MTX. Differently from 
previous works, these nanoparticles were realized using a lipid-MTX conjugate, obtained by 
reacting MTX with the lipid chain 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). 





delivery of the anti-inflammatory molecule. For the polymeric nanoparticles, the DSPE-MTX 
conjugate was dispersed as a regular payload within the hydrophobic core; whereas for the 
liposomes, the DSPE-MTX was integrated in the lipid by-layer thus providing both a therapeutic 
and a structural function. After extensive biophysical and pharmacological characterizations, 
MTX-loaded Spherical Polymeric Nanoparticles (MTX-SPN) and MTX-loaded Liposomes 
(MTX-LIP) were tested in vitro to demonstrate their ability to modulate oxLDL uptake by 
macrophages and in vivo to assess the atheroprotective efficacy in hyperlipidemic mice. 
 
3.3. Materials and Methods 
 
Materials: Poly(D, L-lactide-co-glycolide) acid terminated (PLGA, lactide:glycolide 50:50, Mw 
23,000-25,000 and 38,000-54,000), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
Hydroxysuccinimide (NHS), Triethylamine (TEA), Low-density lipoproteins (LDL) and 
cholesterol quantitation kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Methotrexate (MTX) was bought by AlfaAesar (Haverhill, MA, USA). 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[succinyl(polyethylene glycol)-2000] (DSPE-PEG-COOH), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE_NH2), 1,2-Dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) were purchased from Avanti Polar Lipid (Alabaster, AL, USA). All 
reagents and solvents were used without further purification. 
 
Synthesis of DSPE-MTX.  
DSPE-MTX was synthesized as reported by Ferreira and coworkers with some modifications. 
[119] Briefly, MTX was incubated with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / 
N-Hydroxysuccinimide (NHS) in Dimethyl sulfoxide (DMSO) for 30 minutes, at room 
temperature. A solution of DSPE in DMSO was added to the previous solution. A catalytic 
amount of triethylamine (TEA) was added to the reaction and left to stir for 72 hours. The 
mixture was washed with cold diethyl ether. Finally, the conjugate was lyophilized and stored 





including DMSO and DMF, which are toxic and exhibit a very high boiling point (above 150° C). 
On the other hand, lipid-MTX can be efficiently separated from an original DMSO solution by 
using cold diethyl ether and readily used to synthesize particles without employing DMSO or 
DMF. 
 
Synthesis of SPNs.  
Spherical Polymeric Nanoparticles (SPNs) were synthesized by a sonication-emulsion 
technique method, as described elsewhere. [166] Briefly, carboxyl terminated poly(lactic-co-
glycolic acid) (PLGA), DSPE-MTX and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
were dissolved in chloroform in a 5:2:1 ratio to obtain an homogeneous solution (oil phase). 
The aqueous phase was prepared by dissolving 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000 (DSPE-PEG-COOH) in 4% 
ethanol. Then, the oil phase was added drop wisely to the aqueous phase under ultrasonication 
(100% amplitude for 1 min and 30 sec). The obtained emulsion was then placed under 
magnetic stirring to facilitate solvent evaporation. SPNs were centrifuged, first, for 5 min at 
1,500 rpm to settle down any possible debris, and then the supernatant was centrifuged 3 more 
times for 20 minutes at 12,000 rpm. The pellet were washed in water after every centrifugation 
step. Different SPN formulations were synthetized.  
In order to label the SPNs with the near infra-red dye Cy5. A DSPE-Cy5 (0.002mg) was used 
instead of DSPE-MTX.  
 
Synthesis of MTX-LIP.  
Liposomes (LIP) were prepared by thin layer evaporation (TLE). [167] Briefly DPPC, 
cholesterol, DSPE-PEG and DSPE-MTX were dissolved in chloroform in a round bottomed 
flask (ratio 6:3:1:1). The thin layer lipid film was obtained with the evaporation of the organic 
solvent at 60° under reduced pressure. The lipid film was left under the hood overnight to 
remove any trace of residual solvent. For the production of the multilamellar liposomes, the 





each) of warming at 60 °C (thermostated water bath) and vortexing at 700 rpm. The sample 
was dialyses against HEPES for 1h. For the preparation of Cy5-LIP, DSPE-Cy5 was used 
instead of DSPE-MTX. The purification step to remove excess of Cy-5 was conducted by 
ultracentrifugation (1h, 45,000 rpm) instead of dialysis. For the preparation of 64Cu-LIP, 20% 
w/w of DSPE-PEG was replaced with lipid-DOTA. LIP were obtained using the previous 
method. DOTA-LIP were then resuspended in 3 mL was water, and 200 µL of Acetate buffer 
(1mM, pH=6.0) and conjugated with 64CuCl2 (1 mCi) solution for 2h at 37°C. The excess of 
radioactive was removed by dialyses against PBS for 1h. 
 
Characterization of LIP and SPNs.  
Liposomes were fixed for 2 h in 2% glutaraldehyde in 0.1 M cacodylate buffer. After fixation, 
the samples were washed twice with the same buffer and post fixed for 1h in 1% osmium 
tetroxide in 0.1 M cacodylate buffer. After several washes with distilled water, samples were 
subsequently dehydrated in a graded ethanol series, 1:1 ethanol:hexamethyldisilazane 
(HMDS), and 100% HMDS and dried overnight. Samples were sputtered using gold. SEM 
images were collected using JEOL JSM-7500FA (Jeol, Tokyo, JAPAN) operating at 5 kV of 
accelerating voltage. For SPNs, a drop of nanoparticle solution was deposited on a silicon 
wafer, dried and mounted on a stab for SEM analysis. The hydrodynamic diameter, 
polidispersity index and surface electron ζ-potential of LIP and SPNs were measured using 
dynamic light scattering (DLS, Malvern Nano ZS).  
 
Drug loading and release.  
To measure the MTX encapsulation efficiency (EE) and loading efficiency (LE), the samples 
were lyophilized, dissolved in acetonitrile/H2O (1:1, v/v), and analyzed by high-performance 
liquid chromatography (HPLC) (Agilent 1260 Infinity, Germany) equipped with a 100 μL sample 
loop injector. A C18 Column (2.1× 250 mm, 5 μm particle size, Agilent, USA) was used for the 





system [H2O + 0.1% (v/v) TFA, 43:57 v/v] pumped at a flow rate of 1.0 mL/min. The ultraviolet 
(UV) detection was set at 430 nm. 
EE and LE were determined using the following equations:  
 
𝐸𝐸 (%) =
𝑀𝑇𝑋 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑀𝑇𝑋 𝑖𝑛𝑖𝑧𝑖𝑎𝑙 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
× 100                      (1) 
 
𝐿𝐸 (%) =
𝑀𝑇𝑋 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
× 100                     (2) 
 
To study MTX and Cy5-release kinetics, 200 μL of MTX-nanoparticle (SPN or LIP) or Cy5-
nanoparticles (SPN or LIP) solution were placed into Slide-A-Lyzer MINI dialysis microtubes 
with a molecular cutoff of 10 kDa (Thermo Scientific) and dialyzed against 4 L of PBS buffer 
(pH 7.4). For each time point, three samples were collected and dried. For the SPNs, samples 
were then dissolved in acetonitrile/H2O (1:1, v/v) and analyzed by HPLC. For LIP samples 
were destroyed with cold methanol, left to dry, dissolved in acetonitrile/H2O (1:1, v/v) and 
analyzed by HPLC for the MTX. The experimental data were fitted by using the Ritger–Peppas 
model for controlled, not swellable drug-delivery systems 52 (Y = k × xn), where Y represents 
the drug percentage released, x is the time of observation, and k and n are the fitting 
parameters.  
In the case of Cy-5, after LIP destruction samples were dissolved in acetonitrile and analyzed 
by the spectrophotometer at ʎ=640 nm. For 64Cu release, LIP were analyzed at the -counter. 
The data was normalize taking into account the decay of 64Cu. 
 
LDL oxidation. 
LDL (2 mg/ml) were incubated with 5 mM CuSO4 at 37°C for 4h without EDTA. The reaction 
was interrupted with the addition of EDTA (5 mM). The formed oxidized LDL molecules (oxLDL) 
were dialyzed against PBS containing 0.01% EDTA at 4°C for 24 h and stored at 4°C. [168] 





used for fluorescently tagging the lipoprotein following a previously published protoCol. [169] 
Briefly, Dil was pre-incubated with LDL overnight at 37°C under agitation. Dil-LDL were then 
oxidized and ultracentrifuged for 5 h at 45,000 rpm and 4° in order to remove unbound 
fluorophore. The obtained Dil-oxLDL were dialyzed against PBS containing 0.01% EDTA at 
4°C for 24 h and stored at 4°C. 
 
Bone Marrow Derived Macrophages. 
For Bone Marrow Derived Macrophages (BMDM), rat femurs were explanted and the 
extremities were cut off. Then, the bone marrow canal was flushed four times with 500 μL of 
medium. The resulting cell suspension was filtered using a 70 μm cell strainers. Cells were 
seeded in a Petri dish and medium was changed after 3 days to remove unattached cells. 
BMDMs were used on the following day. BMDMs were cultured in DMEM supplemented with 
15% FBS, 1% penicillin/streptomycin, and rat M-CSF (according to vendor indications). Cells 
were cultured under controlled environmental conditions (37°C in 5% CO2). 
 
Foam Cell formation and Cholesterol Quantification.  
BMDM/Raw 264.7 cells were cultured in DMEM containing, respectively, 15% and 10% fetal 
bovine serum (FBS), 1% antibiotic (penicillin/streptomycin) and 1% glutamine. Cells were 
seeded at a density of 1x105 cells/mL. For foam cells formation different amount of oxLDL were 
tested (0, 20, 50 and 80 µg/mL of oxLDL). Macrophages were incubated with oxLDL overnight, 
the medium was removed and cells were washed twice with PBS and fixed with a solution of 
paraformaldehyde 3.7% (PFA). Macrophages were incubated with isopropanol and Oil Red O 
(ORO) working solution for 10-20 minutes. Cells were observed at the microscope (Leica 5500) 
and images were acquired with a 20X magnification. [170] 
 
Confocal Fluorescent Microscopy imaging.  
Confocal images of RAW 267.4 were obtained using a Nikon-A1 confocal microscope (Nikon 





macrophages overnight. 50,000 cells (either Raw267.4 or BMDM) were seeded into each well 
of a Nunc™ Lab-Tek™ II Chamber Slide™ System (Thermo Fisher Scientific, USA) 
maintaining culturing conditions, as described for foam cell formation and cholesterol 
quantification protoCol. After 14 h, the culturing media was removed and cells were washed in 
PBS (Thermo Fisher Scientific, USA). Fixation was performed using a 3.7% solution of PFA 
(Sigma Aldrich, USA) for 5 minutes. Lysosomes were stained with LysoTracker™ Green 
(Thermo Fisher Scientific, USA) and nuclei with DAPI (Thermo Fisher Scientific, USA) following 
the vendors' indications. A z-stack section was acquired using a 60X objective (≥ 12 steps of 
1,000 nm each were acquired per image). 
 
Time Lapse Microscopy Analysis.  
For time lapse microscopy experiment, 20,000 BMDMs were seeded into a Nunc™ Lab-Tek™ 
II Chamber Slide™ System (Thermo Fisher Scientific, USA). Same experimental conditions 
were used: BMDMs were incubated overnight with 50 µg/mL Dil-oxLDL and an equal amount 
of Dil. The experiment was performed using a Nikon Eclipse-Ti-E microscope (Nikon 
Corporation, Japan). During the image acquisition cells were kept in controlled environmental 
conditions: 37 °C in a humidified 5% CO2 atmosphere. Movies were acquired at a frame rate 
of 80fps using a 60X objective.  
Analysis of Dil-oxLDL uptake and expulsion. After inducing the transformation of BMDM in foam 
cells with Dil-oxLDL, cells were treated for 24 h with 0.16 µM of free MTX, empty nanoparticles 
and MTX-nanoparticles. At the end of the treatment, the medium was removed and cells were 
washed twice with PBS. Cell fixation was performed using a 3.7% solution of PFA (Sigma-
Aldrich, USA) for 15 min. Actin was stained with Alexa Fluor™ 488 Phalloidin (Thermo Fisher 
Scientific, USA) and nuclei with DAPI (Thermo Fisher Scientific, USA), following the vendors 






Cholesterol quantification.  
BMDM total cholesterol (free cholesterol and cholesteryl ester) was quantified using a 
Cholesterol Quantitation Kit (Sigma-Aldrich, Italy), following the manufacturer’s instruction. 
Firstly, cells were treated with oxLDL, then with free MTX and MTX loaded-nanoparticles as 
described previously. Cholesterol quantification was normalized on the total amount of protein 
calculated using Pierce Brentford Protein Assay Kit (thermos Scientific). 
 
TEM Characterization: 
Transmission electron microscopy (TEM) micrographs were acquired using JEOL JEM 1011 
(Jeol, Japan) electron microscope operating with an acceleration voltage of 100 kV and 
recorded with a 11 MegaPixel fiber optical charge-coupled device (CCD) camera (Gatan Orius 
SC-1000). LDL was diluted 1:100, dropped on 150-mesh glow discharged ‘Ultrathin’ carbon-
coated Copper TEM grids and dried. Dried TEM samples were negatively stained using 2% 
Uranyl Acetate aqueous solution. In order to observe LDL uptake in foam cells, RAW 264.7 
cells were cultured and treated on glass coverslips. Samples were fixed for 2 h in 1.5% 
glutaraldehyde in 0.1 M Sodium Cacodylate buffer (pH 7.4), post fixed in 1% osmium tetroxide 
in the same buffer and stained overnight with 1% uranyl acetate aqueous solution. Samples 
were then dehydrated in a graded ethanol series, infiltrated with series of ethanol/resin solution 
and finally embedded in epoxy resin (Epon 812, TAAB). Thin sections were cut with the Leica 
UC6 ultra-microtome (Leica Microsystems, Germany), equipped with a diamond knife 
(Diatome).  In order to better localize the fluorescent LDL molecules inside cells, LDL uptake 
in foam cells was investigated by means of Correlative Light and Electron Microscopy. Foam 
cells were cultured and treated on grid-etched glass coverslips. After fluorescence microscopy 
observation, samples were fixed for 1.5 h in 4% paraformaldehyde (PFA), 0.2% Glutaraldehyde 
solution prepared in 0.1 M Phosphate Buffer. Fluorescence images were acquired using a 
Nikon-A1 confocal microscope (Nikon Corporation, Japan). Dil-oxLDL was used for the 
treatment. The nuclei were stained with DAPI and the lysosomes with the LysoTracker™ Green 





for TEM analysis as described above, using reference marks. Image analysis and merging 
were performed using the PhotoShop image processing software. 
 
Gene expression and toxicity.  
BMDMs were cultured at 37°C in 5% CO2, in high-glucose DMEM, supplemented with 15% 
FBS and 1% L-glutamine, according to ATCC instructions. Cells were seeded into 96-well 
plates at a density of 20 × 103 cells per well and incubated for 24, 48, 72 h. Cells were treated 
with different concentrations of free MTX, DSPE-MTX, MTX-SPNs, MTX-LIP (namely, 0.0064, 
0.032, 0.16, 0.8, 4, 10 and 0 μM of MTX), or empty SPNs/LIP. The MTT solution was added 
for 4 h and the formed formazan crystals were dissolved in ethanol. Absorbance was measured 
at 570 nm, using 650 nm as the reference wavelength (Tecan, Männedorf, Swiss). The 
percentage of cell viability was assessed according to the following equation:  
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴𝑏𝑠𝑇
𝐴𝑏𝑠𝐶 
× 100             (3) 
 
where AbsT is the absorbance of treated cells and AbsC is the absorbance of untreated cells 
(control). 
The anti-inflammatory effects of MTX, MTX-SPNs and MTX-LIP was tested on foam cells at 8 
and 24 h by measuring gene expression of three pro-inflammatory cytokines, namely tumor 
necrosis factor- α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in rat BMDMs.  
The gene expression of foam cells markers (CD36 and SRA-1) and cholesterol expulsion ATP-
binding cassette transporter 1 (ABCA1) was also assessed. Cells were cultured under 
controlled environmental conditions (37 °C in 5% CO2) and seeded into 6-well plates at a 
density of 4 × 105 cells per well. After 10 h, BMDMs were incubated with oxLDL overnight. 
Cells were treated with MTX-nanoparticles at 0.16 µM of MTX and incubated for 8 and 24 h. 
RNA was extracted using a RNAeasy Plus Mini Kit (Qiagen) and quantified by NanoDrop2000 
(Thermo Scientific, Waltham, Massachusetts, USA). Three independent biological replicates 





GAPDH gene expression as a housekeeping gene. Reactions were performed in a final volume 
of 10 μL. Primer pair sequences are listed below: GAPDH: 5′-
CATCACTGCCACCCAGAAGACTG-3′ and 5′-ATGCCAGTGAGCTTCCCGTTCAG-3′; TNF-α: 
5′-GGTGCCTATGTCTCAGCCTCTT-3′ and 5′-GCCATAGAACTGATGAGAGGGAG-3′; IL-1β: 
5′-AACCTGCTGGTGTGTGACGTTC-3′ and 5′-CAGCACGAGGCTTTTTTGTTGT-3′; IL-6: 5′-
TACCACTTCACAAGTCGGAGGC-3′ and 5′-CTGCAAGTGCATCATCGTTGTTC-3′; CD36: 5′-
ATGGGCTGTGATCGGAACTG-3′ and 5′-GTCTTCCCAATAAGCATGTCTCC-3′; SRA-1: 5’-
CTGAGACCTCTGGAACAGGCAT-3’ and 5′-TGCACTAGCAGTGCCATCCTCT-3′; ABCA1: 5′-
GGAGCCTTTGTGGAACTCTTCC-3′ and 5′- CGCTCTCTTCAGCCACTTTGAG-3′. 
 
Internalization study. 
Flow cytometry was performed using a FACS ARIA (Becton Dickinson, USA). 200,000 
macrophages/foam cells were seeded into each well of a 12 well plate maintaining culturing 
conditions indicated in foam cell formation and cholesterol quantification protoCol. Cells were 
treated for 2, 8 and 24h with Cy5-LIP and Cy5-SPNs. After treatment, cells were washed using 
cold PBS in order to facilitate the scraping procedures. After washing, a volume of 200 µl of 
PBS was used to detach the cells by gentle scraping the plastic bottom. Samples were 
immediately stored in ice and vortexed right before the analysis. A cell population was selected 
setting a scatter gate that would exclude the negligible amounts of debris and aggregates while 
taking into account the side scatter (SSC) shift due to internal complexity changes caused by 
the internalized particles. The cell population positive for internalization was selected 
considering the basal level of fluorescence in untreated cells. 
 
Animals.  
B6.129P2-Apoe(tm1Unc)/J (apoE-/-) mice were bred in-house (Central Research Facility, 
University of Glasgow). Animals were maintained on a 12/12-h light/dark cycle with free access 
to food and water. All the procedures were performed in accordance with local ethical and UK 





(Western RD diet, 21% fat, 0.2% cholesterol, supplemented with 150 ppm fenbendazole, Diet 
code: 823963 - Special Diet Services, Essex, UK) for 28 days. Empty or MTX-LIP (2.5 mg/kg) 
were injected intravenously (i.v.) administered starting from day 0 every third day. Mice were 
culled at 28 days and samples processed as described below. At the end of the experimental 
protoCol mice were perfused with ice cold PBS; the heart was embedded in Tissue-Tec OCT 
(Tissue Tek, Sakura Finetek Europe, Zoeterwoude, The Netherlands), frozen at -80°C, and 
sectioned (10 μm). Aortic sinus sections were stained with oil red O counterstained with 
hematoxylin. Picrosirius red viewed with polarized light was used to detect Collagen. For each 
animal, 10 sections were analyzed to determine atherosclerotic lesion size and 4 section were 
analyzed to determine the Collagen content, as previously described. [171] The analyses were 
carried out using Image J software (National Institutes of Health Imaging; 
http://rsbweb.nih.gov/ij), and the results are expressed as mean lesion area and mean 
percentage Collagen area. 
 
Cytokine Detection Assays.  
Concentrations of eotaxin, fibroblast growth factor-basic, granulocyte-macrophage Colony-
stimulating factor, IFN-γ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 
(p40), IL-12 (p70) IL-13, IL-17A, KC, monocyte chemoattractant protein-1, macrophage 
inflammatory protein-1α, macrophage inflammatory protein-1β, RANTES (Regulated on 
Activation, Normal T Cell Expressed and Secreted), tumor necrosis factor-α were assessed in 
serum using a Bio-Plex Pro™ Mouse Cytokine 23-plex Assay, according to the manufacturer’s 
instructions (Bio-Rad), and analyzed using a Bio-Rad Luminex 200 Plate Reader (Hemel 




To determine nanoparticles distribution, apoE-/- mice were culled 24 h after the final injection 
of fluorescent Cy-5-LIP (the amount of particle used was equivalent to the one used for one 





OCT (Tissue Tek, Sakura Finetek Europe, Zoeterwoude, the Netherlands) and snap frozen for 
immunohistochemical analysis. 10 µm sections were cut. For staining, sections were fixed in 
acetone for 10 min, air dried, and rehydrated with PBS before incubation in serum-free Protein 
Block (DakoCytomation, Glostrup, Denmark) for 30 min. Aortic sinus sections were incubated 
with FITC-conjugated anti-α-SMA antibodies. Hoechst was used to identify nuclei as previously 
described. [172] Images were acquired using a Zeiss Cell Observer SD confocal microscope 
(Zeiss, Oberkochen, Germany). 
 
Serum lipid analysis.  
Measurements of mouse blood total cholesterol levels were performed with the 
Cholesterol/Cholesteryl Ester Quantitation kit (ab65359, Abcam, Toronto, ON) according to the 
manufacturer’s instructions. 
 
Biodistribution of LIP in Naïve Mice. 
LIP labeled with Cu64 were injected in 5 naïve mice (C57BL/6). At 24h post injection, the mice 
were sacrificed and the major organs (liver, spleen, kidneys, intestine, brain, lungs and heart) 
explanted and analyzed for their radioactive activity at the -counter. The data were then 
normalized for the weight of the organs. 
 
Statistical Analysis.  
All the in vitro data were represented as the average ± standard deviation (SD) of 3 different 
measurements, unless differently specified. The statistical significant difference was assessed 
using ANOVA test, with Bonferroni’s Multiples Comparison Test as post-hoc test. All statistical 
in vitro analyses were performed using GraphPad Prism v.5 (GraphPad Software, USA). In 
vivo results are expressed as mean ± SEM of the number of animals. Normality distribution 
was tested and Student t-test was used to compare 2 groups. All statistical in vivo analyses 
were performed using GraphPad Prism v.7 (GraphPad Software, USA). A p value ≤ 0.05 was 







Physico-chemical and pharmacological characterization of MTX-loaded 
nanoparticles.  
Methotrexate (MTX) is a potent anti-inflammatory molecule with a low solubility in physiological 
fluids [173] and a modest half-life in blood. [174] The formulation of MTX into nanoparticles can 
overcome the limitations above, thus harnessing the full potential of this drug. Two different 
nanotechnological platforms –Spherical Polymeric Nanoparticles (SPN) and Liposomes (LIP) 
– were considered for the systemic delivery of methotrexate. The MTX-SPN were realized via 
a single emulsion technique resulting in a PLGA hydrophobic core that is externally stabilized 
by a lipid monolayer, including carboxyl-terminated DSPE-PEG molecules (Figure 3.2A). The 
MTX-LIP were realized via a thin layer evaporation method (TLE) using DPPC, cholesterol and 
carboxyl-terminated DSPE-PEG chains (Figure 3.2B). The anti-inflammatory molecule MTX 
was included in the structure of the two nanoparticles in the form of a DSPE-MTX conjugate 
(Figure 3.S1). This was generated by reacting 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-amino (DSPE-NH2) with a DCC/NHS pre-activated MTX. The 
resulting DSPE-MTX conjugate is highly lipophilic and was included within the hydrophobic 
PLGA core and surface stabilizing lipid layer of SPN and, for the LIP, it was integrated naturally 
in the double lipid layer. 
Scanning electron microscopy images of MTX-SPN and MTX-LIP are provided in Figure 3.1C 
and 1D, respectively. The top right insets provide magnified views of the same nanoparticles. 
The electron microscopy analysis demonstrates the sphericity and uniform size distribution of 
both MTX-loaded nanoparticles exhibiting a diameter in the neighbor of 200 nm. More 
precisely, a Dynamic Light Scattering analysis returned an average hydrodynamic diameter of 
208  2 nm and 174  2 nm for the MTX-SPN and MTX-LIP, respectively (Figure 3.1E). Both 
nanoparticle formulations were characterized by a moderate polidispersity index PDI  0.15, in 
agreement with the electron microscopy observations. Given the presence of carboxyl-





electrostatic  potential of - 45  0.02 mV for the MTX-SPN and - 38  0.26 mV for the MTX-
LIP. These values are also listed in the table included in Figure 3.1E.  
 
Figure 3.1. A., B. Schematic representation of MTX-SPN and MTX-LIP, respectively. C., D. 
Scanning electron microscopy images of SPN and LIP, respectively (Scale bar: 500 nm; up-
right inset scale bar: 100 nm). E., F. Hydrodynamic diameter and colloidal stability of MTX-SPN 
and MTX-LIP via dynamic light scattering analysis. G. Release studies for MTX from MTX-SPN 
and MTX-LIP. The table summarizes the absolute drug mass, encapsulation efficiency (%EE), 






For both nanoformulations, Colloidal stability tests were performed under physiological 
conditions at pH = 7.4 and in a slightly acidic environment with a pH = 6.5. The average 
hydrodynamic diameters and PDI of both nanoparticles were monitored up to 4 days. Under 
physiological conditions, the data in Figure 3.1F show very stable formulations with a 
percentage change in size and PDI lower than 10% through the entire observation period. 
Differently, at pH = 6.5, the data in Figure 3.S2 present a steadily growing size for both MTX-
LIP and MTX-SPN most likely resulting from the progressive rearrangement of the Colloidal 
solution. Overall, however, the MTX-LIP resulted to be more stable than the MTX-SPN. It is 
here important to recall that the conjugate in the MTX-LIP provides also a structural contribution 
in addition to the pharmacological function in that it is directly included into the double-lipid 
layer of the liposomes. 
Next, High Performance Liquid Chromatography (HPLC) was employed to measure the loaded 
and released amounts of MTX from the two nanoformulations. MTX encapsulation efficiency 
EE was evaluated as the percentage ratio between the actual loaded mass of the drug and the 
input mass of the drug during nanoparticle realization. For the MTX-LIP, a significantly high EE 
was measured to be equal to 70.5 ± 4.8%, whereas this value dropped to only 1.5  0.7% for 
the MTX-SPN, with a total mass of the loaded DSPE-MTX corresponding to 705 ± 48 and 3  
0.34 g per single nanoparticle preparation, respectively. The MTX-loading was 1.86  0.04% 
for LIP and 0.61  0.15% for the SPN. The modest drug loading associated with the SPN is in 
line with previous data from the authors on other hydrophobic drug molecules.[175] Note that, 
in the MTX-LIP, the DSPE-MTX conjugate can intercalate with the DPPC and DPSE-PEG 
chains in forming the liposome double-lipid membrane. This increases significantly the amounts 
of drug that can be incorporated into the particles. The release profiles for MTX from SPN and 
LIP were determined in a 4 L PBS solution (infinite sink condition) and are plotted in Figure 
3.1G. MTX was more rapidly released from the SPN as compared to the LIP. At 9 h post study 
initiation, over 80% of the drug was released out of the SPN, whereas about 50% came out of 
the MTX-LIP. After 1 day, almost 90% of the encapsulated MTX was released from both 





Indeed, the higher stability of MTX-LIP over MTX-SPN is also shown by the overall lower MTX 
release rates associated with the former particles. 
It is here important to note that the EE = 1.5  0.7% for the SPN results from an extensive and 
systematic optimization process that led to define 12 different MTX-loaded SPN formulations 
with the final objective of improving drug loading in these particles. From the data listed in the 
Figure 3.S3, the following parameters were changed in the synthesis of SPN: total mass of 
PLGA, ranging from 0.5 to 2 mg; molecular weight of PLGA, varying from low (23-35 kDa) to 
high (38-53 kDa); and the ratios between DPPC, DSPE-PEG and DSPE-MTX. The resulting 
encapsulation efficiency varied from a minimum of 0.13% to a maximum of 1.5%. In the rest of 
the manuscript, MTX-SPN are referred as realized with 2 mg of high molecular weight PLGA, 
no DPPC, 0.2 mg of DSPE-MTX and 0.11 mg of DSPE-PEG. 
 
Macrophage Maturation to Foam Cells and Nanoparticle Uptake. 
Foam cells were obtained by feeding macrophages with oxidized low-density lipoproteins 
(oxLDL). The continuous accumulation of these ~ 20 nm oxidized lipid particles into 
macrophages is responsible for their maturation into foam cells, which is a fundamental step in 
the progression of atherosclerotic plaques.  
LDL oxidation was performed using copper salts (CuSO4) and two different cell types were 
exposed to oxLDL, namely the murine cell line Raw 264.7 and the primary Bone Marrow 
Derived Macrophages (BMDM) isolated from the femur of rats. First, the dose-dependent 
engulfment of oxLDL molecules into phagocytic cells was assessed. To this end, Raw 264.7 
were incubated overnight with different amounts of oxLDL, namely 0, 20, 50 and 80 µg/ml, and 
then stained with Oil Red O (ORO). In Figure 3.S5, the fluorescent intensity associated with 
the ORO staining is shown to grow proportionally with the initial amount of oxLDL. An 
intermediate concentration of 50 µg/ml oxLDL was considered as appropriate for all foam cell 
experiments.  
Then, the precise intracellular localization of oxLDL molecules was assessed via Correlative 
Light and Electron Microscopy (CLEM). [176] This technique allowed the authors to co-register 





the fluorescent microscopy experiments, the DiI dye was stably adsorbed onto oxLDL (Figure 
3.S6 and Supplementary Videos), while macrophages were treated with 488-lysotracker and 
DAPI to highlight the lysosomes and nuclei, respectively. Figure 3.2A shows a transmission 
electron micrograph (left) and a confocal fluorescent image (center) of a representative foam 
cell, obtained by feeding RAW 264.7 cells overnight with 50 µg/ml oxLDL. In the right inset of 
the same image, the TEM and confocal images were registered and combined together. These 
figures demonstrate a massive localization of oxLDL molecule (red) into lysosomes (green) 






Figure 3.2. Macrophage Maturation to Foam Cells and Nanoparticle A. Correlative light and 





lipoprotein (oxLDL) – Transmission electron microscopy image (left); confocal fluorescent 
microscopy image (center) showing the cell nucleus (blue – DAPI), the cell lysosomes (green 
– LysoTrackerTMGreen), oxLDL molecules (red – Dil); light and electron microscopy images 
overlap (right). (Scale bar: 2 µm). B. Representative confocal images of BMDM and foam cells 
exposed to SPN (left) and LIP (right) at different time points (2, 8 and 24 hours). C. Flow 
cytometry analysis BMDM and foam cells exposed to SPN and LIP at different time points (2, 
8 and 24 hours). *** p < 0.001 
 
Also, the TEM image shows the lysosomes as light structures due to the high lipid content and 
local density. Indeed, in TEM analyses of control cells (Figure 3.S7), lysosomes appear 
significantly darker. This again would support the notion that oxLDL molecules are uptaken in 
a dose-dependent manner by phagocytic cells and tend to localize within the lysosomes. 
In order to deliver their therapeutic cargo, MTX-loaded nanoparticles should cross the plasma 
membrane and be uptaken by the macrophages. Therefore, the time-dependent internalization 
of LIP and SPN into BMDM (i.e., before exposure to oxLDL) and foam cells (i.e., after exposure 
to oxLDL) was assessed via confocal fluorescent microscopy and flow cytometry analysis. 
Figure 2B shows representative confocal fluorescent images of macrophages (BMDM) and 
foam cells incubated with Cy5-labeled SPN (left) and Cy5-labeled LIP (right). Both 
nanoparticles (red dots) were readily internalized from the two cell types. However, a significant 
difference was detected in uptake propensity between the BMDM (no exposure to oxLDL) and 
foam cells. The latter tend to engulf a smaller number of nanoparticles. This was also confirmed 
and quantified via flow cytometry, with the data presented in Figure 2C for both LIP and SPN. 
The percentage of BMDM associated with nanoparticles (i.e.: percentage of positive events) 
was quite constant over time for both LIP and SPN. Specifically, for the three tested time points 
(2, 8 and 24h), this percentage was equal to 86.66 ± 3.59; 90.60 ± 2.23 and 87.30 ± 0.96 for 
LIP; 82.2 ± 1.1; 83.43 ± 2.82 and 82.87 ± 2.67 for SPN. In foam cells, for the three tested time 
points (2, 8 and 24h), this same percentage was generally lower as compared to BMDM and 
equal to 76.7 ± 0.14; 66.1 ± 2.26; 54.6 ± 0.71 for LIP, and 70.8 ± 5; 67.1 ± 2.54 ; 57.65 ± 1.06 





at the latest time point (24h). This difference could be associated with the fact that the large 
amounts of oxLDL stored in the lysosomes of foam cells would affect the internalization 
capacity of the cell. Notice also, that in agreement with the above results, other authors have 
documented that macrophages fed with huge amounts of lipids tend to lose their phagocytic 
capacity.[177-179] It is just important to highlight that the Cy5-SPN and Cy5-LIP are 
comparable in size and surface properties to the parent MTX-SPN and MTX-LIP. Also, the 
conjugation of Cy5 molecules on the particle surface was shown to be very stable (Figure 
3.S8).  
 
The role of Methotrexate in Macrophage Maturation to Foam Cells. 
As feeding macrophages with oxLDL is responsible for the progressive transition towards foam 
cells, a reduction of intracellular oxLDL would restore cell homeostasis and reverse the 
maturation process. Indeed, this could be achieved in two different ways: limit the uptake of 
oxLDL and foster the efflux of oxLDL. Importantly, MTX atheroprotection has been speculated 
to be associated to both its anti-inflammatory effect and ability to modulate cholesterol 
transport. [180] Therefore, in order to assess the effect of MTX on LDL trafficking, BMDM were 
first treated overnight with 50 µg/ml of Dil-oxLDL to induce foam cell formation, then the same 
cells were treated for 24h with different interventions, namely free MTX, empty LIP, MTX-LIP, 
empty SPN and MTX-SPN. After 24h, fluorescent images were acquired to quantify the 
amounts of intracellular DiI-oxLDL. Figure 3.3A shows representative microscopy pics for the 
untreated foam cells (control experiment), free MTX and empty LIP treated foam cells; MTX-
LIP treated foam cell; empty SPN treated foam cells; MTX-SPN treated foam cell; and the 
original BMDM, which were not exposed to oxLDL. These images clearly demonstrate the 
progressive decrease in fluorescent intensity associated with the cells as moving from the 
untreated foam cells (top) to the MTX-loaded nanoparticle treated cells (bottom). The 
fluorescent intensity for the different interventions is also quantified in the bar chart of Figure 
3.3B, where the data are normalized by the number of cells within the region of interest. No 
statistical significant difference was observed between the three control groups – untreated 





treated foam cells (0.39 ± 0.03/cell); and free MTX treated foam cells (0.36 ± 0.015/cell). On 
the other hand, the MTX-LIP and MTX-SPN are significantly more effective than the free drug 
in decreasing the amounts of intracellular lipids (0.09 ± 0.009/cell and 0.09 ± 0.026/cell, 
respectively, vs 0.36 ± 0.015/cell – p < 0.0001). This should be probably ascribed to the fact 
that the MTX-loaded nanoparticles are more efficiently uptaken by the cells as compared to the 
free drug molecules. In all fluorescent images, filamentous actin was stained to highlight the 







Figure 3.3. The role of Methotrexate in Macrophage Maturation to Foam Cells. A. 
Representative fluorescence images of different treatments conducted on BMDM forced to 
become foam cell following exposure to oxLDL (50 μg/ml). Red: Dil-oxLDL; blue: DAPI; green: 
F-Actin. From top to bottom, untreated foam cells, 24h free MTX-treated foam cells; 24h empty 
LIP-treated foam cells; 24h MTX-LIP treated foam cells; 24h empty SPN-treated foam cells; 





Quantification of the oxLDL accumulation into cells expressed as the ratio between the size of 
the red area (Dil-oxLDL) and cell number. (Data are expressed as average ± SEM of n = 10 
biological replicates. *** p < 0.0001). C., D. Quantification of the total cholesterol in 
macrophages treated with oxLDL (50 μg/ml) and exposed to MTX, MTX-LIP or MTX-SPN for 8 
and 24h. (Data are reported as average ± SD of n = 4 biological replicates. (* p < 0.01, *** p < 
0.0001). 
 
In addition to the fluorescent signal quantification, the intracellular total cholesterol amounts 
were also measured, following the same treatment conditions as per the confocal microscopy 
analysis above. However, in this case, two different time points were considered, namely 8 and 
24h, for the intervention. Data are provided in Figure 3.3C and D for the LIP- and SPN-based 
treatments at 8 and 24h, respectively. The intracellular total cholesterol analysis confirmed the 
trends observed via confocal fluorescent microscopy. The cholesterol content was observed to 
reduce as moving from untreated foam cells to free MTX-treated foam cells, MTX-LIP and MTX-
SPN treated foam cells and eventually the BMDM, both at 8 and 24h. Larger differences 
between the control groups and the nanoparticle-treated foam cells were detected at 24h as 
compared to the earlier 8h time point. Notice that both MTX-LIP and MTX-SPN were able to 
decrease the intracellular cholesterol content at 8h, returning values of 0.25 ± 0.09 µg/µg 
protein and 0.25± 0.16 µg/µg protein, respectively. At 24h, the two formulations reduced the 
cholesterol amounts to 0.20 ± 0.08 µg/µg protein and 0.31 ± 0.07 µg/µg protein as compared 
to the untreated foam cells 0.44 ± 0.12 µg/µg protein. In general, MTX-LIP tended to be more 
effective than the MTX-SPN, especially at 24h. 
 
Modulating the Expression of Cholesterol Transport and Inflammatory 
Genes in MTX-treated Foam Cells.  
 
The expression of three foam cells markers (ABCA1, CD36 and SRA-1) and three inflammatory 





treatment conditions, namely free MTX, empty LIP, empty SPN, MTX-LIP, MTX-SPN. 
Untreated foam cells and BMDM (not exposed to oxLDL) were used as control groups. The 
foam cell marker ABCA1 is involved in cholesterol efflux; whereas the markers CD36 and SRA-
1 are known to regulate cholesterol influx. The overexpression of CD36 and SRA-1 is a 
landmark for the maturation of macrophages into foam cells. Specifically, it should be here 
recalled that CD36 recognizes the lipid moieties in the oxLDL molecules while SRA-1 binds to 
the oxidized portion of the lipoprotein. [181] The gene expression analysis was performed at 
two different time points, namely 8 and 24h. Data are presented in Figure 3.4 and Figure 3.S9 
and S10, where the gene expression levels are normalized with respect to foam cells, which 
are arbitrarily taken as equal to 1. Importantly, a direct comparison between BMDM (not 
exposed to oxLDL) and foam cells reveals a 2 to 3 times increase in the expression of CD36 
and SRA-1, at both 8 and 24h. Indeed, this continues to demonstrate that an overnight 






Figure 3.4. Expression of Cholesterol Transport and Inflammatory Genes in Macrophages and 
Cell Viability. A. Expression level of foam cells markers (ABCA1, CD36, and SRA-1) in 
macrophages treated with free MTX, MTX-LIP and MTX-SPN for 8h. B. Expression level of 
Pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α,) in macrophages treated with free MTX, 
MTX-LIP and MTX-SPN for 24h. (Data are expressed as average ± SD (n = 5). *** p < 0.0001; 
** p < 0.001; * p < 0.01). C. BMDM viability upon incubation with MTX-LIP (left). The table (right) 
summarizes the IC50 values on BMDM at 24, 48 and 72h post exposure to different therapeutic 






Figure 3.4A shows the expression of the three genes regulating the transport of cholesterol at 
8h. For ABCA1, the relative fold expression increase was equal to 1.383 ± 0.468 for free MTX; 
2.048 ± 0.31 for MTX-LIP; and 2.793 ± 1.14 for MTX-SPN. Indeed, an increase in ABCA1 would 
be mirrored into an increase in cholesterol efflux. For CD36 and SRA-1, modest variations 
around a relative fold expression of 1 were observed for almost all treatments, implying that 
MTX has lower or no significant effect on these genes. Specifically, the relative fold expression 
induced by LIP-MTX was 1.156 ± 0.257 for CD36 and 0.668±0.269 for SRA-1; and that induced 
by MTX-SPN was 0.454 ± 0.279 for CD36 and 0.485 ± 0.096 for SRA-1. This data would 
suggest that the treatment of foam cells with the nanoformulated MTX would induce a 
significant overexpression of ABCA1, thus boosting cholesterol efflux; and a moderate 
downregulation of CD36, which is involved in cholesterol influx. At 24h, on the other hand, a 
strong reduction in the expression of all three genes was recorded for the MTX-SPN (Figure 
3.S9), whereas for the MTX-LIP a significant reduction was observed only for the SRA-1. 
As per the inflammatory response, an overall decrease of all three genes was observed at both 
8 and 24h upon treating the foam cells with either free MTX or MTX-loaded nanoparticles 
(Figure S10). However, the anti-inflammatory effect appears more clearly a 24h (Figure 4B). 
For IL-1β, the relative fold expression was reduced to 0.143 ± 0.129 for the MTX-LIP and to 
0.215 ± 0.065 for the MTX-SPN, which are both comparable with the level of relative expression 
measured in BMDM (0.127±0.067). Free MTX treatment was also able to reduce the IL-1β 
expression but only down to 0.470 ± 0.233. Similarly for IL-6, the level of expression reduced 
by 3 times in comparison to foam cells when using MTX-LIP (0.28 ± 0.18) and MTX-SPN 
(0.2334 ± 0.186) and by 2 times only in the case of free MTX (0.46 ± 0.20). For TNF-α, the 
effect of MTX-LIP and MTX-SPN, as compared to the free drug, was less significant. 
Specifically, the TNF-α relative fold expression levels decreased to 0.302 ± 0.080 for the MTX-
LIP; 0.138 ± 0.101 for the MTX-SPN; and 0.316 ± 0.186 for the free MTX. 
 
In the Figure 3.S9 and S10, data are also provided for the empty LIP and empty SPN. On the 
genes associated with cholesterol transport, the empty LIP induced only a modest decrease in 





the liposomes was negligible. Very differently, the empty SPN were observed to downregulate 
the expression of ABCA1 and upregulate the expression of SRA-1, both at 8 and 24h. On the 
pro-inflammatory genes, both nanoparticles increased the expression of IL-1β, IL-6 and TNF-
α above the levels measured for BMDM (not exposed to oxLDL). This was indeed expected for 
the liposomes, but the pro-inflammatory effect was much higher for the empty SPN than for the 
empty LIP, at all time points and for all genes. This must be related to the low encapsulation 
efficiency and, consequently, large number of SPN needed to administer the prescribed doses 
of MTX, which could eventually lead to medium acidification and local inflammation. [46, 182]  
Before performing animal experiments, the viability of BMDM exposed to different 
concentration of MTX and MTX-loaded nanoparticles was assessed via a conventional MTT 
assays. Figure 3.4C and Figure 3.S11 show the viability of cells treated with free MTX, free 
DSPE-MTX, MTX-LIP and MTX-SPN with a drug concentration ranging from 6 nM to 10 µM. 
Empty LIP and SPN were also tested using a number of particles equivalent to those needed 
for the delivery of a specific MTX dose. The IC50 corresponding to the different treatments are 
provided in the table of Figure 3.4. DSPE-MTX presented a slightly lower IC50 in comparison 
to free MTX of 1.04 ± 0.11 µM vs 2.44 ± 0.13 µM. MTX-LIP showed a similar cytotoxicity to the 
conjugate, with a IC50 = 0.86 ± 0.1; whereas MTX-SPN revealed a slightly higher cytotoxicity 
with a IC50 of 0.42 ± 0.12 µM. No significant toxicity was observed with empty LIP. Differently 
for the empty SPN, a toxicity similar to that of MTX-SPN was found. Again, this negative result 
associated with SPN should be ascribed to the low encapsulation efficiency and large number 
of particles needed to deliver the required amounts of MTX. Based on these observations, the 
following pre-clinical studies were only conducted with MTX-LIP. 
 
Pre-clinical characterization of MTX-Liposomes.  
To directly investigate the effect of MTX-loaded nanoparticles on atherogenesis, apoE-/- mice 
were subjected to 28 days High Fat Diet (HFD) to induce lesion development. Mice were 
concomitantly treated with MTX-LIP or empty LIP for 28 days, with a MTX dose of 2.5 mg 
administered systemically every three days. At the end of the treatment, mice were sacrificed. 





with MTX-LIP presented an area of the aortic sinus plaque that was significantly smaller than 
that detected in control mice, which were treated with empty LIP (Figure 3.5A). Also, the MTX-
LIP treatment had no effect on plaque Collagen content (Figure 3.5B). Analysis on serum 
samples were also conducted (Figure 3.5C). No significant differences in total cholesterol were 
noticed between the two experimental groups. It is therefore unlikely that changes in lipid levels 
could account for the decreased pathology observed with the MTX-nanoparticle treated mice. 
To determine other systemic changes that MTX-LIP may exert on atherosclerosis-driven 
immune responses, a Luminex analysis was performed to quantify a broad spectrum of 
cytokines in the serum samples (Figure 3.5C). A significant (P<0.01) decrease in RANTES 
(CCL5) was detected. This chemokine is expressed by many hematopoietic and non-
hematopoietic cell types and plays an important role in homing and migration of immune cells. 








Figure 3.5. Pre-clinical characterization of MTX-Liposomes. A. Representative 
photomicrographs (left) of oil red O (ORO)-stained aortic sinuses (scale bar: 500 μm) and 
quantification of the mean lesion area (right) for empty LIP and MTX-LIP treatments. B. 
Representative images of plaque Collagen content (left) by picrosirius red staining (scale bar: 
500 μm) and quantification of the Collagen area (right) for empty LIP and MTX-LIP treatments. 
For plots in (A) and (B), individual data points represent average value per mouse; horizontal 





for empty LIP and MTX-LIP treatments. Individual data points represent average value per 
mouse, horizontal bars denote mean. Results are presented as mean ± SEM and analyzed by 
Student unpaired t-test. * p < 0.05, ** p < 0.01. D. Cy5-LIP (red signal) bio-distribution in Liver, 
Spleen, Kidneys and aortic Sinus. Green: α-smooth muscle actin (α-SMA); Blue: cell nuclei. In 
the aortic sinus image: M indicates Media; P indicates Plaque (Scale bar: 20 μm). 
 
Concentrations of eotaxin, fibroblast growth factor-basic, granulocyte-macrophage Colony-
stimulating factor, IFN-γ, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70) 
IL-13, IL-17A, KC, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, 
macrophage inflammatory protein-1β and tumor necrosis factor-α did not differ significantly 
between the two experimental groups or were below the level of detection (Table 3.S2). 
These data may suggest that MTX-LIP mainly exert a local anti-inflammatory effect with minor 
systemic implications. This consideration is in accordance with the biodistribution analysis that 
was performed by immunohistochemistry using Cy5-LIP. These particles maintain the same 
physiochemical features of the MTX-LIP in terms of size and surface charge. Twenty-four hours 
after i.v. injection, Cy5-LIP were detected in the spleen and kidneys (Figure 5D), whereas more 
particles were detected in the liver, as expected, and, more importantly, in the atherosclerotic 
plaque of the aortic root. A similar distribution was also observed in aged (1 year old) apoE-/- 
mice with Cy5-LIP clearly detectable in the plaque core and fibrous cap in the sinus and artic 
arch, in addition to kidney and liver (Figure 3.S12). It is here worth noticing that, as previously 
documented by the authors and other groups [47, 183-185], the percentage of injected 
nanoparticles accumulating in atherosclerotic plaques upon systemic administration is minimal 
as compared to the amounts depositing in organs of the reticuloendothelial system (RES), such 
as the liver and the spleen. To quantitatively assess particle biodistribution, LIP were labeled 
with 64Cu (64Cu-LIP) and injected systemically in healthy mice (C57BL/6). Figure 3.S13.A-B 
documents that the hydrodynamic size of the 64Cu-LIP is comparable to that of MTX-LIP and 
that the radioisotope 64Cu is firmly conjugated to the LIP surface via the chelating agent DOTA. 
Figure 3.S13.C shows the quantitative biodistribution of the 64Cu-LIP confirming a significant 







The oxLDL internalization data and the gene expression results presented in Figure 3.2 – 4 
would suggest that MTX treatments are capable to halt, and possibly reverse, the process of 
maturation of macrophages into foam cells, which is indeed a pivotal step in the process of 
atherogenesis and atherosclerosis progression. Overall, MTX treatments have been shown to 
lower the intracellular deposition of oxLDL in primary rat macrophages mostly by increasing 
the efflux rates (over expression of ABCA1) with a modest variation of the influx rates 
(downregulation of CD36 and SRA-1) (Figure 3.3 and 4A). In particular, at 8h, MTX-LIP and 
MTX-SPN had a different effect on the CD36: MTX-SPN induced a statistically higher reduction 
in CD36 expression as compared to MTX-LIP. This effect of MTX-LIP on the expression of 
CD36 should be ascribed to the very nature of the lipid-based particles. Indeed, liposomes do 
contain cholesterol that could trigger the expression of CD36, as previously reported. [186] 
MTX treatments appeared to have also a significant effect on modulating inflammation by 
reducing the production of different cytokines. Especially at 24h post MTX treatment, the 
expression of IL-1β, IL-6 and TNF-α went down significantly as compared to the foam cell case 
(Figure 3.4B), where inflammation was only induced by direct exposure to oxLDL molecules. 
Importantly, beside the CD36 expression, the effect of MTX-LIP appeared to be statistically 
comparable to that of MTX-SPN in most other cases. This demonstrates that the 
nanoformulations of MTX, even with totally different particles, leads to similar results with a 
general increase in the expression of genes involved in cholesterol efflux, decrease in the 
expression of genes involved in cholesterol influx, and mitigation of the pro-inflammatory 
cytokines production. Inflammation also represents a pivotal step in atherosclerosis initiation 
and progression, in that it favors the sustained recruitment of circulating monocytes within 
vascular lesions and supports their maturation in macrophages and eventually foam cells. 





of the cells to metabolize cholesterol [187] and generate reactive oxygen species triggering 
and sustaining local inflammation. Thus, controlling both oxLDL transport in and out of cells 
and the local state of inflammation may have dramatic implications in halting and possibly 
reversing atherosclerosis. 
It is here important to recall that, recently, it was demonstrated that clinical use of low-dose 
MTX was associated with increased ABCA1 mRNA in peripheral blood mononuclear cells 
(PBMC) of rheumatoid arthritis patients. [188] This change in expression in PBMC was closely 
related to MTX activity. [188] ABCA1 expression is regulated by the adenosine and MTX 
promotes adenosine release, thus causing the overexpression of ABCA1. [39] Thus, the 
efficient delivery of MTX to circulating monocytes and macrophages residing within arterial 
lesions could promote the overexpression of ABCA1 and modulate the risks of acute 
cardiovascular syndromes. However, a low-dose treatment with MTX was not sufficient to 
mitigate the occurrence of cardiovascular events as demonstrated by the recent failure of 
CIRT. [42] Indeed, nanoparticles could more efficiently deliver the therapeutic cargo to the 
biological target, as opposed to the free drug administration, reducing also the risk of adverse 
effects. Importantly, this work shows that even in vitro the nanoformulated MTX is more 
effective than free MTX in modulating foam cell formation and alleviating cell inflammation (see 




Two MTX-loaded nanomedicines were designed, realized and characterized in vitro for their 
physico-chemical and pharmacological properties and in vivo for their ability to modulate 
atherosclerosis in high-fat fed apoE-/- mice. The lipid conjugate DSPE-MTX was either 
dispersed within the hydrophobic PLGA core of Spherical Polymeric Nanoparticles (MTX-SPN) 
or was integrated in the lipid by-layer of liposomes (MTX-LIP). The encapsulation of the MTX 





The ability of MTX to modulate inflammation and regulate the expression of genes involved in 
the transport of oxLDL was extensively demonstrated using different in vitro assays. In general, 
possibly because of the higher loading and encapsulation efficiency, MTX-LIP showed a larger 
impact in reducing the accumulation of oxLDL into macrophages as compared to MTX-SPN 
and free MTX. This was demonstrated both via confocal fluorescent microscopy and gene 
expression quantification. Finally, in apoE-/- mice fed on high-fat diet for 28 days, MTX-LIP were 
shown to accumulate in atherosclerotic plaques developing within the aortic root. This was 
accompanied by a significant decrease in circulating levels of RANTES (CCL5), which is an 
inflammatory chemokine playing a key role in homing and migration of immune cells in the 
vessel walls, and significant reduction in atherosclerotic plaque size.  
Overall, this work would suggest that MTX-nanoparticles could resuscitate the use of this 






3.7. Supporting Information 
 
DSPE-MTX prodrug synthesis. Considering the poor solubility of the Methotrexate (MTX), a 
prodrug with amphiphilic properties was generated by binding MTX to 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-amino (DSPE-NH2). In order to generate the prodrug, 
MTX was pre-activated in loco with a mixture of DCC and NHS, then conjugated with DSPE-
NH2. Compound purification was achieved by precipitation in cold diethyl ether. 
 
Figure 3.S1. Synthesis of prodrug.  
 
MTX-loaded nanoparticles stability under slightly acidic conditions 
pH=6.5






































Figure 3.S2. Particle stability at pH=6.5. 
 
MTX-SPN optimization. Optimization of SPN. To find the optimal formulation, MTX-SPNs 
were produced using different amounts of PLGA and DPPC and using PLGA with different 





optimal formulation, MTX-SPNs were produced using different amounts of PLGA and DPPC 
and using PLGA with different molecular weights (25-35KDa or 38-53KDa). All the formulations 
presented average sizes ranging from 200 to 225 nm and showed a negative ζ-potential 
ranging from - 41 to - 54 mV. With the increase of PLGA amount a relative increase on the 
nanoparticles size was retrieved. The negative charge is related to DSPE-PEG-COOH 
carboxylic groups exposed on SPNs surface. As shown in Figure S3A and B the amount of 
PLGA also affected DSPE-MTX encapsulation efficiency (EE%) which increases proportionally 
to PLGA amount, passing from about 0.2% to 0.5 % for the lowest molecular weight PLGA 
(25-35KDa) and from 0.4% to 1.5% for the highest (38-53kDa). EE% was also affected by the 
presence of DPPC, by removing DPPC the amount of internalized prodrug increased. This 
finding is probably related to a competition between DSPE-MTX and DPPC on the stabilization 
of the PLGA during the addition to the aqueous phase on the preparation of the nanoparticles. 
Basing on these considerations, SPNs 12 formulation was selected (Table S1, Figure S3). 
Starting from now on, we will refer to SPNs12 as MTX-SPNs. 
 











Figure 3.S3. A. and B. Different formulations with different amounts of PLGA and DPPC: EE% 
of DSPE-MTX.  
 
Oxidized Low Density Lipoproteins (oxLDL) 
 
Figure 3.S4. TEM images of LDL molecules (left), oxLDL molecules (center), Dil-oxLDL (right) 
(scale bar = 50 μm). 
 
Figure 3.S5. Incubation of oxLDL with macrophages (RAW 264.7). A. 0 g/ml oxLDL; B. 20 






Intracellular localization of oxLDL. To observe oxLDL intracellular distribution at confocal 
microscopy oxLDL were stained using DiI; for this experiment living RAW 264.7 were treated 
with 488-lysotracker to highlight lysosomes and with a concentration of Dil-oxLDL equivalent 
to 50 µg/ml of oxLDL. As it is possible to appreciate the green signal from lysosomes and the 
red signal from oxLDL co-localize almost completely, proving oxLDL accumulation mainly 
occurs into lysosomes (Figure S6A). Control cells were treated only with DiI (instead of DiI-
oxLDL) following the same conditions, as it is possible to observe in Figure S6B. No co-
localization at lysosomes was observed. Red signal coming from DiI was confined to plasma 
membrane. It is also important to underline that in cells treated with DiI-oxLDL no fluorescent 




Figure 3.S6. Raw 264.7 cells treated with A. Dil-oxLDL and B. Free Dil. In red Dil and Dil-






Figure 3.S7. TEM images of macrophages. A. RAW 264.7 cells not exposed to oxLDL show 
dark lysosomal structures. B. RAW 264.7 cells exposed to oxLDL (overnight, 50 g/ml) show 
light lysosomal structures due to the high lipid content. 
 
Stable association of Dil and oxLDL molecules. To furtherly demonstrate the stability of 
oxLDL and DiI a time-lapse microscopy experiment was performed (Movie S1 and S2). 
Following the same condition living BMDM were incubated overnight with Dil-oxLDL or with 
Dil. 14 hours after treatment cells were observed at the microscope and movies (Movie S1) 
were recorded. In Dil-oxLDL treated cells it is possible to note particulate movement inside the 
cell referring to Dil-oxLDL trafficking; in free Dil treated cells, Movie S2, instead the fluorescent 
signal is revealed from firm spots most likely located in plasma membrane. 
 
 








Expression levels for the genes regulating the cholesterol transport 
 
 
Figure 3.S9. A-D. Foam cells markers expression level (ABCA1, CD36, and SR-A1) in foam 
cells (treated for 8 and 24 hours with the free and empty/loaded drug in LIP and SPN). Results 










Expression levels for the genes associated with the anti-inflammatory cytokines 
 
 
Figure 3.S10. A-D. Pro-inflammatory cytokines expression levels (TNF-α, IL-1β, and IL-6) in 
foam cells (treated for 8 and 24 hours with the free and empty/loaded drug in LIP and SPN). 







Figure 3.S11. A-E. Viability of BMDM incubated with MTX, DSPE-MTX, empty SPN, MTX-


























Figure 3.S12. Representative Bio-distribution confocal imaging after injection of Cy5-
liposomes (red signal) in a one-year-old female apoE-/- mouse. Liver (A), and kidney (B), aortic 
arch: initial portion (C), middle portion (D) and aortic sinus (C). In C and D α-smooth muscle 
actin (α-SMA) was stained by immunofluorescence (green signal), in all of the images cell 
nuclei were stained using DAPI (blue signal). Insets: M= Media; P= Plaque. 
 
Figure 3.S13. Bio-distribution study. A. DLS analysis of 64Cu-LIP. B. Release study of 64Cu 
from LIP. C. Quantitative assessment of radioactivity distribution in selected tissues 24 h after 






Chapter 4  
 
Lipid nanoparticles encapsulating Methotrexate and 




Inflammation is one of the hallmarks in initiation, progression and in eventual thrombotic 
manifestations in Atherosclerosis. Hence, treatment with anti-inflammatory drugs, like 
methotrexate (MTX) and Colchicine (Col), could decrease the inflammation. Here, MTX-lipid 
conjugates, based on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and Col were 
proposed as drugs and co-loaded in the lipid bi-layer of liposomes (LipComb). The particles 
had an average size of 100 nm and presented a stability up to 4 days. They showed an 
encapsulation efficiency of ~ 28 % for MTX and ~ 33 % for Col with a ratio of 1:16. Treatment 
with the liposomes was found to significantly reduce LPS induced inflammation in primary 
BMDM cell line. At the same time, they also mitigated the overexpression of ABCA1, a gene 
involved in the oxLDL efflux from the cells. This also resulted in a strong reduction of the 
expression of IL-1β by 3-fold, IL-6 by 2-fold and also moderately of TNF-α. These results 
suggest that the combination of the chemotherapeutic drugs could strongly reduce the 








Atherosclerosis is a complex disease process that shows inflammation as one of the key 
players in its initiation, progression, and eventually thrombotic manifestations. It is 
characterized by the formation of complex subintimal plaques that restrict luminal blood flow, 
increasing the possibility of thrombotic occlusion and tissue infarction.[189] Stable plaques are 
characterized by chronic inflammatory infiltrate, while vulnerable plaques present active 
inflammation that could lead to plaque rupture [190]. Inflammation is involved in all the forms 
of plaque [22, 191]. In fact, van der Wall et al. provided evidence that there is a relationship 
among an inflammatory infiltrate, plaque rupture, and thrombosis [192]. These observations 
suggested that macrophages had a pathogenic role at the site of cap rupture in patients with 
fatal acute myocardial infarction [192]. The current therapies for atherosclerotic coronary artery 
disease (CAD), like the lipid-lowering statins, do not adequately control plaque inflammation. 
In the last years, the attention was focalized on alternative strategy using generic drugs with a 
broad anti-inflammatory properties for atheroprotection. Particularly, Methotrexate and 
Colchicine are currently under investigation in clinical trials.  The first one is an inexpensive 
chemotherapeutic drug with pleiotropic upstream anti-inflammatory activity. It is used as first 
line therapy for conditions characterized by systemic inflammation, such as rheumatoid arthritis 
and psoriasis. Low dose of Methotrexate increases levels of adenosine down-regulating 
inflammation through several mechanisms.[193, 194] While, Colchicine is an anti-inflammatory 
drug used for the treatment of gout and other disorders, like familial Mediterranean fever (FMF) 
and recurrent pericarditis. Recently, it was discovered that it attenuated the activation of the 
NLR family pyrin domain containing 3 (NLRP3) inflammasome in Colchicine-treated 
neutrophils and macrophages as a response to monosodium urate crystals in the setting of 
gout. [195, 196] However, it is important to underline the various side effects on patients (e.g., 
neutropenia, infection, thrombocytopenia, liver and gastrointestinal toxicity, anemia, mucositis, 
and others) caused from both the drugs[148, 197]. To overcome the side effects, anti-





previous work, the authors conjugated MTX to a lipid chain and deliver the prodrug using 
liposomes[90]. The authors showed that MTX-liposomes were able to increase the expulsion 
of cholesterol from foam cells leading to a reduction of pro-inflammatory cytokines expression 
compare with free drug. In vivo studies demonstrated that MTX-liposomes effectively reduced 
plaque area in ApoE-/- supporting the concept that a systemic delivery of MTX loaded particles 
may constitute an effective strategy to inhibit early atherogenesis.[90] In contemporaneous, 
other studies have shown the potency of nano-systems delivering Colchicine. [91, 198] 
Delivering Colchicine, by using a thermo-sensitive polymer hydrogel, resulted in a more 
efficient treatment than the free drug, alleviating the cardiac inflammation and inhibiting 
myocardial apoptosis and fibrosis. This data was reflected on the increased survival rate study 
on a group receiving the system compare to free administration of Colchicine in murine model. 
[198] 
In this work, MTX and COL were co-loaded, into liposomes to improve and increase its 
therapeutic efficiency. In contrast to previous works, these nanoparticles were realized using 
a microfluidic system, Nanoassemblr. Specifically, lipid-MTX conjugate, obtained by reacting 
MTX with the lipid chain 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) was 
incorporated in the structure or in the bilayer of the liposomes while Col was encapsulated in 
the aqueous core. After extensive biophysical and pharmacological characterizations, MTX-
COL-loaded liposomes (LipComb) were tested in vitro to demonstrate their ability to reduce 
the inflammation, modulating oxLDL uptake, on the macrophages. 
 
4.3. Materials and Methods 
 
Materials: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-Hydroxysuccinimide 
(NHS), Triethylamine (TEA), Low-density lipoproteins (LDL) and Colchicine were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Methotrexate (MTX) was bought by AlfaAesar 
(Haverhill, MA, USA). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-





phosphoethanolamine (DSPE_NH2), 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
were purchased from Avanti Polar Lipid (Alabaster, AL, USA). All reagents and solvents were 
used without further purification. 
 
Synthesis of DSPE-MTX.  
DSPE-MTX was synthesized as reported by Di Francesco and coworkers.[90] Briefly, 30 mg 
of MTX was incubated with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / N-
Hydroxysuccinimide (NHS) in Dimethyl sulfoxide (DMSO) for 30 minutes, at room temperature. 
After the dissolution of the DSPE in DMSO, it was added to the previous solution. A catalytic 
amount of triethylamine (TEA) was added to the reaction and left to stir for 72 hours. The 
mixture was washed with cold diethyl ether. Finally, the prodrug was lyophilized and stored at 
-20°C. 
 
Synthesis of LipCombo.  
DPPC, cholesterol, DSPE-PEG2000 (6:3:1) and DSPE-MTX (1.5mg/ml) was dissolved in 
EtOH, while Colchicine (0.005 mg/ml) in PBS. The organic solvent with dissolved lipids and an 
aqueous solution with Colchicine was injected into the two inlets of the Nanoassemblr. 
Aqueous dispersions of the liposomes was Collected from the outlet, resulting from the mixing 
of two adjacent streams and dialysed against PBS for 1h a 4°C in order to remove the excess 
EtOH. 
 
Drug loading and release.  
To measure the MTX and Col encapsulation efficiency (EE), the samples were lyophilized, 
dissolved in acetonitrile/H2O (1:1, v/v), and analyzed by high-performance liquid 
chromatography (HPLC) (Agilent 1260 Infinity, Germany) equipped with a 100 μL sample loop 





chromatographic separation. MTX and Col was eluted under isocratic conditions using a binary 
solvent system [H2O + 0.1% (v/v) TFA, 43:57 v/v] pumped at a flow rate of 1.0 mL/min.  
EE was determined using the following equation:  
 
𝐸𝐸 (%) =
𝑀𝑇𝑋/𝐶𝑂𝐿 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑀𝑇𝑋/𝐶𝑂𝐿 𝑖𝑛𝑖𝑧𝑖𝑎𝑙 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑎𝑚𝑜𝑢𝑛𝑡
× 100 
  
To study MTX and Col-release kinetics, 200 μL of MTX-Col-nanoparticle solution was placed 
into Slide-A-Lyzer MINI dialysis microtubes with a molecular cutoff of 10 kDa (Thermo 
Scientific) and dialysed against 4 L of PBS buffer (pH 7.4). For each time point, three samples 
were Collected and dried. All the samples were destroyed with cold methanol, left to dry, 
dissolved in acetonitrile/H2O (1:1, v/v) and analyzed by HPLC for the MTX. The experimental 
data were fitted by using the Ritger–Peppas model for controlled, not swellable drug-delivery 
systems [199] (Y = k × xn), where Y represents the drug percentage released, x is the time of 
observation, and k and n are the fitting parameters.  
 
LDL oxidation.  
LDL (2 mg/ml) were incubated with 5 mM CuSO4 at 37°C for 4h without EDTA. The reaction 
was interrupted with the addition of EDTA (5 mM). The formed oxidized LDL molecules (oxLDL) 
were dialyzed against PBS containing 0.01% EDTA at 4°C for 24 h and stored at 4°C. 
 
Bone Marrow Derived Macrophages.  
For Bone Marrow Derived Macrophages (BMDM), rat femurs were explanted and the 
extremities were cut off. Then, the bone marrow canal was flushed four times with 500 μL of 
medium. The resulting cell suspension was filtered using a 70 μm cell strainers. Cells were 
seeded in a Petri dish and medium was changed after 3 days to remove unattached cells. 





15% FBS, 1% penicillin/streptomycin, and rat M-CSF (according to vendor indications). Cells 
were cultured under controlled environmental conditions (37°C in 5% CO2). 
 
Foam Cell formation.  
BMDM cells were cultured in DMEM containing, respectively, 15% fetal bovine serum (FBS), 
1% antibiotic (penicillin/streptomycin) and 1% glutamine. Cells were seeded at a density of 
1x105 cells/mL. Macrophages were incubated with 50 µg/ml oxLDL overnight.   
 
Confocal Fluorescent Microscopy imaging and analysis of Aspect Ratio 
and Circularity.  
Confocal images of BMDM were obtained using a Nikon-A1 confocal microscope (Nikon 
Corporation, Japan). MTX-Col-nanoparticles were incubated with macrophages for 5 hours. 
50,000 cells (BMDM) were seeded into each well of a Nunc™ Lab-Tek™ II Chamber Slide™ 
System (Thermo Fisher Scientific, USA) maintaining culturing conditions, as described before. 
After 5 h, the bacterial LPS were added at a concentration of 100 ng/mL and incubated for 4 
h. Macrophages with the culturing media was removed and cells were washed in PBS (Thermo 
Fisher Scientific, USA). Fixation was performed using a 3.7% solution of PFA (Sigma Aldrich, 
USA) for 5 minutes. Cytoskeletal-membrane was stained with Wheat Germ Agglutinin (WGA) 
(Thermo Fisher Scientific, USA) and nuclei with DAPI (Thermo Fisher Scientific, USA) following 
the vendors indications.  For each condition 10 images were taken. Data were analyzed with 
ImageJ. 
 
Gene expression and toxicity.  
BMDMs were cultured at 37°C in 5% CO2, in high-glucose DMEM, supplemented with 15% 
FBS and 1% L-glutamine, according to ATCC instructions. Cells were seeded into 96-well 
plates at a density of 20 × 103 cells per well and incubated for 24, 48, 72 h. Cells were treated 





0.0064, 0.032, 0.16, 0.8, 4, 10 and 0 μM of MTX and 0.4, 2, 10, 50, 250, 625 nM of Col), or 
empty Lip. The MTT solution was added for 4 h and the formed formazan crystals were 
dissolved in ethanol. Absorbance was measured at 570 nm, using 650 nm as the reference 
wavelength (Tecan, Männedorf, Swiss). The percentage of cell viability was assessed 
according to the following equation:  





where AbsT is the absorbance of treated cells and AbsC is the absorbance of untreated cells 
(control). 
The anti-inflammatory effects, namely tumor necrosis factor- α (TNF-α), interleukin-1β (IL-1β), 
and interleukin-6 (IL-6), on the BMDM were tested.LipComb, DSPE-MTX, COL, free Comb 
were incubated for 5h with cells. Then, bacterial LPS was added at a concentration of 100 
ng/mL and incubated for 4 h. At the end, RNA was extracted using a RNAeasy Plus Mini Kit 
(Qiagen) and quantified by NanoDrop2000 (Thermo Scientific, Waltham, Massachusetts, 
USA). Real-time RTPCR was used to measure mRNA levels of inflammatory cytokines. 
The anti-inflammatory effects of LipComb was also tested on foam cells at 8 and 24 h by 
measuring gene expression of three pro-inflammatory cytokines, namely tumor necrosis factor- 
α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in rat BMDMs. The gene expression 
of foam cells markers (CD36 and SRA-1) and cholesterol expulsion ATP-binding cassette 
transporter 1 (ABCA1) was also assessed. Cells were cultured under controlled environmental 
conditions (37 °C in 5% CO2) and seeded into 6-well plates at a density of 4 × 105 cells per 
well. After 10 h, BMDMs were incubated with oxLDL overnight. Cells were treated with MTX-
Col-nanoparticles at 0.16 µM and 0.01 of µM of MTX and Col, respectively and incubated for 
8 and 24 h. To investigate the acute inflammation, BMDM were seeded into 6-well plates and 
treated with MTX-Col-nanoparticles at 0.16 µM and 0.01 of µM of MTX and Col, respectively 
and incubated for 5 hours. Then, bacterial LPS were added at a concentration of 100 ng/mL 





quantified by NanoDrop2000 (Thermo Scientific, Waltham, Massachusetts, USA). Three 
independent biological replicates were run using a Power SYBR Green RNA-to-CT 1-Step Kit 
(Applied Biosystems) and using GAPDH gene expression as a housekeeping gene. Reactions 
were performed in a final volume of 10 μL. Primer pair sequences are listed below: GAPDH: 
5′-CATCACTGCCACCCAGAAGACTG-3′ and 5′-ATGCCAGTGAGCTTCCCGTTCAG-3′; 
TNF-α: 5′-GGTGCCTATGTCTCAGCCTCTT-3′ and 5′-GCCATAGAACTGATGAGAGGGAG-
3′; IL-1β: 5′-AACCTGCTGGTGTGTGACGTTC-3′ and 5′-CAGCACGAGGCTTTTTTGTTGT-3′; 
IL-6: 5′-TACCACTTCACAAGTCGGAGGC-3′ and 5′-CTGCAAGTGCATCATCGTTGTTC-3′; 
CD36: 5′-ATGGGCTGTGATCGGAACTG-3′ and 5′-GTCTTCCCAATAAGCATGTCTCC-3′; 
SRA-1: 5’-CTGAGACCTCTGGAACAGGCAT-3’ and 5′-TGCACTAGCAGTGCCATCCTCT-3′; 
ABCA1: 5′-GGAGCCTTTGTGGAACTCTTCC-3′ and 5′- CGCTCTCTTCAGCCACTTTGAG-3′. 
 
Statistical Analysis.  
All the in vitro data were represented as the average ± standard deviation (SD) of 3 different 
measurements, unless differently specified. The statistical significant difference was assessed 
using ANOVA test, with Bonferroni’s Multiples Comparison Test as post-hoc test. All statistical 




Physico-chemical and pharmacological characterization of MTX-loaded 
nanoparticles.  
Methotrexate (MTX) and Colchicine (Col), two conventional chemotherapeutics with potent 
anti-inflammatory effects, were used to investigate the effect on the treatment of affected by 
atherosclerosis. Problems associated with drugs solubility and bioavailability could be 





both improving their bioavailability and reducing the side effects by enhancing the 
pharmacokinetic and pharmacodynamic properties.  
To this end, MTX and Col were co-loaded in the liposomal structure: MTX in the form of DSPE-
MTX in the bilayer while Col in the aqueous core. This formulation was obtained by a 
systematic optimization process (table 4.1) in order to have a ratio between MTX: Col 16: 1. 
[90, 200, 201] As listed in the table, the concentration of the Colchicine was decreased from 
0.5 to 0.001 mg/ml. Liposomes realized in this work were obtained with 0.005 mg/ml of 
Colchicine in the aqueous phase and 1.5 mg/ml of DSPE-MTX in the organic phase.  
 
Table 4.1. Optimization of the ratio between MTX and COL 
 
 
Particle size and size distribution were evaluated by Dynamic Light Scattering. Particles 
presented an average hydrodynamic diameter of 100 ± 1 nm, with a polydispersity index (PDI) 
0.16 ± 0.02 nm (Figure 4.1A). Given the presence of carboxyl-terminated DSPE-PEG chains, 
LipComb presented a negative  potential of -40 ± 2 mV (Figure 4.1A). Particle stability under 
physiological condition (PBS buffer pH = 7.4, 1X) was evaluated up to 4 days. The liposomal 
formulation appeared stable under physiological conditions showing a percentage change in 
size and PDI lower than 5% through the entire observation period as reported in Figure 4.1B.  
Then, the Encapsulation Efficiency (EE) and the release profile of MTX and Col from the 
nanoformulation was determined using HPLC. MTX and Col encapsulation efficiency was 





mass of the same used during nanoparticle preparation. LipComb presented a modest EE for 
both drugs: 28.2 ± 1.6% and 33.8 ± 5.9 for MTX and Col, respectively with a loading 423.5 ± 
24.7 µg for MTX and 1.7 ± 0.28 µg for Col (Figure 4.1C). The release profiles for MTX and Col 
from Lip were obtained in 4 L PBS buffer (pH= 7.4, 1X) in order to mimic an infinite sink 
condition (Figure 4.1D). Both drugs were rapidly released from Lip. After 9 h, over 70% of both 
drugs were released out from liposomes while after 1 day, almost 90% release of both 
encapsulated MTX and Col was reached. 
 
Figure 4.1. Physico-chemical and pharmacological characterization of MTX-Col-loaded 
nanoparticles. A., B. Hydrodynamic diameter and Colloidal stability of LipComb via dynamic 
light scattering analysis. C. Encapsulation efficiency (%EE); D. release studies for MTX and 






Therapeutic Efficacy of MTX-Col-co-loaded Liposomes  
Before studying the interaction of the liposomes with inflamed macrophages, the potential 
toxicity of free Col, DSPE-MTX, free Comb, and LipComb was assessed on primary phagocytic 
cells (BMDM). A drug concentration ranging from 60 nM to 10 µM and 0.4 to 625 nM was 
tested for the DSPE-MTX and for the Col, respectively. As shown in Figure 4.2, the cell viability 
was dose dependent, but time independent. For further in vitro experiments, a dug 
concentration of 160 nM for DSPE-MTX and 10 nM for the Col was used. In the previous work, 
it was observed that 160 nM had an anti-inflammatory effect and hence it was selected as the 
MTX concentration in this study.12 In the case of COL, 10 nM was the concentration used in 
vitro as the anti-inflammatory drug concentration [200, 201]. 
 
 
Figure 4.2. Cell Viability. BMDM viability upon incubation with DSPE-MTX (A), Colchicine (B), 






For demonstrating the anti-inflammatory activity of these two drugs, BMDM were incubated 
with Col, DSPE-MTX, free Comb, and LipComb (160 nM of DSPE-MTX and 10 nM of Col). 
Then, BMDM were stimulated with LPS for inducing the secretion of TNF-α, IL-1β, and IL-6. 
As reported in Figure 4.3A-C, drugs, free or co-loaded in liposomes, reduced the expression 
of the studied pro-inflammatory cytokines. In particular, when drugs were co-loaded inside 
liposomes, the inflammation was significantly reduced for all tested genes compared to the 
CTR and was slightly higher than the free Comb (Figure 4.3A-C). Results were also confirmed 
by morphology analysis (Figure 4.3D-I). Importantly, cell shape changes have been 
associated with different functional states of cells [202] and morphological modifications 
associated with inflammatory responses [203]. However, there was insufficient information 
about the effect of LPS and other cytokines released in its effect on the morphology of these 
cells[203]. In general, LPS induced a visible change of the morphology and shape of the BMDM 
cells. For the analysis, same treatments were done on BMDM: incubation with Col, DSPE-
MTX, free Comb, and LipComb for 5h followed by LPS stimulation for 4h. At this point, cells 
were washed with PBS, fixed with PFA and stained. Fluorescent images were acquired to 
analyze cells shape. As reported in Figure 4.3D-I, most of the cells maintained a round shape 
in case of control or pretreatment with Col, DSPE-MTX, free Comb, and especially with 
LipComb, while stellate shapes were demonstrated in LPS-stimulated cells. Also, the aspect 
ratio and the circularity of macrophages pre-treated with LipComb were similar to the ones of 
BMDM (untreated control). The analysis suggested that treatments with drug, especially with 






Figure 4.3. Expression of Inflammatory Genes in Macrophages. A-C. Expression level of Pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-α,) in macrophages pre-treated with free DSPE-
MTX, COL, free Comb, LipComb for 5h and with LPS for 4h. (Data are expressed as average 
± SD (n = 5). *** p < 0.0001; ** p < 0.001; * p < 0.01). D. Representative confocal images of 
BMDM pre-treated with LipComb followed by 4h of LPS treatment. H-I. Analysis of Aspect 
Ratio (AR) and circularity of BMDM after treatment with liposomes and LPS. 
 
For evaluating the anti-inflammatory effect in atherosclerosis, the expression of three foam 
cells markers, such as ABCA1, CD36 and SRA-1, and three inflammatory genes, such as IL-





of different treatment conditions (free MTX and Col, free Comb,LipComb) was measured by 
real time PCR. 
The ABCA1 is a foam cell marker involved in the cholesterol cell expulsion and its 
overexpression is correlated to an augmented LDL expulsion, while CD36 and SRA1 are 
involved in oxLDL uptake and their overexpression is considered essential in the transition 
from macrophage to foam cell.[90, 181] In particular, CD36 recognizes oxLDL lipid moieties 
and SRA1 binds the oxidized apo-lipoprotein portion. [181] Gene expression analysis was 
performed at two different time points, namely 8 and 24h, using untreated foam cells and 
BMDM (not exposed to oxLDL) as control groups presented in Figure 3.4. The gene 
expression levels were normalized with respect to foam cells, arbitrarily taken as equal to 1. 
Importantly, a direct comparison between BMDM (not exposed to oxLDL) and foam cells 
revealed an increase of 2 to 3 times of the expression of CD36 and SRA-1, at both time points. 
Indeed, this supports the hypothesis that an overnight exposure of BMDM to 50 µg/ml of oxLDL 
was sufficient to trigger the maturation into foam cells.  
Figure 4.4 (top row) showed the expression of the three genes involved on cholesterol 
transport at 8h. For ABCA1, the relative fold expression increase with respect to untreated 
foam cells was equal to 1.31 ± 0.11 for free DSPE-MTX and 1.084 ± 0.334 for the free Col, 
1.296 ± 0.682 for free Comb, and 1.91 ± 0.66 for LipComb, supporting the idea of an increase 
of cholesterol efflux. For CD36 and SRA-1, slight variations around a relative fold expression 
of 1 were observed for almost all treatments, except for LipComb. Specifically, in this case, the 
relative fold expression induced by LipComb was 0.677 ± 0.083 for CD36 and 0.803±0.0742 
for SRA-1, while 0.909 ± 0.383 for CD36 and 0.854 ± 0.403 for SRA-1 in the case of free Comb. 
Data would suggest that the treatment of foam cells with the nanoformulated LipComb would 
induce a significant overexpression of ABCA1, thus boosting cholesterol efflux. Also, it induced 
a moderate downregulation of CD36, involved in cholesterol influx. On the other hand, after 
24h, a reduction in the expression of all three genes was recorded for all the treatment 







Figure 4.4. Expression of Cholesterol Transport Genes in Macrophages. A. Expression level 
of foam cells markers (ABCA1, CD36, and SRA-1) in macrophages treated with free DSPE-
MTX, COL, free Comb, LipComb for 8h and 24h. (Data are expressed as average ± SD (n = 
5).  * p < 0.01). 
 
As per the inflammatory response, an overall decrease of all three genes expression was 
observed at both 8 and 24h upon treating the foam cells with either free MTX, COL or free 
Comb or MTX-COL-loaded nanoparticles. However, the efficacy of the drug combination on 






Figure 4.5. Expression of Cholesterol Transport and Inflammatory Genes in Macrophages and 
Cell Viability. Expression level of Pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in 
macrophages treated with free DSPE-MTX, COL, free Comb, LipComb for 8h and 24h. (Data 
are expressed as average ± SD (n = 5). *** p < 0.0001; ** p < 0.001; * p < 0.01). 
 
For IL-1β, the relative fold expression was reduced to 0.429 ± 0.154 for the LipComb and to 
0.645 ± 0.211 for the free Comb. Free MTX and Col treatments were also able to reduce the 
IL-1β expression down to 0.504 ± 0.180 and 0.545 ± 0.284, respectively. Similar behavior was 
reported for IL-6. Its expression reduced by 2 times in comparison to foam cells when using 
LipComb (0.400 ± 0.097) and free Comb (0.353 ± 0.289), but also a reduction was observed 
in the case of free DSPE-MTX (0.384 ± 0.295) and free COL (0.514 ± 0.291). For TNF-α, the 
effect of LipComb and free Comb, as compared to the free drugs alone was not significant. 
Specifically, the relative fold expression levels of TNF-α decreased to 0.460 ± 0.148 for the 
LipComb, 0.721 ± 0.217 for the free Comb, and 0.586 ± 0.236 and 0.666 ± 0.210 for the free 







Inflammation represents a key process at the basis of atherosclerosis development and 
progression. In order to target this, MTX and Col were loaded in liposomal formulation with a 
mass ratio of 1: 16 Col: DSPE-MTX. This ratio was selected because, in the previous work, 
authors demonstrated that 160 nM of MTX in liposomes was optimum to obtain important 
results in preventing and reverting the foam cells formation, and so on the inflammation[90].In 
case of Colchicine, Yang et al. demonstrated that 10 nM of the drug inhibited endothelial cell 
inflammation and pyroptosis induced by cholesterol crystals, suggesting its potential use in 
atherosclerosis[201]. The selected ratio between the two drugs was also reflected on their 
EE%. In the previous work[90], authors synthesized, by thin layer evaporation (TLE), 
liposomes-MTX with a size of ~ 150 nm and an EE% ~ 70%. Here, liposomes were obtained 
using a microfluidic device – Nanoassemblr, with different features. These nanoparticles 
presented a hydrodynamic size of 100 nm and an EE% of ~28% for DSPE-MTX and ~34% for 
Colchicine. The lower EE% observed in this case, compared to the previous one, was linked 
to the precise ratio that was chosen. As for the MTX-LIP, the obtained formulation appeared 
stable under physiological conditions up to 4 days (Figure 4.1.) and it resulted in a strong anti-
inflammatory effect on a primary cell line (BMDM). In fact, as reported in Figure 4.3. the 
combination MTX-Col treatment, as free or co-loaded in liposomes, were able to reduce the 
inflammation by decreasing the expression of different cytokines. In particular, after the pre-
treatment of MTX-Col treatment, the expression of IL-1β, IL-6 and TNF-α decreased 
significantly after the stimulation of LPS. In addition, MTX-Col combination treatments, as free 
or co-loaded in liposomes, were capable of stopping, and perhaps reverse, the progression of 
maturation of macrophages into foam cells, the pivotal step in the process of atherogenesis 
and atherosclerosis progression. LipComb increased significantly the expression of ABCA 1 
in foam cells, the gene involved in the efflux of cholesterol from the cell (Figure 4.4). 





as compared to the foam cell, especially after 24h (figure 4.5.). It is important to underline that 
in the foam cell model, inflammation was only induced by exposure to oxLDL molecules.  
These results highlight the ability of LipComb to reduce the expression of inflammatory 
cytokines, to act, both on the genes involved in cholesterol influx (MTX) and on inflammasome 
(Col). These effects were investigated in two different types of inflammation, one induced by 
LPS, and the other induced in foam cells by oxLDL.  In our previous work, [90] we 
demonstrated the role of the MTX on the foam cell maturation and the progression of 
inflammation. Inflammation recalls the recruitment of monocytes in the vascular lesion, 
promoting their differentiation in macrophages and eventually foam cells.[143] As already 
reported, inflammation has an important role in the onset and progression of atherosclerosis 
and thrombosis. In particular, the chronic inflammation, immune activation, and oxidative 
stress of the arterial wall characterize atherosclerosis. [86] Moreover, all the cardiovascular 
risks start with the promotion of endothelial dysfunction and vascular damage. [87] The 
hypothesis that combined the effect of MTX and Col could be a good strategy for the reduction 
of the inflammation was also investigated by Robert G. Weiss at the Johns Hopkins University. 
He started a clinical trial for exploring the therapeutic efficacy of Methotrexate, Colchicine 
and/or their combination on coronary arteries function (Inflammation and Coronary Endothelial 
Function), more specifically on the inner lining of the arteries called the endothelium 
(ClinicalTrials.gov Identifier: NCT02366091). He is currently investigating the effect of 
inflammation on the artery's normal function using magnetic resonance imaging (MRI). This 
study is still ongoing, but MTX and Col anti-inflammatory effect, as a combination, needs to be 
investigated in detail. This study, also, highlights the synergic effect that these drugs could 
have when combined, supporting the idea/results of this work. Again, inflammation has an 
important role in the atherosclerosis and acting on it could reduce the progression of the 
pathology. Many authors investigated the effect of single drugs in atherosclerosis. It was 
demonstrated that Methotrexate loaded liposomes acts consistently on intracellular 





delivered using thermos-sensitive polymer hydrogel, alleviated cardiac inflammation and 
inhibited myocardial apoptosis and fibrosis.[198] Indeed, the use of a drug delivery system 
could more efficiently deliver the two chemotherapeutic drugs to the target reducing the risk of 
adverse effects. Notably, this is the first work which demonstrated in vitro that liposomes co-
loaded MTX and Col reduced the inflammation in a better way compared to free MTX, Col or 





Liposomes were synthesized with a microfluidic system (Nanoassemblr). This formulation 
was optimized for the co-loading of potent chemotherapeutic molecules, such as 
Methotrexate (conjugated a lipid chain) and Colchicine.  Obtained particles were stable in 
the physiological environment up to 4 days, with a hydrodynamic average size of 100 nm. 
They were characterized and loaded with potent chemotherapeutic molecules, 
Methotrexate (conjugated a lipid chain), and Colchicine. MTX, conjugated with a lipid 
chain, was intercalated in the bilayer (becoming a part of the liposome structure) while the 
COL was loaded in the aqueous core. They were characterized in vitro for their Physico-
chemical and pharmacological properties. The potency in reducing the inflammation was 










Methotrexate (MTX) has played an important role in the treatment of several diseases [96, 204]. 
However, its application is limited by its poor solubility, toxic side effects, and nonspecific 
accumulation in the target site [124]. One of the first outcomes of this experimental work was to 
establish strategies for increasing MTX efficacy and decreasing side effects by combining 
chemistry and nanomedicine. In this attempt, chemical modifications were performed in order to 
improve MTX solubility in common organic solvents used for particle synthesis, such as chloroform 
and Dichloromethane. Two different compounds, DSPE and PEG, were selected for developing 
MTX-prodrugs (DSPE-MTX and PEG-MTX). These modifications had an impact on the solubility 
of the original molecule. Three different software (Biovia, VCCLab and ACD ChemSchetch) were 
used to analyze the partition coefficient (Log P) of MTX and the two developed prodrugs. The 
mathematical analysis revealed that MTX and PEG-MTX could be equally dissolved both in water 
and organic solvents (MTX: log P. = 0.11; -0.91; 0.023; PEG-MTX: log P. = -0.67; 0.42; -0.43), 
while DSPE-MTX was mainly soluble in organic solvents (DSPE-MTX: log P. = 13.84; 7.53; 16.63). 
On the contrary, experimentally, MTX had shown a very low solubility both in water and organic 
solvents. Although the PEG-MTX featured a similar theoretical solubility, experimentally, it 
presented a more hybrid behavior, revealing a higher solubility in water and organic solvents 
compared to MTX. The reason for this behavior might be related to the amphiphilic properties of 
this prodrug, which could spontaneously organize in small structures. This factor was probably not 
taken into consideration by the software algorithms. Similar amphiphilic behavior was observed for 
MTX-DSPE. Due to this behavior, DSPE-MTX, PEG-MTX or both compounds were loaded 





The three formulations, DSPE-MTX/Lip, PEG-MTX/Lip and Combo-Lip, presented a similar 
physio-chemical feature but different stability over time in the acidic microenvironment (pH=6.5). 
In this environment, liposomes with PEG-MTX showed stability up to 3 days compared to the 
liposomes with DSPE-MTX or both prodrugs. All three formulations showed a biphasic release 
profile under infinite sink conditions (v = 4L). Specifically, DSPE-MTX and PEG-MTX formulations 
showed a burst drug release within the first 9 hours, with approximately 60% of the drug released, 
while the combo exhibited a faster release with 75% of DSPE-MTX/PEG-MTX after 9 hours. The 
remaining portion of drugs was slowly and continuously released over time, yielding a ~ 95% 
release after 1 day for Combo and 3 days for both DSPE-MTX or PEG-MTX. In general, multiple 
mechanisms, such as diffusion and erosion, act simultaneously during the release study for all the 
three liposomal formulations, as demonstrated by fitting the release data in various mathematical 
models. These might be related to the different interactions of the prodrugs with lipids and PEG-
lipids in the liposomal structure.  
In the last decade, MTX was proposed as an anti-inflammatory agent for treating atherosclerosis 
in patients affected by chronic inflammatory diseases [32].  Considering this, we suggested the 
use of MTX for reducing or reverting foam cell formation (mainly responsible for the plaque 
formation). The prodrug DSPE-MTX was loaded in two different nanoplatforms, the previously 
synthesized liposomes (LIP), and new polymeric nanoparticles (SPNs), to study their efficacy for 
the treatment of atherosclerosis. An in vitro comparative study was effectuated to assess the 
effectivity of the platforms. While LIP are spherical vesicles composed of a phospholipid bilayer, 
SPNs are spherical particles characterized by a hydrophobic core of PLGA stabilized by a lipid 
monolayer. 
Particles with an average size of around 200 nm for both lipidic and polymeric formulations were 
obtained. Both formulations were characterized by a moderate polydispersity index (PDI)  0.15, 
and a negative surface electrostatic ζ potential. They presented similar stability under physiological 
conditions (pH = 7.4) and an instability in a slightly acidic environment (pH = 6.5). However, a 





MTX-LIP an encapsulation efficiency equal to 70.5 ± 4.8% was achieved, whereas this value 
dropped to only 1.5  0.7% for the MTX-SPN. Their anti-inflammatory activity was evaluated in 
vitro on foam cells. Both formulations were actively uptaken by Bone Marrow-Derived Monocytes 
(BMDM). Results showed that the percentage (86.66 ± 3.59; 90.60 ± 2.23 and 87.30 ± 0.96 for 
LIP; 82.2 ± 1.1; 83.43 ± 2.82 and 82.87 ± 2.67 for SPN) of BMDM (used as control) associated 
with nanoparticles (i.e., percentage of positive events) was quite constant over time for both LIP 
and SPN for the three tested time points (2, 8 and 24h). The same study was realized on foam 
cells. It emerges from this study that the uptake was slightly lower when compared with BMDM 
(76.7 ± 0.14; 66.1 ± 2.26; 54.6 ± 0.71 for LIP, and 70.8 ± 5; 67.1 ± 2.54; 57.65 ± 1.06 for SPN), 
probably due to the large amounts of oxLDL stored in their lysosomes that could affect the cells’ 
internalization capacity. 
The variation of cholesterol on the cells before and upon the treatment was also quantified. Results 
showed that total intracellular cholesterol reduced as we moved from untreated foam cells to free 
MTX-treated foam cells, to MTX-LIP (0.20 ± 0.08 µg/µg) or MTX-SPNs (0.31 ± 0.07 µg/µg) treated 
foam cells (0.44 ± 0.12 µg/µg protein), and eventually to the BMDM, at 24h. In general, MTX-LIP 
was found to be more effective than the MTX-SPN. These results were in agreement with the 
expression of three foam cell markers (ABCA1, CD36, and SRA-1) and three inflammatory genes 
(IL-1β; IL-6, and TNF-α). In fact, MTX treatments, at 8h, appeared to have a significant effect on 
modulating inflammation by increasing the production of ABCA1, especially MTX-nanoparticles 
(1.383 ± 0.468 for free MTX; 2.048 ± 0.31 for MTX-LIP; and 2.793 ± 1.14 for MTX-SPN) and modest 
variations around a relative fold expression of 1 were observed for the CD36 and SRA-1. At 24h 
post MTX treatment, the expression of IL-1β, IL-6, and TNF-α went down significantly as compared 
to the case of foam cells. Both formulations were also tested for their biocompatibility on BMDM. 
Results showed that polymer formulation, empty or loaded MTX (IC50 of 1.7 ± 0.07 and 0.42 ± 0.12 
µM, respectively) has a slightly higher cytotoxicity than LIP one (IC50 = 0.86 ± 0.1 µM). No 
significant toxicity was observed with empty LIP. Based on these observations, the following pre-





demonstrated that the mice treated with MTX-LIP presented a reduction of the aortic sinus plaque 
compared with the control mice treated with empty LIP. No significant differences in total 
cholesterol and Luminex analysis were noticed between the two experimental groups. These data 
may suggest that MTX-LIP mainly exerted a local anti-inflammatory effect with minor systemic 
implications, as supported by the biodistribution study.  
Based on these results and the new evidence on the impact of inflammation on arteriosclerosis, a 
strategy was envisaged to increase the anti-inflammatory effect of the previously developed 
liposomal formulation. In particular, the anti-inflammatory effect of MTX in combination with 
Colchicine, a chemotherapeutic drug, was investigated. Colchicine (COL) is generally used as an 
anti-inflammatory drug to treat gout and other disorders [68]. Recently, it was discovered that it 
attenuated the activation of the NLRP3 inflammasome. Based on this evidence, both drugs, COL 
and DSPE-MTX, were co-loaded in liposomal constructs to boost the anti-inflammatory effect by 
acting in different pathways of the inflammatory cascade. For this purpose, the nanoformulation 
was developed with the help of a microfluidic system, Nanoassemblr. With the use of the 
microfluidic system, particles presented an average size of around 100 nm, slightly lower than the 
liposomes from the previous study, a narrow size distribution (0.16 ± 0.02), and a negative ζ 
potential -40 ± 2 mV. A molar ratio between the two drugs of 16:1 MTX: COL was fixed after 
systematic optimization. MTX-Col-LIP presented an EE of 28.2 ± 1.6% and 33.8 ± 5.9 for MTX and 
Col, respectively. The developed formulation was stable under a physiological environment 
(pH=7.4) within 4 days.  After evaluating their cytotoxicity activity, particles were tested for their 
anti-inflammatory effect in vitro on foam cells. Results showed that drug co-loaded liposomes 
reduced the inflammation significantly compared to the CTR for all the genes taken into account 
(TNF-α, IL-1β, and IL-6), as also confirmed by the morphological analysis. Combo-lip treatment for 
8 h induced higher production of ABCA1 than the single drugs, either alone or in combination. 
However, the anti-inflammatory effect of the drug combination loaded liposomes appears more 
clearly after 24h of treatment. These are only preliminary results, and further investigations are 





the treatment of atherosclerosis. In vivo studies will be performed in order to assess the effect of 
MTX and Col as a combination in liposomes on the plaque progression, plaque composition, and 
vessel wall inflammation. For the quantification of plaque burden that is a good indicator of future 
coronary events, imaging techniques including magnetic resonance imaging (MRI) can be used. . 
Additionally, positron-emission tomography with 18F-fluorodeoxyglucose combined with computed 
tomography (18F-FDG PET/CT) can be used to analyze the inflammatory activity within the 
atherosclerotic vessel (by monitoring the change of 18F-FDG uptake). On the other hand, the 
histological density of macrophages can be used to confirm the infiltration of macrophages in an 
area characterized by more inflammation. In conclusion, the thesis provides important insights into 






List of Publications 
 
 Di Francesco V, Di Francesco M, Decuzzi P, Palomba R, Ferreira MFMM. “Synthesis of 
Two Methotrexate Prodrugs for Optimizing Drug Loading into Liposomes”. Pharmaceutics, 
2021, 13.3: 332. doi.org/10.3390/pharmaceutics13030332. 
 
 Di Francesco V, Gurgone D, Palomba R, Ferreira MFMM, Catelani T, Cervadoro A, Maffia 
P, Decuzzi P. “Modulating lipoprotein transcellular transport and atherosclerotic plaque 
formation in apoE -/- mice via nanoformulated lipid-methotrexate” ACS Appl Mater 
Interfaces. 2020 Jul 28. doi: 10.1021/acsami.0c12202. 
 
 Ferreira M, Rizzuti IF, Palange AL, Barbato MG, Di Francesco V, Di Francesco M, Decuzzi 
P, “Optimizing the pharmacological properties of discoidal polymeric nanoconstructs 
against triple negative breast cancer cells”, Front Bioeng Biotechnol, 2020, doi: 
10.3389/fbioe.2020.00005. 
 
 Di Francesco M, Primavera R, Summa M, Pannuzzo M, Di Francesco V, Di Mascolo D, 
Bertorelli R, Decuzzi P,”Engineering shape-defined PLGA microPlates for the sustained 




Best oral communication award at the 1st International Northern-Southern Europe Workshop in 









1. Abubakar, I., T. Tillmann, and A. Banerjee, Global, regional, and national age-sex specific all-
cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis 
for the Global Burden of Disease Study 2013. Lancet, 2015. 385(9963): p. 117-171. 
2. Mozaffarian, D., Global scourge of cardiovascular disease: time for health care systems 
reform and precision population health. 2017, American College of Cardiology Foundation 
Washington, DC. 
3. Roth, G.A., et al., Global, regional, and national burden of cardiovascular diseases for 10 
causes, 1990 to 2015. Journal of the American College of Cardiology, 2017. 70(1): p. 1-25. 
4. WHO. About cardiovascular diseases. Geneva: World Health Organization. November 6, 
2019]; Available from: https://www.who.int/cardiovascular_diseases/about_cvd/en/. 
5. Lnsis, A., Atherosclenrosis. Nature, 2000. 407: p. 233-241. 
6. Lusis, A.J., Insight review articles. Nature. Nat Publ Gr, 2000. 407: p. 233-41. 
7. Hossain, S.S., et al., Magnetic resonance imaging-based computational modelling of blood 
flow and nanomedicine deposition in patients with peripheral arterial disease. Journal of The 
Royal Society Interface, 2015. 12(106): p. 20150001. 
8. Davies, P.F., Hemodynamic shear stress and the endothelium in cardiovascular 
pathophysiology. Nature clinical practice Cardiovascular medicine, 2009. 6(1): p. 16-26. 
9. Gargiulo, S., M. Gramanzini, and M. Mancini, Molecular imaging of vulnerable 
atherosclerotic plaques in animal models. International journal of molecular sciences, 2016. 
17(9): p. 1511. 
10. Cochain, C. and A. Zernecke, Macrophages in vascular inflammation and atherosclerosis. 
Pflügers Archiv-European Journal of Physiology, 2017. 469(3-4): p. 485-499. 
11. Skålén, K., et al., Subendothelial retention of atherogenic lipoproteins in early 
atherosclerosis. Nature, 2002. 417(6890): p. 750-754. 
12. Ley, K. and Y. Huo, VCAM-1 is critical in atherosclerosis. Journal of Clinical Investigation, 
2001. 107(10): p. 1209-1210. 
13. Escate, R., T. Padro, and L. Badimon, LDL accelerates monocyte to macrophage 
differentiation: effects on adhesion and anoikis. Atherosclerosis, 2016. 246: p. 177-186. 
14. Rubic, T., M. Trottmann, and R.L. Lorenz, Stimulation of CD36 and the key effector of reverse 
cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochemical 
pharmacology, 2004. 67(3): p. 411-419. 
15. Jamkhande, P., et al., Therapeutic approaches to drug targets in atherosclerosis, Saudi 
Pharm. Saudi Pharmaceutical Journal, 2014. 
16. Ross, S., et al., Effect of bile acid sequestrants on the risk of cardiovascular events: a 
Mendelian randomization analysis. Circulation: Cardiovascular Genetics, 2015. 8(4): p. 618-
627. 
17. Naghavi, M., et al., From vulnerable plaque to vulnerable patient: a call for new definitions 
and risk assessment strategies: Part I. Circulation, 2003. 108(14): p. 1664-1672. 
18. Tarkin, J.M., et al., Imaging atherosclerosis. Circulation research, 2016. 118(4): p. 750-769. 
19. Kockx, M. and M. Knaapen, Pathological changes in the coronary arteries in the acute 
coronary syndromes. Heart, 2006. 92(11): p. 1557-1558. 
20. Rioufol, G., et al., Multiple atherosclerotic plaque rupture in acute coronary syndrome: a 
three-vessel intravascular ultrasound study. Circulation, 2002. 106(7): p. 804-808. 
21. Hansson, G.K., Inflammation and atherosclerosis: the end of a controversy. Circulation, 2017. 
136(20): p. 1875-1877. 
22. Ross, R., Atherosclerosis—an inflammatory disease. New England journal of medicine, 1999. 





23. Palmer, R.D. and M. Vaccarezza, New promises and challenges on inflammation and 
atherosclerosis: insights from CANTOS and CIRT Trials. Frontiers in cardiovascular medicine, 
2019. 6: p. 90. 
24. Riccioni, G. and V. Sblendorio, Atherosclerosis: from biology to pharmacological treatment. 
Journal of geriatric cardiology: JGC, 2012. 9(3): p. 305. 
25. Galván-Peña, S. and L.A. O’Neill, Metabolic reprograming in macrophage polarization. 
Frontiers in immunology, 2014. 5: p. 420. 
26. Hoeksema, M.A., J.L. Stöger, and M.P. de Winther, Molecular pathways regulating 
macrophage polarization: implications for atherosclerosis. Current atherosclerosis reports, 
2012. 14(3): p. 254-263. 
27. Bi, Y., et al., M2 macrophages as a potential target for antiatherosclerosis treatment. Neural 
plasticity, 2019. 2019. 
28. Chan, E.S. and B.N. Cronstein, Mechanisms of action of methotrexate. Bulletin of the NYU 
Hospital for Joint Diseases, 2013. 71(suppl 1): p. S5. 
29. !!! INVALID CITATION !!! . 
30. Chistiakov, D.A., et al., Mechanisms of foam cell formation in atherosclerosis. Journal of 
Molecular Medicine, 2017. 95(11): p. 1153-1165. 
31. Chistiakov, D.A., Y.V. Bobryshev, and A.N. Orekhov, Macrophage‐mediated cholesterol 
handling in atherosclerosis. Journal of cellular and molecular medicine, 2016. 20(1): p. 17-28. 
32. De Vecchis, R., C. Baldi, and L. Palmisani, Protective effects of methotrexate against ischemic 
cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel 
therapeutic insights coming from a meta-analysis of the literature data. Anatolian journal of 
cardiology, 2016. 16(1): p. 2. 
33. Bulgarelli, A., et al., Treatment with methotrexate inhibits atherogenesis in cholesterol-fed 
rabbits. Journal of cardiovascular pharmacology, 2012. 59(4): p. 308-314. 
34. Nishina, N., et al., Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with 
early rheumatoid arthritis: a potential biomarker for radiographic progression. Clinical 
rheumatology, 2013. 32(11): p. 1661-1666. 
35. Singh, J.A., et al., 2012 update of the 2008 American College of Rheumatology 
recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents 
in the treatment of rheumatoid arthritis. Arthritis care & research, 2012. 64(5): p. 625-639. 
36. Micha, R., et al., Systematic review and meta-analysis of methotrexate use and risk of 
cardiovascular disease. The American journal of cardiology, 2011. 108(9): p. 1362-1370. 
37. Gerards, A.H., et al., Inhibition of cytokine production by methotrexate. Studies in healthy 
volunteers and patients with rheumatoid arthritis. Rheumatology, 2003. 42(10): p. 1189-
1196. 
38. Rho, Y.H., et al., Drugs used in the treatment of rheumatoid arthritis: relationship between 
current use and cardiovascular risk factors. Archives of drug information, 2009. 2(2): p. 34-
40. 
39. Coomes, E., E.S. Chan, and A.B. Reiss, Methotrexate in atherogenesis and cholesterol 
metabolism. Cholesterol, 2011. 2011. 
40. Reiss, A.B., et al., Adenosine A2A receptor occupancy stimulates expression of proteins 
involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. 
Journal of leukocyte biology, 2004. 76(3): p. 727-734. 
41. McPherson, J.A., et al., Adenosine A2A receptor stimulation reduces inflammation and 
neointimal growth in a murine carotid ligation model. Arteriosclerosis, thrombosis, and 
vascular biology, 2001. 21(5): p. 791-796. 
42. Ridker, P.M., et al., Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. 





43. Thornton, C., et al., Methotrexate-mediated activation of an AMPK-CREB-dependent 
pathway: a novel mechanism for vascular protection in chronic systemic inflammation. 
Annals of the Rheumatic Diseases, 2016. 75(2): p. 439-448. 
44. Ferrari, M., Frontiers in cancer nanomedicine: directing mass transport through biological 
barriers. Trends in Biotechnology, 2010. 28(4): p. 181-188. 
45. Agyare, E. and K. Kandimalla, Delivery of polymeric nanoparticles to target vascular diseases. 
Journal of biomolecular research & therapeutics, 2014. 3(1). 
46. Di Mascolo, D., et al., Rosiglitazone-loaded nanospheres for modulating macrophage-specific 
inflammation in obesity. Journal of Controlled Release, 2013. 170(3): p. 460-468. 
47. Stigliano, C., et al., Methotraxate‐Loaded Hybrid Nanoconstructs Target Vascular Lesions and 
Inhibit Atherosclerosis Progression in ApoE−/− Mice. Advanced healthcare materials, 2017. 
6(13): p. 1601286. 
48. Maranhão, R.C., et al., Methotrexate Carried in Lipid Core Nanoparticles Reduces Myocardial 
Infarction Size and Improves Cardiac Function in Rats. International journal of nanomedicine, 
2017. 12: p. 3767. 
49. Gomes, F.L., et al., Regression of atherosclerotic plaques of cholesterol-fed rabbits by 
combined chemotherapy with paclitaxel and methotrexate carried in lipid core nanoparticles. 
Journal of cardiovascular pharmacology and therapeutics, 2018. 23(6): p. 561-569. 
50. Ridker, P.M., Residual inflammatory risk: addressing the obverse side of the atherosclerosis 
prevention coin. European heart journal, 2016. 37(22): p. 1720-1722. 
51. Westlake, S.L., et al., The effect of methotrexate on cardiovascular disease in patients with 
rheumatoid arthritis: a systematic literature review. Rheumatology, 2010. 49(2): p. 295-307. 
52. Choi, H.K., et al., Methotrexate and mortality in patients with rheumatoid arthritis: a 
prospective study. The Lancet, 2002. 359(9313): p. 1173-1177. 
53. Gridneva, G., et al., Evaluation of methotrexate effect on the acute-phase response in 
rheumatoid arthritis after 12-week treatment. Klinicheskaia meditsina, 2014. 92(3): p. 59-63. 
54. Bäck, M. and G.K. Hansson, Anti-inflammatory therapies for atherosclerosis. Nature reviews. 
Cardiology, 2015. 12(4): p. 199. 
55. Mach, F., et al., Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 
1998. 394(6689): p. 200-203. 
56. Hansson, G.K. and A. Hermansson, The immune system in atherosclerosis. Nature 
immunology, 2011. 12(3): p. 204. 
57. Schroder, K. and J. Tschopp, The inflammasomes. cell, 2010. 140(6): p. 821-832. 
58. Shi, X., et al., Expression of the NLRP3 inflammasome in carotid atherosclerosis. Journal of 
Stroke and Cerebrovascular Diseases, 2015. 24(11): p. 2455-2466. 
59. Whitman, S.C., P. Ravisankar, and A. Daugherty, Interleukin-18 enhances atherosclerosis in 
apolipoprotein E−/− mice through release of interferon-γ. Circulation research, 2002. 90(2): 
p. e34-e38. 
60. Merhi-Soussi, F., et al., Interleukin-1 plays a major role in vascular inflammation and 
atherosclerosis in male apolipoprotein E-knockout mice. Cardiovascular research, 2005. 
66(3): p. 583-593. 
61. Galea, J., et al., Interleukin-1β in coronary arteries of patients with ischemic heart disease. 
Arteriosclerosis, thrombosis, and vascular biology, 1996. 16(8): p. 1000-1006. 
62. Mallat, Z., et al., Expression of interleukin-18 in human atherosclerotic plaques and relation 
to plaque instability. Circulation, 2001. 104(14): p. 1598-1603. 
63. Elhage, R., et al., Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-
knockout mice. Cardiovascular research, 2003. 59(1): p. 234-240. 
64. Dinarello, C.A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. 





65. Libby, P., Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of 
CANTOS and beyond. Journal of the American College of Cardiology, 2017. 70(18): p. 2278-
2289. 
66. Jin, Y. and J. Fu, Novel Insights Into the NLRP 3 Inflammasome in Atherosclerosis. Journal of 
the American Heart Association, 2019. 8(12): p. e012219. 
67. Li, X., et al., Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and 
migration: implication of a novel role of inflammasome in atherogenesis. PloS one, 2014. 
9(1). 
68. Yüksel, Ş., L. Ayvazyan, and A.Y. Gasparyan, Familial Mediterranean fever as an emerging 
clinical model of atherogenesis associated with low-grade inflammation. The open 
cardiovascular medicine journal, 2010. 4: p. 51. 
69. Crittenden, D.B., et al., Colchicine use is associated with decreased prevalence of myocardial 
infarction in patients with gout. The Journal of rheumatology, 2012. 39(7): p. 1458-1464. 
70. Langevitz, P., et al., Prevalence of ischemic heart disease in patients with familial 
Mediterranean fever. The Israel Medical Association journal: IMAJ, 2001. 3(1): p. 9-12. 
71. Yang, L.P., Oral colchicine (Colcrys [R]) in the treatment and prophylaxis of gouty: profile 
report. Drugs & aging, 2010. 27(10): p. 855-858. 
72. Terkeltaub, R.A., et al., High versus low dosing of oral colchicine for early acute gout flare: 
twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐
controlled, parallel‐group, dose‐comparison colchicine study. Arthritis & Rheumatism, 2010. 
62(4): p. 1060-1068. 
73. Nidorf, M. and P.L. Thompson, Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-
reactive protein independent of aspirin and atorvastatin in patients with stable coronary 
artery disease. The American journal of cardiology, 2007. 99(6): p. 805-807. 
74. Jordan, K.M., et al., British Society for Rheumatology and British Health Professionals in 
Rheumatology guideline for the management of gout. Rheumatology, 2007. 46(8): p. 1372-
1374. 
75. Hentgen, V., et al. Evidence-based recommendations for the practical management of 
Familial Mediterranean Fever. in Seminars in arthritis and rheumatism. 2013. Elsevier. 
76. Nidorf, S.M., et al., Low-dose colchicine for secondary prevention of cardiovascular disease. 
Journal of the American College of Cardiology, 2013. 61(4): p. 404-410. 
77. Naruko, T., et al., Neutrophil infiltration of culprit lesions in acute coronary syndromes. 
Circulation, 2002. 106(23): p. 2894-2900. 
78. Nidorf, S.M., et al., The effect of low-dose colchicine in patients with stable coronary artery 
disease: The LoDoCo2 trial rationale, design, and baseline characteristics. American heart 
journal, 2019. 218: p. 46-56. 
79. Demidowich, A.P., et al., Effects of colchicine in adults with metabolic syndrome: A pilot 
randomized controlled trial. Diabetes, Obesity and Metabolism, 2019. 21(7): p. 1642-1651. 
80. Imazio, M., et al., Colchicine for prevention of postpericardiotomy syndrome and 
postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. Jama, 2014. 312(10): 
p. 1016-1023. 
81. Hennessy, T., et al., The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: 
A pilot randomized placebo controlled trial of colchicine following acute myocardial 
infarction. American heart journal, 2019. 215: p. 62-69. 
82. Ridker, P.M., From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to 
identify novel targets for atheroprotection. Circulation research, 2016. 118(1): p. 145-156. 
83. Tardif, J.-C., et al., Efficacy and safety of low-dose colchicine after myocardial infarction. New 
England Journal of Medicine, 2019. 381(26): p. 2497-2505. 
84. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke 





85. Colchicine and Spironolactone in Patients With STEMI/SYNERGY Stent Registry (CLEAR-
SYNERGY). Available from: https://clinicaltrials.gov/ct2/show/NCT03048825?term=CLEAR-
SYNERGY&draw=2&rank=2  
86. Galkina, E. and K. Ley, Immune and inflammatory mechanisms of atherosclerosis. Annual 
review of immunology, 2009. 27. 
87. Gimbrone Jr, M.A. and G. García-Cardeña, Endothelial cell dysfunction and the pathobiology 
of atherosclerosis. Circulation research, 2016. 118(4): p. 620-636. 
88. Inflammation and Coronary Endothelial Function. Available from: 
https://clinicaltrials.gov/ct2/show/NCT02366091. 
89. Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL 
Like Nanoparticles. Available from: https://clinicaltrials.gov/ct2/show/NCT04616872. 
90. Di Francesco, V., et al., Modulating lipoprotein transcellular transport and atherosclerotic 
plaque formation in apoe-/-mice via nanoformulated lipid-methotrexate conjugates. ACS 
Applied Materials & Interfaces, 2020. 
91. Zoghebi, K.A., et al., Design and Biological Evaluation of Colchicine-CD44-Targeted Peptide 
Conjugate in an In Vitro Model of Crystal Induced Inflammation. Molecules, 2020. 25(1): p. 
46. 
92. Chen, Y., et al., An injectable thermosensitive hydrogel loaded with an ancient natural drug 
colchicine for myocardial repair after infarction. Journal of Materials Chemistry B, 2020. 
93. Purcell, W.T. and D.S. Ettinger, Novel antifolate drugs. Current Oncology Reports, 2003. 5(2): 
p. 114-125. 
94. Abolmaali, S.S., A.M. Tamaddon, and R. Dinarvand, A review of therapeutic challenges and 
achievements of methotrexate delivery systems for treatment of cancer and rheumatoid 
arthritis. Cancer chemotherapy and pharmacology, 2013. 71(5): p. 1115-1130. 
95. Kasim, N.A., et al., Molecular Properties of WHO Essential Drugs and Provisional 
Biopharmaceutical Classification. Molecular Pharmaceutics, 2004. 1(1): p. 85-96. 
96. Bedoui, Y., et al., Methotrexate an old drug with new tricks. International Journal of 
Molecular Sciences, 2019. 20(20): p. 5023. 
97. Genestier, L., et al., Mechanisms of action of methotrexate. Immunopharmacology, 2000. 
47(2-3): p. 247. 
98. Oh, J.-M., et al., Efficient delivery of anticancer drug MTX through MTX-LDH nanohybrid 
system. Journal of Physics and Chemistry of Solids, 2006. 67(5): p. 1024-1027. 
99. Bailey, L.B. and J.F. Gregory, 3rd, Folate metabolism and requirements. J Nutr, 1999. 129(4): 
p. 779-82. 
100. van Roon, E.N. and M.A. van de Laar, Methotrexate bioavailability. Clin Exp Rheumatol, 
2010. 28(5 Suppl 61): p. S27-32. 
101. Li, Y., et al., Self-assembly of multifunctional integrated nanoparticles loaded with a 
methotrexate–phospholipid complex: combining simplicity and efficacy in both targeting and 
anticancer effects. RSC advances, 2016. 6(89): p. 86717-86727. 
102. Chan, E.S. and B.N. Cronstein, Methotrexate—how does it really work? Nature Reviews 
Rheumatology, 2010. 6(3): p. 175-178. 
103. Iqbal, M.P., Accumulation of methotrexate in human tissues following high-dose 
methotrexate therapy. 1998. 
104. Conway, R. and J.J. Carey, Risk of liver disease in methotrexate treated patients. World 
journal of hepatology, 2017. 9(26): p. 1092. 
105. Prey, S. and C. Paul, Effect of folic or folinic acid supplementation on methotrexate‐
associated safety and efficacy in inflammatory disease: a systematic review. British Journal 
of Dermatology, 2009. 160(3): p. 622-628. 
106. Romao, V.C., et al., Three decades of low-dose methotrexate in rheumatoid arthritis: can we 





107. Schnabel, A. and W.L. Gross. Low-dose methotrexate in rheumatic diseases—efficacy, side 
effects, and risk factors for side effects. in Seminars in arthritis and rheumatism. 1994. 
Elsevier. 
108. Karasulu, H.Y., et al., Controlled Release of Methotrexate from W/O Microemulsion and Its In 
Vitro Antitumor Activity. Drug Delivery, 2007. 14(4): p. 225-233. 
109. Li, M.-H., et al., Dendrimer-based multivalent methotrexates as dual acting nanoconjugates 
for cancer cell targeting. European journal of medicinal chemistry, 2012. 47(1): p. 560-572. 
110. Nogueira, D.R., et al., In vitro antitumor activity of methotrexate via pH-sensitive chitosan 
nanoparticles. Biomaterials, 2013. 34(11): p. 2758-72. 
111. Sartori, T., et al., Development and validation of a fast RP-HPLC method for determination of 
methotrexate entrapment efficiency in polymeric nanocapsules. J Chromatogr Sci, 2008. 
46(6): p. 505-9. 
112. Zhang, Y., T. Jin, and R.X. Zhuo, Methotrexate-loaded biodegradable polymeric micelles: 
preparation, physicochemical properties and in vitro drug release. Colloids Surf B 
Biointerfaces, 2005. 44(2-3): p. 104-9. 
113. Curcio, M., et al., Facile synthesis of pH-responsive polymersomes based on lipidized PEG for 
intracellular co-delivery of curcumin and methotrexate. Colloids and Surfaces B: 
Biointerfaces, 2018. 167: p. 568-576. 
114. Guimarães, D., et al., Increased Encapsulation Efficiency of Methotrexate in Liposomes for 
Rheumatoid Arthritis Therapy. Biomedicines, 2020. 8(12): p. 630. 
115. Celia, C., et al., Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the 
Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and 
Taxol. Advanced Therapeutics: p. 2000121. 
116. Popa, M. and C.V. Uglea, Polymeric Nanomedicines. 2013: Bentham Science Publishers. 
117. Sercombe, L., et al., Advances and challenges of liposome assisted drug delivery. Frontiers in 
pharmacology, 2015. 6: p. 286. 
118. Lamichhane, N., et al., Liposomes: clinical applications and potential for image-guided drug 
delivery. Molecules, 2018. 23(2): p. 288. 
119. Ferreira, M., et al., Optimizing the Pharmacological Properties of Discoidal Polymeric 
Nanoconstructs Against Triple Negative Breast Cancer Cells  Frontiers in Bioengineering and 
Biotechnology, 2020. 8: p. 5. 
120. Tetko, I.V., et al., Estimation of Aqueous Solubility of Chemical Compounds Using E-State 
Indices. Journal of Chemical Information and Computer Sciences, 2001. 41(6): p. 1488-1493. 
121. Tetko, I.V., V.Y. Tanchuk, and A.E. Villa, Prediction of n-octanol/water partition coefficients 
from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf 
Comput Sci, 2001. 41(5): p. 1407-21. 
122. ACDLabs. Partition Coefficient Calculation with ACD/LogP. 2021; Available from: 
https://www.acdlabs.com/products/percepta/predictors/logp/index.php. 
123. De Rose, R.F., et al., PDE5 inhibitors-loaded nanovesicles: Physico-chemical properties and in 
vitro antiproliferative activity. Nanomaterials, 2016. 6(5): p. 92. 
124. dos Santos, A.M., et al., Computational and experimental approaches for development of 
methotrexate nanosuspensions by bottom-up nanoprecipitation. International Journal of 
Pharmaceutics, 2017. 524(1-2): p. 330-338. 
125. Palanikumar, L., et al., pH-responsive high stability polymeric nanoparticles for targeted 
delivery of anticancer therapeutics. Communications biology, 2020. 3(1): p. 1-17. 
126. Aigner, T. and S. Söder, Histopathological examination of joint degeneration: typing, grading 
and staging of osteoarthritis. Der Pathologe, 2006. 27(6): p. 431-438. 
127. Rajamäki, K., et al., Extracellular acidosis is a novel danger signal alerting innate immunity 






128. Di Francesco, M., et al., Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to 
Treat Metastatic and Non-Metastatic Breast Cancer. ACS Omega, 2021. 
129. Mircioiu, C., et al., Mathematical modeling of release kinetics from supramolecular drug 
delivery systems. Pharmaceutics, 2019. 11(3): p. 140. 
130. Rigter, P. and N. Peppas, A simple equation for description of solute relase I. Fickian and non-
fickian release from non-swellable devices in the form of slabs, spherer, cylinders or discs. J. 
Control. Release, 1987. 5: p. 23-36. 
131. Mohan, A., et al., Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated 
nanoliposomes improve chemotherapeutic efficacy of combination against head and neck 
squamous cell carcinoma. BioMed research international, 2014. 2014. 
132. Er, Y., et al., The encapsulation and release of guanosine from PEGylated liposomes. Journal 
of liposome research, 2009. 19(1): p. 29-36. 
133. Jain, A. and S.K. Jain, In vitro release kinetics model fitting of liposomes: An insight. 
Chemistry and physics of lipids, 2016. 201: p. 28-40. 
134. Prakash, J.D., et al., Formulation and In vitro Characterization of Ketoconazole Liposomal Gel 
for Transdermal Delivery. Research Journal of Pharmacy and Technology, 2017. 10(1): p. 
205-215. 
135. Tiwari, G., et al., Development and Optimization of Liposomes Containing 5 Fluorouracil and 
Tretinoin for Skin Warts: 32 Experimental Design. FABAD Journal of Pharmaceutical Sciences, 
2019. 44(1): p. 17-26. 
136. Wei, Y., et al., Preparation, pharmacokinetics and biodistribution of baicalin-loaded 
liposomes. International journal of nanomedicine, 2014. 9: p. 3623. 
137. Zhang, T., et al., Curcumin-and Cyclopamine-Loaded Liposomes to Enhance Therapeutic 
Efficacy Against Hepatic Fibrosis. Drug Design, Development and Therapy, 2020. 14: p. 5667. 
138. Jeong, C., et al., Self-Assembled Supramolecular Bilayer Nanoparticles Composed of Near-
Infrared Dye as a Theranostic Nanoplatform To Encapsulate Hydrophilic Drugs Effectively. 
ACS Biomaterials Science & Engineering, 2019. 6(1): p. 474-484. 
139. Cadinoiu, A.N., et al., Aptamer-functionalized liposomes as a potential treatment for basal 
cell carcinoma. Polymers, 2019. 11(9): p. 1515. 
140. Libby, P. and G.K. Hansson, Taming Immune and Inflammatory Responses to Treat 
Atherosclerosis. 2018, Journal of the American College of Cardiology. 
141. Kim, Y., et al., Probing Nanoparticle Translocation Across the Permeable Endothelium in 
Experimental Atherosclerosis. Proceedings of the National Academy of Sciences, 2014. 
111(3): p. 1078-1083. 
142. Moore, K.J. and I. Tabas, Macrophages in the Pathogenesis of Atherosclerosis. Cell, 2011. 
145(3): p. 341-355. 
143. Welsh, P., et al., Targeting Inflammation to Reduce Cardiovascular Disease Risk: a Realistic 
Clinical Prospect? British journal of pharmacology, 2017. 174(22): p. 3898-3913. 
144. Ridker, P.M., et al., Antiinflammatory Therapy with Canakinumab for Atherosclerotic 
Disease. New England journal of medicine, 2017. 377(12): p. 1119-1131. 
145. Weber, C. and H. Noels, Atherosclerosis: Current Pathogenesis and Therapeutic Options. 
Nature medicine, 2011. 17(11): p. 1410. 
146. Cronstein, B.N., D. Naime, and E. Ostad, The Antiinflammatory Mechanism of Methotrexate. 
Increased Adenosine Release at Inflamed Sites Diminishes Leukocyte Accumulation in an in 
Vivo Model of Inflammation. The Journal of clinical investigation, 1993. 92(6): p. 2675-2682. 
147. Bălănescu, A.R., et al., Cardiovascular Effects of Methotrexate in Immune‑Mediated 
Inflammatory Diseases. Experimental and Therapeutic Medicine, 2019. 17(2): p. 1024-1029. 
148. Kivity, S., et al., Clinical Characteristics and Risk Factors for Low Dose Methotrexate Toxicity: 





149. Chen, M., et al., Folate Receptor-Targeting and Reactive Oxygen Species-Responsive 
Liposomal Formulation of Methotrexate for Treatment of Rheumatoid Arthritis. 
Pharmaceutics, 2019. 11(11): p. 582. 
150. Alekseeva, A.A., et al., Liposomal formulation of a methotrexate lipophilic prodrug: 
assessment in tumor cells and mouse T-cell leukemic lymphoma. The International Journal of 
Nanomedicine, 2017. 12: p. 3735. 
151. Bulgarelli, A., et al., Anti-Atherogenic Effects of Methotrexate Carried by a Lipid 
Nanoemulsion that Binds to LDL Receptors in Cholesterol-Fed Rabbits. Cardiovascular drugs 
and therapy, 2013. 27(6): p. 531-539. 
152. Robbins, C.S., et al., Local Proliferation Dominates Lesional Macrophage Accumulation in 
Atherosclerosis. Nature medicine, 2013. 19(9): p. 1166. 
153. Beldman, T.J., et al., Hyaluronan Nanoparticles Selectively Target Plaque-Associated 
Macrophages and Improve Plaque Stability in Atherosclerosis. ACS nano, 2017. 11(6): p. 
5785-5799. 
154. Zhang, L., et al., Promoting the Delivery of Nanoparticles to Atherosclerotic Plaques by DNA 
Coating. ACS applied materials & interfaces, 2018. 11(15): p. 13888-13904. 
155. Davies, P.F., Hemodynamic Shear Stress and the Endothelium in Cardiovascular 
Pathophysiology. Nature Reviews Cardiology, 2009. 6(1): p. 16. 
156. Taylor, C.A., T.J. Hughes, and C.K. Zarins, Finite Element Modeling of Three-Dimensional 
Pulsatile Flow in the Abdominal Aorta: Relevance to Atherosclerosis. Annals of biomedical 
engineering, 1998. 26(6): p. 975-987. 
157. Hossain, S.S., T.J. Hughes, and P. Decuzzi, Vascular Deposition Patterns for Nanoparticles in 
an Inflamed Patient-Specific Arterial Tree. Biomechanics and modeling in mechanobiology, 
2014. 13(3): p. 585-597. 
158. Charoenphol, P., et al., Targeting Therapeutics to the Vascular Wall in Atherosclerosis–
Carrier Size Matters. Atherosclerosis, 2011. 217(2): p. 364-370. 
159. Beldman, T.J., et al., Nanoparticle-Aided Characterization of Arterial Endothelial Architecture 
during Atherosclerosis Progression and Metabolic Therapy. ACS nano, 2019. 13(12): p. 
13759-13774. 
160. Wei, X., et al., Nanoparticle Functionalization with Platelet Membrane Enables Multifactored 
Biological Targeting and Detection of Atherosclerosis. Acs Nano, 2018. 12(1): p. 109-116. 
161. Kheirolomoom, A., et al., Multifunctional Nanoparticles Facilitate Molecular Targeting And 
miRNA Delivery to Inhibit Atherosclerosis in ApoE–/–Mice. ACS nano, 2015. 9(9): p. 8885-
8897. 
162. Ye, M., et al., SR-A-Targeted Phase-Transition Nanoparticles for the Detection and Treatment 
of Atherosclerotic Vulnerable Plaques. ACS applied materials & interfaces, 2019. 11(10): p. 
9702-9715. 
163. Liu, Y., et al., Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging 
with Positron Emission Tomography and Potential for Clinical Translation. ACS applied 
materials & interfaces, 2019. 11(17): p. 15316-15321. 
164. Nahrendorf, M., et al., Nanoparticle PET-CT Imaging of Macrophages in Inflammatory 
Atherosclerosis. Circulation, 2008. 117(3): p. 379. 
165. Flores, A.M., et al., Pro-Efferocytic Nanoparticles are Specifically Taken Up by Lesional 
Macrophages and Prevent Atherosclerosis. Nature Nanotechnology, 2020: p. 1-8. 
166. Lee, A., et al., Dexamethasone-Loaded Polymeric Nanoconstructs for Monitoring and 
Treating Inflammatory Bowel Disease. Theranostics, 2017. 7(15): p. 3653. 
167. Di Francesco, M., et al., Physicochemical Characterization of pH-Responsive and Fusogenic 
Self-Assembled Non-Phospholipid Vesicles for a Potential Multiple Targeting Therapy. 
International journal of pharmaceutics, 2017. 528(1-2): p. 18-32. 
168. Shen, C.-M., et al., Stimulation of Smooth Muscle Cell Proliferation by ox-LDL-and Acetyl LDL-





169. Xu, S., et al., Evaluation of Foam Cell Formation in Cultured Macrophages: an Improved 
Method with Oil Red O Staining and DiI-oxLDL Uptake. Cytotechnology, 2010. 62(5): p. 473-
481. 
170. Yan, P., et al., Biological Characteristics of Foam Cell Formation in Smooth Muscle Cells 
Derived From Bone Marrow Stem Cells. International journal of biological sciences, 2011. 
7(7): p. 937. 
171. MacRitchie, N., et al., Plasmacytoid Dendritic Cells Play a Key Role in Promoting 
Atherosclerosis in Apolipoprotein E–Deficient Mice. Arteriosclerosis, thrombosis, and 
vascular biology, 2012. 32(11): p. 2569-2579. 
172. MacRitchie, N., et al., The Aorta Can Act as Site of Naïve CD4+ T Cell Priming. Cardiovascular 
research, 2019. 
173. Moshikur, R.M., et al., Ionic Liquids with Methotrexate Moieties as a Potential Anticancer 
Prodrug: Synthesis, Characterization and Solubility Evaluation. Journal of Molecular Liquids, 
2019. 278: p. 226-233. 
174. Tishler, M., et al., Synovial and Serum Levels of Methotrexate During Methotrexate Therapy 
of Rheumatoid Arthritis. Rheumatology, 1989. 28(5): p. 422-423. 
175. Lee, A., et al., Spherical Polymeric Nanoconstructs for Combined Chemotherapeutic and Anti-
Inflammatory Therapies. Nanomedicine: Nanotechnology, Biology and Medicine, 2016. 
12(7): p. 2139-2147. 
176. Santarella-Mellwig, R., et al., Correlative Light Electron Microscopy (CLEM) for Tracking and 
Imaging Viral Protein Associated Structures in Cryo-immobilized Cells. JoVE (Journal of 
Visualized Experiments), 2018(139): p. e58154. 
177. Pulanco, M.C., et al., Complement Protein C1q Enhances Macrophage Foam Cell Survival and 
Efferocytosis. The Journal of Immunology, 2017. 198(1): p. 472-480. 
178. Yokode, M., et al., Stimulated Arachidonate Metabolism During Foam Cell Transformation of 
Mouse Peritoneal Macrophages with Oxidized Low Density Lipoprotein. The Journal of 
clinical investigation, 1988. 81(3): p. 720-729. 
179. Lu, S.M. and G.D. Fairn, 7‐Ketocholesterol Impairs Phagocytosis and Efferocytosis Via 
Dysregulation of Phosphatidylinositol 4, 5‐Bisphosphate. Traffic, 2018. 19(8): p. 591-604. 
180. Reiss, A.B., et al., Atheroprotective Effects of Methotrexate on Reverse Cholesterol Transport 
Proteins and Foam Cell Transformation in Human THP‐1 Monocyte/Macrophages. Arthritis & 
Rheumatism: Official Journal of the American College of Rheumatology, 2008. 58(12): p. 
3675-3683. 
181. Nicholson, A.C. and D.P. Hajjar, CD36, Oxidized LDL and PPAR Gamma: Pathological 
Interactions in Macrophages and Atherosclerosis. Vascular Pharmacology, 2004. 41(4-5): p. 
139. 
182. Conniot, J., et al., Immunization with Mannosylated Nanovaccines and Inhibition of the 
Immune-Suppressing Microenvironment Sensitizes Melanoma to Immune Checkpoint 
Modulators. Nature nanotechnology, 2019. 14(9): p. 891-901. 
183. Alaarg, A., et al., A Systematic Comparison of Clinically Viable Nanomedicines Targeting 
HMG-CoA Reductase in Inflammatory Atherosclerosis. J Control Release, 2017. 262: p. 47-57. 
184. Beldman, T.J., et al., Hyaluronan Nanoparticles Selectively Target Plaque-Associated 
Macrophages and Improve Plaque Stability in Atherosclerosis. ACS Nano, 2017. 11(6): p. 
5785-5799. 
185. Tang, J., et al., Immune Cell Screening of a Nanoparticle Library Improves Atherosclerosis 
Therapy. Proc Natl Acad Sci U S A, 2016. 113(44): p. E6731-E6740. 
186. Han, J., et al., Native and Modified Low Density Lipoproteins Increase the Functional 
Expression of the Macrophage Class B Scavenger Receptor, CD36. Journal of Biological 
Chemistry, 1997. 272(34): p. 21654-21659. 
187. Volobueva, A., et al., Foam Cell Formation and Cholesterol Trafficking and Metabolism 





188. Chen, D.-Y., et al., Blood Lipid Profiles and Peripheral Blood Mononuclear Cell Cholesterol 
Metabolism Gene Expression in Patients With and Without Methotrexate Treatment. BMC 
medicine, 2011. 9(1): p. 4. 
189. Nguyen, M.T., et al., Inflammation as a therapeutic target in atherosclerosis. Journal of 
clinical medicine, 2019. 8(8): p. 1109. 
190. Spagnoli, L.G., et al., Role of inflammation in atherosclerosis. Journal of nuclear medicine, 
2007. 48(11): p. 1800-1815. 
191. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. New England 
Journal of Medicine, 2005. 352(16): p. 1685-1695. 
192. van der Wal, A.C., et al., Site of intimal rupture or erosion of thrombosed coronary 
atherosclerotic plaques is characterized by an inflammatory process irrespective of the 
dominant plaque morphology. Circulation, 1994. 89(1): p. 36-44. 
193. Malaviya, A.N., et al., Low‐dose and high‐dose methotrexate are two different drugs in 
practical terms. International journal of rheumatic diseases, 2010. 13(4): p. 288-293. 
194. Cutolo, M., et al., Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. 
Annals of the rheumatic diseases, 2001. 60(8): p. 729-735. 
195. Martinon, F., et al., Gout-associated uric acid crystals activate the NALP3 inflammasome. 
Nature, 2006. 440(7081): p. 237-241. 
196. Leung, Y.Y., L.L.Y. Hui, and V.B. Kraus. Colchicine—Update on mechanisms of action and 
therapeutic uses. in Seminars in arthritis and rheumatism. 2015. Elsevier. 
197. Ades, S., Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to 
practice. 2009. 
198. Chen, Y., et al., An injectable thermosensitive hydrogel loaded with an ancient natural drug 
colchicine for myocardial repair after infarction. Journal of Materials Chemistry B, 2020. 8(5): 
p. 980-992. 
199. Singhvi, G. and M. Singh, In-Vitro Drug Release Characterization Models. Int J Pharm Stud 
Res, 2011. 2(1): p. 77-84. 
200. Abu-Fanne, R., et al., α-Defensins induce a post-translational modification of low density 
lipoprotein (LDL) that promotes atherosclerosis at normal levels of plasma cholesterol. 
Journal of Biological Chemistry, 2016. 291(6): p. 2777-2786. 
201. Yang, M., et al., Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis 
through activating AMPK/SIRT1 pathway. Oxidative medicine and cellular longevity, 2020. 
2020. 
202. Folkman, J. and A. Moscona, Role of cell shape in growth control. Nature, 1978. 273(5661): p. 
345-349. 
203. Singh, R., et al., Quantitative assessment of morphology and sub-cellular changes in 
macrophages and trophoblasts during inflammation. Biomedical Optics Express, 2020. 11(7): 
p. 3733-3752. 
204. Kasim, N.A., et al., Molecular properties of WHO essential drugs and provisional 
biopharmaceutical classification. Molecular pharmaceutics, 2004. 1(1): p. 85-96. 
 
 
